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CHAPTER I. 
GENERAL INTRODUCTION 
I.l. LYSOSOMES 
Like many other important discoveries the lysosome was 
discovered by serendipity. Cell fractionation studies on rat 
liver by the group of de Duve led to the lysosomal concept as 
we know it nowadays. During the characterization of glucose 6-
phosphatase, acid phosphatase activity was observed in the 
mitochondrial fraction of rat liver (Berthet and de Duve 
1951), and this latter enzyme could be activated by a number 
of treatments such as hypotonic media, freezing, mechanical 
homogenization and detergents. This incidental finding is 
later commented by de Duve as 11 0ur interest in this uninspi-
ring enzyme was largely negative, extending only sofar as it 
provided a suitable contrast for glucose 6-phospatase" (de 
Duve 1969). Since latency of acid phosphatase was found to be 
associated with sedimentability, it was concluded that acid 
phosphatase was particle bound. Initially, it was thought to 
be related to mitochondria, but when better separation methods 
were developed, the association of acid phosphatase with a 
special class of cytoplasmic granules was established (Appel-
mans et a1. 1955). 
Simultaneously, similar observations were made by Walker 
(1952) for B-glucuronidase. De Duve and coworkers extended 
their observations to a total of five enzymes, 
acid phosphatase in distribution pattern and in 
all resembling 
their hydro1y-
tic action on different substrates at low pH. Since all these 
enzymes were thought to play a role in intracellular di-
gestion, the term "lysosome" (lytic particle) was introduced 
for the class of organelles containing these enzymes (de Duve 
et al. 1955; for reviews see de Duve 1969, 1983). 
Lysosomes were visualized for the first time under the 
electronmicroscope as morphologically heterogeneous vesicles 
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surrounded by a membrane by Novikoff and coworkers (for review 
see Novikoff 1973). These data resulted in a better under-
standing of their role (for reviews see Holtzman 1976, Dingle 
et al. 1984, Barranger and Brady 1984). It is now welles-
tablished that lysosomes are a constant feature of almost all 
eukaryotic cells and have a major function in intracellular 
digestion {chemically: hydrolysis) of substrates derived 
either from the extracellular environment by endocytosis, or 
from the cell's own constituents and organelles through cel-
lular autophagy. By controlling these digestive processes 
lysosomes are important for metabolic regulation, nutrition, 
cell defence and developmental modulation (e.g. insect meta-
morphosis). 
Lysosomal digestion is dependent upon substrates reaching 
the lysosomal compartment. For exogenous substrates this· 
occurs via endocytosis (for review see Pastan and Willingham 
1985). Three different types of endocytosis are distinguished: 
1) Pinocytosis ("cell drinking"), the uptake of large bubbles 
of extracellulair medium; 
2) Phagocytosis ("cell eating"), engulfment of large particles; 
3) Receptor-mediated endocytosis, uptake of molecules via a 
specific recognition site. 
The type of endocytosis is dependent on the cell type and 
extracellular environment. The complexity of the various path-
ways is illustrated in Fig. 1. 
ad 1) Pinocytosis 
(See left part of Fig. 1, arrows marked with 1). 
Substrates taken up by pinocytosis are enclosed in pine-
somes, which fuse with vesicles budding off from a specialized 
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RECEPTOR-MEDIATED 
ENDOCYTbSJS 
.. 
3. ~ 
Fig. I.l. Schematic diagram of a human cell showing the three 
major pathways by which substrates enter the lysosomes. The 
figure also shows how the different cell organelles keep contact 
with each other. Numbered arrows refer to passages in the text. 
o Receptors; A Ligands; ~ Lysosomal enzymes. 
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region of the golgi apparatus (TGR, Trans Golgi Reticulum). 
These vesicles contain hydrolytic enzymes and are called pri-
mary lysosomes. After fusion, which may involve many different 
vesicles, secondary lysosornes are formed and the breakdown of 
substrate can start. After hydrolysis, the resulting small 
molecules can leave the lysosome and may be reutilized in 
metabolic processes. The enzymatic process of hydrolysis will 
be discussed in more detail in the next chapter on lysosomal 
enzymes. Some undegradable substances accumulate in residual 
bodies. 
ad 2) Phagocytosis 
(See left part of Fig. 1, arrows marked with 2). 
Substrates taken up by phagocytosis are enclosed in pha-
gosornes. Phagocytosis is restricted to specialized cells such 
as rnacrophages. Larger particles (0.5-l~m) are internalized in 
this way. Phagosomes fuse with primary lysosomes and degra-
dation can start. 
ad 3) Receptor-mediated endocytosis 
(See right part of Fig. 1, arrows marked with 3). 
A wide variety of substrates has been shown to enter the 
cell via receptor-mediated endocytosis. Rapid developments 
have been made in this field (for reviews see Goldstein et al. 
1979, Brown et al. 1983, Pastan and Willingham 1983, Wileman 
et al. 1985 and Stahl and Schwartz 1986). At least seven 
classes of ligand receptor systems have been recognized, 
functioning for e.g. nutrition, defense, transport and pro-
cessing. Among the nutritional ligand-receptor systems the 
best known is the LDL system. The most important system for 
posttranslational modification of glycoproteins is the mannose 
6-phosphate receptor system. This system which is essential 
for the processing of lysosomal enzymes, will be discussed in 
the next chapter. 
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Molecules (ligands) bind to specific cell surface recep-
tors which cluster to a certain region of the plasma membrane. 
Cage-like structures are formed by specific protein complexes, 
the most important component of which is clathrin. Subse-
quently invaginations of the plasma membrane appear containing 
the clustered receptors: "coated pits". The clathrin coat is 
removed by an 
·are formed. 
"uncoating" ATPase and endosornes (receptosomes) 
Acidification occurs by an endosomal proton pump 
and some receptors release their ligands. There are several 
different pathways depending on the function of the specific 
receptor-ligand system. Receptors may be recycled to the plas-
ma membrane and the ligand is either targeted to the lysosome 
for breakdown, or to the opposite plasma membrane (transcyto-
sis) in certain specialized cells (e.g. transport of nutrients 
by epithelial cells) (Mostov and Simister 1985). Some recept-
ors even cotransfer together with their unreleased ligands. 
Other 
after 
receptors are not recycled and 
the release of their ligands. 
are degraded in 
Morphologically 
lysosomes 
this part 
of the route from "coated pit" via endosome to lysosome is 
still uncertain. 
Several hypotheses all based on electronrnicroscopical 
observations have been proposed. Endosomes are believed to be 
formed either from "coated pits" that pinch off and subse-
quently lose their "coat" within several minutes, or from 
invaginations from the "necks", that are narrow tubuli that 
still connect the "coated" vesicle with the plasma membrane. 
After endosome formation the "coated pit" is left on the 
pla:sma membrane. Endosomes may form extensions, in which re-
cycling receptors are clustering and small vesicles pinch off 
and move back to the plasma membrane. Endosomes may also fuse 
with other endosomes to form big multivesicular endosomes. 
These may fuse with lysosomes to initiate the breakdown pro-
cess. Another possibility is that endosomes fuse with the 
Trans Golgi Reticulum (TGR) , to deliver ligand and/or receptor 
finally to primary lysosomes, which bud off probably by a 
mechanism similar to that for "coated pits" formed on the 
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plasma membrane. The intracellular release of ligand from 
their receptors is believed to occur in an acidifying compart-
ment: the compartment for uncoupling of receptor and ligand 
(CURL) (Geuze et al. 1983). This CURL may be the same as the 
extension forming endosomes (Willingham and Pastan 1985), or 
may be even similar as the TGR. The morphological appearance 
seems to be dependent on the cell type studied. Details of the 
sorting mechanisms required for the recycling of membrane and 
receptors, are largely unknown necessitating future research 
in this area. 
Autophagy is another way for substrates to reach lyse-
somes is (Fig.l, arrow marked with 4 ). In this process mem-
branes, probably of the endoplasmic reticulum, form vacuoles 
(autophagosomes) by engulfing the cell constituents destined 
to be degraded. For this purpose autophagosomes fuse with 
lysosomes. 
It is clear that lysosomes have a key function in cell 
processes requiring degradation. It is however also evident, 
that this function is performed by a highly sophisticated 
vesicle transport system, resembling the blood plasma as the 
extracellular transport system. 
So far we have discussed by which routes substrates can 
enter the lysosome. In the next chapter we will focus on the 
special equipment of the lysosome, the lysosomal enzymes, and 
how they reach the lysosomal compartment after their synthe-
sis. 
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I.2. LYSOSOMAL ENZYMES 
Since digestion is the main function of lysosomes, it is 
not surprising that these organelles contain a large number of 
digestive enzymes: the lysosomal hydrolases. In fact, the 
presence of five of these enzymes led to the definition of the 
lysosome as discussed in chapter I.l. Digestion does not occur 
exclusively in the lysosomes, but in a few instances also 
outside the cell through lysosomal enzymes secreted by exocy-
tosis (e.g. resorption of bone by osteoclasts) (Hers 1973, 
Vaes 1973, Lerner 1980). All lysosomal hydrolases have a low 
pH optimum and all have a specific function in the breakdown 
of complex biological substances into low molecular weight 
constituents which diffuse through the lysosomal membrane into 
the cytoplasm, where they may be further metabolized. For 
instance proteins are degraded into their aminoacids, carbohy-
drates into monosaccharides, phospholipids into fatty acids 
and glycerol or glycerophosphodiesters, sphingolipids into 
fatty acids, inorganic phosphate, free monosac-sphingosine, 
charides and choline, and nucleic acids into nucleosides and 
inorganic phosphate. 
Lysosomal enzymes are not only involved in the breakdown 
of foreign substances taken up by endocytosis, but also in the 
degradation of the cell's own components by autophagy. 
It is important point to consider that lysosomal enzymes 
themselves are (glyco) proteins. Immunocytochemical studies at 
the ultrastructural level have shown that in fibroblasts every 
lysosome contains all the different lysosomal hydrolases (van 
Dongen et al. 1984). A mechanism must therefore exist which 
protects the lysosomal enzymes against degradation by neigh-
bouring hydrolases. The same applies to the lysosomal mem-
brane, which like all biornembranes consists of proteins and 
phospolipids. 
About seventy lysosomal hydrolases are known and they can 
be classified according to their digestive properties as fol-
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lows: carboxyl/thiolester hydrolases, phosphatases, sulphuric 
esterases, glycosidases, peptidases and amidases. Of these 
groups the glycosidases represent the majority (Barrett and 
Heath 1977). 
In general lysosomal hydrolases are specific for only one 
type of chemical linkage ("linkage specificity"), independent 
of the structure in which this linkage is present. Most are 
exoenzymes and different enzymes are therefore needed in a 
sequential action to degrade a certain substrate. However, a 
few lysosomal endoenzymes exist, such as cathepsins B and D. 
Some enzymes involved in the degradation of certain lipophilic 
substrates need so called "activator proteins" for a proper 
functioning. These activator proteins have a detergent-like 
function by serving the interaction between water-soluble 
hydrolases and their membrane-bound glycolipid substrates (for 
reviews see Sandhoff and Conzelmann 1979, Li and Li 1984). For 
the lysosomal enzymes 6-galactosidase and arylsulfatase the 
existence of gene products (protective proteins), which di-
rectly or indfrectly stabilize these enzymes has been demon-
strated (D'Azzo et al. 1982, Waheed et al. 1982). 
Lysosomal enzymes are glycoproteins that are synthesized 
like other proteins on ribosomes. Like secretory proteins, 
lysosomal enzymes are synthesized on ribosomes bound to the 
endoplasmic reticulum. For a long time it remained unexplained 
how the lysosomal enzymes find their way into the lysosome. In 
recent years the work of the groups of Neufeld, Blobel, Sly, 
Kornfeld, Von Figura and others has contributed significantly 
to the elucidation of this question, although some aspects of 
this mechanism are still unclear (for reviews see Neufeld 
1981, Hasilik and Von Figura 1984, Goldberg et al. 1984, Creek 
and Sly 1984, Skudlarek et al. 1984, Erickson et al. 1984, 
Kornfeld 1986). During synthesis the precursor forms of lyso-
somal enzymes are translocated across the rough endoplasmic 
reticulum. Here, a proteolytic cleavage step is required (re-
moving of "signal" sequence) together with glycosylation of 
asparagine residues (enbloc transfer of a large preformed 
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oligosaccharide, 3 glucose, 9 mannose, 2 N-acetylglucosamine 
residues, from a lipid-linked intermediate to the nascent 
polypeptide). The carbohydrate part is then trimmed by se-
quential removal of glucose and mannose residues, followed by 
formation of mannose 6-phosphate residues of a complex or 
hybrid structure during transport to and through the Golgi 
stacks. Then secretion or segregation from secretory products 
occurs by a specific receptor-ligand system as indicated in 
the first chapter. A crucial role is played by the rnannose 6-
phosphate residues present on the carbohydrate part of the 
lysosomal enzyme precursors, which function as ligand. These 
ligands are recognized by specific receptor proteins, mannose 
6-phosphate receptors (MPR), that are present on the internal 
side of the Golgi stacks. 
The receptor-bound enzymes are now clustered in vesicles 
("coated pits"), that bud off from the Trans Golgi Reticulum 
(TGR). These vesicles ( 11 pre-lysosomes") acidify by the working 
of a proton pump, resulting in release by MPR of their ligands 
{lysosomal enzyme precursors). The receptors then recYcle back 
to the Golgi apparatus and may be reutilized. The released 
lysosomal enzyme precursors are now packed into primary lyse-
somes. At present it is unclear how these last steps are 
performed, but several mechanisms have been proposed (Geuze et 
al. 1985). The most likely hypothesis is that the TGR is the 
same as the so called CURL (Compartment for Uncoupling Recep-
tor and Ligand) , and primary lysosomes (containing lysosomal 
enzymes but no MPR !) are formed after acidification of coated 
vesicles. Within the lysosome the last posttranslational pro-
cessing steps occur. These final proteolytic maturation steps 
may involve activation, as is the case for the lysosomal 
enzyme cathepsin D and more in general for several zymogens 
like trypsin and chymotrypsin (for review see Neurath and 
Walsh 1976). Another possibility is that the last proteolytic 
steps may involve changes which act as signals to allow con-
formational changes, which may be necessary for stabilization 
or protection against neighbouring hydrolases. The precise 
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mechanisms involved in proteolytic cleavage and the relation-
ship between various lysosomal enzymes, other proteins and the 
lysosomal membrane are yet to be resolved. 
Another possibility is that the last proteolytic proces-
sing step actually is the removal of a peptide which has been 
essential for lysosomal enzyme targeting independent of the 
MPR-ligand system. That such a MPR independent pathway exists 
is evident. For instance the membrane-bound lysosomal enzyme 
S-glucocerebrosidase is transported into lysosomes by a mecha-
nism independent of the MPR system, because no phosphorylation 
of oligosaccharide moieties occurs (for review see Tager 
1985). If other membrane-bound lysosomal enzymes follow this 
MPR independent pathway, is unknown at present. Evidence for 
an alternative routing independent of MPR comes from studies 
of cultured cells from patients with the lysosomal storage 
disorder I-cell disease (for review see d;Azzo 1982). These 
cells are deficient in the Golgi associated enzyme N-acetyl-
glucosaminylphosphotransferase, which normally transfers N-
acetylglucosamine 1-phosphate to the 6-hydroxyl of mannose 
residues present in high mannose-type oligosaccharides of 
lysosomal enzymes (Hasilik et al. 1981, Reitman et al. 1981, 
Varki et al. 1982). Because of the lack of phosphomannosyl 
recognition markers on the enzyme protein, some cells (like 
fibroblasts) from I-cell disease patients, secrete most of 
their lysosomal enzymes extracellularly. Other cell types 
(e.g. hepatocytes and leucocytes), however, have a normal 
transport and are not affected, although the phosphotransfe-
rase activity is also deficient in these cells. Apparently the 
transport of lysosomal enzymes follows in these cells a man-
nose 6-phosphate independent mechanism. 
Recently some cell types (endothelial cells and some 
murine tissue culture lines) were found to have no MPR pro-
tein, but despite this, these cells show normal levels of 
intralysosomal enzymes. However, these enzymes do not follow 
an MPR independent routing, but instead these cells contain a 
different MPR protein. This newly discovered MPR shares most 
ll 
of its physiological properties, as ligand-binding and 
release, with the original described MPR; this new MPR can be 
discriminated by its cation-dependency (Hoflack and Kornfeld 
l985a and 1985b). 
Another interesting point is the fact that a small frac-
tion (5-20%) of the precursors of soluble lysosomal enzymes 
synthesized in fibroblasts is secreted, instead of being 
transferred directly to 
and Von Figura 1984). 
the lysosomes (for review see Hasilik 
These secreted molecules may either be 
"lost" in the extracellular environment or they may be inter-
nalized again by receptor-mediated endocytosis, via MPR pre-
sent on the plasma membrane. Such a routing may represent a 
route reminiscent of older evolutionary organisms, or it re-
presents a route to deliver lysosomal enzymes to the extracel-
lular environment, where they can exert an active function 
(e.g. exocytosis of lysosomal enzymes by osteoclasts during 
bone resorption), although most lysosomal enzyme precursor 
forms may not be very active in extralysosomal compartments. 
For the unraveling of the complex process whereby newly 
synthesized lysosomal enzymes are segregated from secretory 
proteins and packaged into lysosornes, studies of patients with 
defects in this sorting pathway have been very important. 
Studies on cultured (mutant) cells derived from patients with 
lysosomal storage disorders have been crucial in the develop-
ment of concepts in this area. 
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I.3. LYSOSOMAL STORAGE DISORDERS 
Lysosomal storage disorders are relatively rare inborn 
(enzymatic) defects resulting from an inability to degrade or 
release certain metabolic products. The accumulation of non-
degraded products into the lysosomes is thought to interfere 
with the cell's functioning, and ultimately can lead to cell 
death. Accumulated material may originate from extracellular 
products internalized by endocytosis or from the cell's own 
constituents by crinophagy or autophagy (see chapter I.l). 
Most of the lysosomal storage disorders show an autosomal 
recessive mode of inheritance, and a few are X- linked 
(Fabry's disease and Hunter's disease). Since lysosomes occur 
in nearly all cell types pathological and clinical features 
are quite generalized~ There is however considerable hetero-
geneity, both among different lysosomal storage disorders and 
among different variants within one disease~ This heteroge-
neity is related to different genetic and molecular aspects 
of the enzyme defects involved, and to the rate of storage 
under in vivo conditions (for reviews see Hers and van Hoof 
1973, Neufeld et al. 1975, Galjaard 1980, Callahan and Lowden 
1981, Stanbury et al. 1983, Conzelmann and Sandhoff 1983-
1984, Galjaard and Reuser 1984). 
The concept of lysosomal storage disorders was first 
defined by Hers (1965), in Glycogenosis type II (Pompe's 
disease) , due to a genetic deficiency of lysosomal acid a-
glucosidase. During the next twenty years about 30 lysosomal 
storage disorders were recognized to be due to a certain 
lysosomal malfunctioning (for reviews see Galjaard 1980, Gal-
jaard and Reuser 1984, in: Stanbury et al~ 1983) (see Table 
I~l). The incidence of individual diseases varies from about 
1:25000 (for all mucopolysaccharidoses together} to less than 
1:100000 for others~ For some lysosomal storage diseases a 
high incidence has been observed in certain ethnic groups. A 
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TABLE I.l 
Lysosomal stor~ge dise~scs and their molecular defects 
Adapted from H. Galjaard, A.J.J. Reuoer 1984 
· no"i~oeO,~,,,c---------------------------------------no~eCte"o~cc--------------------------------------
Glycogenesis II (Pompe disease) 
Mucopolysaccharidosis 
IH (Hurler disease) 
IS (Schcie syndrolrl<') 
II (Bunter disease) 
III A (Sanfilippo dise~se) 
III a (Sanfilippo disease) 
III C [Sanfilippo disease) 
III 0 (Sanfilippo disc.:>se) 
IV A (Morquio A syndrome) 
IV B (Morquio B syndrome) 
VI (Marotcaux-Lamy syndrome) 
VII (Sly diseased 
Sialidosis (previous mucolipidosis I) 
I-ccll diseazc (mucolipidosis II) 
Mucolipidosis III 
Mucolipidosis IV 
Galactosialidosis 
Fucosidosis 
Mannosidocis 
Farber lipogranulomatosis 
Sphingomyelin lipidosis (Nicmann-Pick disease) 
Glucosylceramide lipidosiz (Gaucher disease) 
Galactosylceramide lipidosis (Krlbbc disease) 
Metachromatic le<Jcodystrophy 
Mucos<Jlfatidosis 
Ceramide trihexoside lipidosiG (Fabry disease) 
GMl-gangliosidosis 
GM2-gangliocidosis type Tay-sachs 
GM2-gangliosidosis type sandhoff 
Wolman disease 
Cystinosis 
Free N-acctylneuraminic acid storage diseace 
acid o- glucosidase 
a-L-iduronidasc 
o-L- iduron ida:::c 
sulfoid<Jronidc sulfat.:>se 
heparan sulf.:>te sulfamino hydrolase 
0-N-acetyl-D-glucosaminidasc 
.:>cctyl-CoA:Q-glucos.:>minide-
N-.:>cetyl transferase · 
N-.:>cetylglucosamine-6-
culfatc S<Jlfatase 
6-sulfo-N-.:>cetylgalactosaminidc S<Jlfat.:>se 
{}-galactosidase 
4-s<Jlfo-N-acctylgalactosaminide s<Jlfa ta:::e 
(.:>ryl:omlfata~ Bl 
C,-glucu con idase 
ll-sialida:;;c (ne<Jraminidase) 
UDP-N-acetylgl<JcOSallline-1-
phosphotransferase 
UDP-N-ace ty lg lucosa mi ne-1-
pho:::photrans(er.:>oe 
ganglioside neuraminidase 
0-g.:>lacto:::idase 'protective protein 
a-fucosidase 
acid a-lll<lnnosida:::e 
cer.:>midasc 
sph ingomyc lin3se 
p-g lucoccrcbrosidase 
p-g.:>l.:>ctoccrebrosidase 
...1rylsulfat.:>se A 
multiple sulfatase deficiency 
ceramide trihexoside a-galactosidase 
GMl-ganglioside p-g-:~lactosidase 
5-N-acetyl hexosaminidasc A 
p-N-acetyl hexos-:~minid.:>se B 
.:>Cid lip.:>Se 
ly:::osomal membrane transport defect 
lysosomal ITK'mbrane tram.;port defect 
All dise.:>scs arc inherited as a<JtOSOill<ll-reccssivetraits except Fabry .:>nd H<Jnter dise.:>se, which are 
x-linked. 
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well known example is the high incidence of GM2-gangliosidosis 
type Tay-Sachs among Ashkenazi jews, where 1 in 30 people is a 
carrier (Kaback 1977 and 1981, Galjaard and Reuser 1984). 
A characteristic morphological feature in all these 
diseases is the abundancy of swollen lysosornes. In some 
instances electronmicroscopical studies reveal the presence of 
a quite characteristic morphology of the storage product, but 
in most instances one may only observe abnormal intralysosomal 
storage as an important diagnostic criterion. Because of the 
increasing vacuolization, ultimately cell function is thought 
to be disturbed, resulting in tissue- and organ failure. De-
pending on the type of lysosomal storage disease and on the 
clinical variant within a certain disorder the pathological 
and clinical features have a progressively fatal, or a later 
onset milder course (for reviews see Galjaard 1980, in: 
Stanbury et al. 1983). 
Historically the discovery and classification of lyso-
somal storage diseases were based on a characteristic combina-
tion of clinical and pathological abnormalities and the pres-
ence of more affected relatives, sometimes in different gener-
ations in larger families. The earlier studies were focussed 
on the demonstration of a storage product and its chemical 
characterization. The accumulated material is often of a hete-
rogeneous nature, and varies considerably in type and quantity 
depending on the disorder and the cell types investigated. In 
some instances, like in various types of mucopolysacchari-
doses, the chemical analysis of storage products in the urine 
has contributed to the diagnosis and to the elucidation of the 
different genetic enzyme deficiencies involved (for review see 
McKusick and Neufeld 1983). 
The expression of lysosomal enzyme activity and of the 
deficiency in patients in a variety of cell types including 
cultured fibroblasts has greatly facilitated the early diag-
nosis of patients and carriers. It also enabled biochemical 
and genetic research of normal and abnormal cell biology. The 
(enzyme) defects responsible for the lysosomal accumulation of 
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certain products in more than 30 genetic diseases could be 
elucidated (Table I.1). 
The development of radioactive and fluorescent substrates 
and the simplification of analytical methods has offered the 
possibility of a rapid and early diagnosis using enzyme assays 
of total leucocytes, tissue biopsies or cultured skin fibro-
blasts (Galjaard 1980). Transport of tissues and cell material 
from patients and carriers all over the world allows biochemi-
cal diagnosis in specialized centres. The possibility of sto-
ring cultured fibroblasts in liquid nitrogen enables the use 
of these cells for diagnostic and research purposes also after 
death of the patient. This is especially important for genetic 
counseling and prenatal diagnosis in couples at increased 
genetic risk. 
Various follow-up studies have shown that a high propor-
tion of couples, who were timely informed about their high 
risk of affected offspring (25% in Mendelian disorders) will 
refrain from pregnancy. For those couples who still want 
children the option of prenatal diagnosis and termination at 
an early stage of pregnancy, in case the fetus is found to be 
affected, is an important alternative (for reviews see Mi-
1unsky 1979, Ga1jaard 1980). 
During the last 18 years prenatal diagnoses of lysosomal 
storage disorders and other genetic metabolic diseases were 
based on biochemical (micro) analysis of cultured amniotic 
fluid cells and comparison of the analytical results with 
those from skin fibroblasts from an affected patient, the 
heterozygous parents and controls. The sampling of amniotic 
fluid by transabdominal amniocentesis is usually performed at 
16 weeks gestation and followed by 2-4 weeks for cell- culti-
vation and biochemical analysis (for review see Galjaard 
1980). 
An important improvement is the recent introduction of 
chorionic villus sampling at 9-10 weeks of gestation via a 
thin polythene catheter introduced through the cervical canal 
under ultrasound control (for reviews see Brambati et al. 1985 
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and Fraccaro et al. 1985 ) . In 10-20 mg. chorionic tissue, 
which is of fetal origin, direct biochemical demonstration of 
lysosomal enzyme deficiencies is possible {Kleijer 1986 and 
Galjaard 1986). Nearly all lysosomal storage disorders can now 
be diagnosed within 1-2 days after chorion sampling at 9-10 
weeks. If the fetus is shown to be affected, the pregnancy can 
be terminated by vacuum aspiration, 
less stressful than an interruption 
amniotic fluid cell analysis. 
which is psychologically 
at 18-20 weeks after 
Although the birth of subsequent affected children can be 
prevented to a certain extent by early diagnosis, carrier 
detection, genetic 
patients will still 
counseling and prenatal 
be born. Unfortunately 
diagnosis, many 
most attempts at 
treatment of lysosomal storage diseases by administration of 
purified normal enzyme (for review see Desnick 1980; Tager 
et al. 1980) or enzyme replacement using transplanted cells or 
organs (for review see Barranger 1984 and Adinolfi (personal 
communication, 1986)) have been unsuccessful. In part this is 
due to problems such as the blood brain barrier and immunolo-
gical reactions, but also the exact molecular background of 
each of the (variants of) lysosomal storage diseases must be 
understood to prevent disappointing effects of administration 
of exogenous enzyme protein. The considerable clinical, patho-
logical and biochemical heterogeneity among patients with a 
certain lysosomal enzyme deficiency may well be based on 
different mutations within the same gene resulting in quite 
different abnormalities at the molecular and cell biological 
level. These differences may be relevant for the success or 
failure of future attempts at treatment. 
During the last few years much research has been focussed 
on the molecular background of the clinical and biochemical 
heterogeneity. Initially, complementation studies after soma-
tic cell hybridization were used to differentiate between 
mutations in different genes, and allelic mutations in pa-
tients with different variants of "the same" disease (for 
review see Galjaard and Reuser 1984, Reuser 1984). Another 
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approach is the analysis of the biochemical and molecular 
properties of the normal lysosomal enzyme and of the enzyme 
protein in cells from different types of patients. In some 
instances certain variants do not show any residual enzyme 
activity, while cells from other variants have different le-
vels of residual activity. The functional properties of the 
latter cell types can be studied and may be related to the 
different clinical phenotypes (Reuser 1984). 
Recently methods were developed that enabled the study of 
the biosynthesis, posttranslational modification and intra-
cellular fate of normal and mutant (lysosomal) proteins irre-
spective of their hydrolytic activity. The basis for this was 
imrnunoprecipitation after labeling of living cells (for review 
see Hasilik and Von Figura 1984). Normal human enzyme is 
purified from an easily available tissue, rich in the 
particular enzyme protein, usually human placenta. Subse-
quently antibodies are raised in animals, which are then used 
for immunoprecipitation studies of cultured fibroblasts 
have previously been labeled in vivo with (3H)-leucine, 
or other labeled components. By compairing cells from normal 
individuals and patients with different variants of a lysoso-
mal storage disease, after different time intervals of culti-
vation in non-labeled medium (npulse chase" studies) immune-
precipitation allows detailed information about the biosynthe-
sis of a specific lysosomal (enzyme) protein. SDS-polyacryla-
mide gel electrophoresis is used to identify the different 
forms of enzyme molecules produced during biosynthesis. Such 
studies have already provided important information about the 
molecular background in diseases like GM1-gangliosidosis, GM2-
gangliosidosis, Glycogenesis type II, Gaucher's disease, I-
cell disease and Galactosialidosis (in: Barranger and Brady 
1984, for review see Tager 1985). 
The classification of lysosomal storage diseases based 
upon the 
(protein) 
nature of storage material and a specific enzyme 
deficiency (Table I.l), may now be extended with 
information on the molecular nature of the enzyme defect. Also 
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immunocytochemical studies at the electronmicroscope level now 
starts to provide information about the intracellular routing 
of normal lysosomal proteins and about the subcellular site 
where a mutant (enzyme) protein shows abnormal behaviour. 
Fig.I.2. shows at which level until now mutations have been 
demonstrated, during the different steps from transcription to 
the expression of mature active enzyme in the lysosome. The 
largest group of lysosomal disorders is caused by lysosomal 
enzyme dysfunctioning and a few diseases are caused by a 
defective transport of certain metabolites across the lysoso-
mal membrane. 
ad 1) Defective enzyme functioning. 
These lysosomal enzyme deficiencies can be subdivided 
on the basis of the nature of the molecular defect as follows:-
a) Disorders in which no precursor form of the defective 
enzyme is synthesized because of lack of the essential mRNA 
molecules (Fig I.2,la). An example is classical Tay-Sachs' 
disease, associated with a 6-hexosaminidase A deficiency (Mye-
rowitz and Proia 1984). 
b) Disorders in which precursor enzyme is synthesized but the 
maturation process is impaired. Abnormal posttranslational 
modification may be expressed at different levels both bio-
chemically and ultrastructurally (Fig I.2,lb): 
For instance at the level of translation (Fig I.2,lb 
leftside) , some variants of GM2-gangliosidosis type Tay-Sachs 
can be distinguished where the precursor forms of the a-chain 
polypeptide of 6-hexosaminidase are insoluble, indicating that 
the mutation may prevent the transport of the precursor out of 
the endoplasmic reticulum (Proia and Neufeld 1982). 
Examples at the posttranslational level (RER->GOLGI, 
Fig. !.2, lb middle) are the mutations leading to defective 
modification of the carbohydrate chain, interfering with phos-
phorylation in some variants with Pompe's disease (Reuser et 
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Fig. I.2. Two main classes of defects that lead to a lysosomal 
storage disorder can be distinguished. The first class can be 
further subdivided into three groups. The diagram shows 
schematically the level at which the different mutations 
interfere with the different steps by which a lysosomal enzyme 
is synthesized, processed in the Golgi-complex, and finally 
transported to lysosomes. The numbers refer to the examples 
mentioned in the text. 
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al. 1985) and in patients with GM1-gangliosidosis (Hoogeveen 
et al~ 1986). Other examples of defective posttranslational 
modification may be found at the GOLGI-Trans GOLGI level, 
where mutations may lead to rapid degradation of precursor 
molecules, e.g. in some variants with late onset forms of 
Pompe's disease {Steckel et al. 1982). Especially interesting 
at this level are some non-classic forms of Tay-Sachs' 
disease, showing a lack of a- and S-chain association which is 
normally required for further proteolytic processing of the a-
chain precursor (d'Azzo et al. 1984). 
Normal precursor synthesis with defective maturation is 
the hall-mark of "!-cell" disease. (Fig. I.2,lb up). A de-
fective phosphotransferase enzyme leads to non-phosphorylation 
and consequently secretion of many lysosomal enzymes, re-
sulting in multiple intracellular lysosomal enzyme deficien-
cies (Hasilik and Neufeld 1980, for review see d'Azzo 1982}. 
c) Disorders with normal precursor synthesis and maturation 
but defective enzyme function or enhanced enzyme degradation. 
This may result from the lack of secondary essential proteins. 
This group of defects is expressed exclusively at the level of 
the lysosome (Fig. I.2,lc). 
Examples are the deficiency of a protective protein for 
6-galactosidase, which normally also serves as a subunit of 
neuraminidase, in galactosialidosis patients (d'Azzo et al. 
1982, Hoogeveen et al. 1983, Verheijen et al. 1985) (Fig. I.2 
lower part, lc upper left), and the hexosaminidase activator 
protein deficiency in some variants with Sandhoff's disease 
(Conzelmann and Sandhoff 1978) (Fig. I.2 lower part, lc upper 
right). 
Examples of another type of defect can be found in types 
of Morquio B disease and Gaucher's disease where the mutation 
results in a change in secondary or tertiary structure which 
in turn interferes with full enzymatic activity or may lead to 
enhanced intralysosornal degradation. (Paschke and Kresse 1982, 
Ginns et al. 1982, van der Horst et al. 1983) (Fig. I. 2 lower 
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part, lc middle). 
ad 2) Defective metabolite transport. 
A totally different group of lysosomal storage disorders 
are the disorders which are due to a defective transport of 
metabolite across the lysosomal membrane (Fig. 1.2, 2). 
Examples are cystinosis with a defective cystine trans-
port mechanism (Gahl et al. 1982) and Salla disease and other 
free N-acetylneuraminic acid (NANA) storage disorders where 
the transport of NANA out of the lysosome is found to be 
impaired (Renlund et al. 1986, Mancini et al. 1986b, Cantz 
1986 personal communication). 
As yet, the molecular defect has been elucidated of only 
a minority of the lysosomal enzyme deficiencies. The classifi-
cation given above is therefore tentative but does provide an 
impression about the research that is currently in progress in 
the area of lysosomal storage diseases and other inborn errors 
of metabolism. 
Another important technical approach is cloning of genes 
coding for the lysosomal (enzyme) proteins (Konings et al. 
1984, Myerowitz and Proia 1984, Ginns et a1. 1984, O'Brien et 
al. 1984, Fukushima et al. 1985). From the gene sequence the 
amino acid sequence can be derived and application of these 
methods to mutant cells will give insight in the exact nature 
of the different gene mutations (for review see Brown and 
Goldstein 1986). Knowledge of the amino acid sequence in 
normal and mutant cells may also provide information about the 
tertiary structure of the (mutant) protein. Such information 
is likely to contribute to a better understanding of the 
interaction between (enzyme) protein and its substrate(s). 
Detailed knowledge on the exact nature of the molecular 
defect in the different variants of lysosomal storage diseases 
is also essential for the planning of future treatment. This 
is clearly demonstrated by model experiments with fibroblasts 
showing that the a-galactosidase deficiency can be corrected 
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in some types of mutant cells, whereas in others the exogenous 
enzyme is rapidly degraded after uptake by the deficient cells 
(Van Diggelen et al. 1982). Similar problems can be expected 
in attempts of gene replacement therapy (Williams and Orkin 
1986). 
The experimental work described in this thesis is fo-
cussed on the elucidation of the molecular nature of human 
lysosomal neuraminidase deficiencies, with special emphasis on 
Galactosialidosis, which is characterized by a combined defi-
ciency of a-galactosidase and neuraminidase. 
In the next chapter the biochemical aspects of neuramini-
dase will be discussed, which are important for the under-
standing of the involvement of lysosomal neuraminidase in 
human genetic disease. 
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CHAPTER II 
BIOCHEMICAL ASPECTS OF NEURAMINIDASE 
II.1. PHYSIOLOGICAL FUNCTION 
Neuraminidases (EC 3.2.1.18 sialidase, N-acetylneur-
aminosyl glycohydrolase) catalyze the hydrolysis of neuraminic 
acid residues (sialic acids} from a variety of neuraminic 
acid-containing compounds. They are widely distributed in 
nature and are found in microorganisms like viruses and bac-
teria, as well as in mammalian tissues. An exception in nature 
seems to be the plant kingdom in which no neuraminidases have 
been found (for reviews see Gottschalk and Bhargave 1971, 
Gottschalk and Drzeniek 1972, Rosenberg and Schengrund 1976, 
Corfield et al. 1981). Although different types of neur-
aminidases have been identified, only a few, mainly from mi-
croorganisms, have been studied in detail (for review see 
Drzeniek 1973). The mammalian neuraminidases have not yet been 
well characterized, not only because of the complex characte-
ristics of mammalian tissues but also because most mammalian 
neuraminidases are membrane-bound and extremely labile. 
Neuraminidases are likely to fulfil an important role in 
many different biological processes. They catalyze the hydro-
lysis of terminal neuraminic acid residues at the non-reducing 
end of carbohydrate chains from a large number of different 
substances like oligosaccharides, glycoproteins and glyco-
lipids (gangliosides) in which these substances are involved. 
Neuraminidase was first discovered in a virus, and was ini-
tially described as RDE (receptor destroying enzyme). This RDE 
was recognized as a glycosidase (Gottschalk 1956), and later 
as 0-glycosidase (Gottschalk 1957) and a-0-glycosidase (Kuhn 
and Brossmer 1958). As a product of interaction between muco-
protein and RDE, N-acetylneuraminic acid (NANA) could be iso-
lated and the enzyme was termed neuraminidase. Its function 
was defined as cleaving the a-ketosidic linkage joining the 
keto groups of terminal NANA to adjacent sugar residues 
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(Gottschalk 1957). 
Besides the receptor destroying activity of viral neura-
minidase, neuraminidases may have many other different physi-
ological functions. These functions will become clear after 
considering the influence of neuraminic acid residues present 
in different substances (for review see in Schauer 1982 en 
1985). 
Sialic acids contribute to the negative charge of a 
molecule, and are important in binding and transport processes 
with positively charged compounds, like aggregation and dis-
aggregation of cells (for review see Reutter et al. 1982) and 
for instance synaptic transmission (Rahmann et al. 1976, Sven-
nerholrn 1980). They may also influence the conformation of 
glycoproteins and so fulfil a role in regulating the resis-
tance to proteases. Another property is the formation of anti-
genic determinants (e.g. blood groups, differentiation anti-
gens). Sialic acids are essential components of receptors 
and/or ligand molecules and may regulate receptor-mediated 
endocytosis (see chapter I.l.), as demonstrated by Ashwell 
and coworkers (Ashwell and Morell 1974, Harford et al. 1984 ) , 
who found that sialylated serum glycoproteins are protected 
against breakdown by the presence of sialic acids on the 
proteins. These sialic acids mask the neighbouring carbo-
hydrate galactose, which upon exposure binds to specific re-
ceptors present on the cell surface of rat hepatocytes. By 
this receptor-mediated endocytosis mechanism asialoglycopro-
teins enter the cell and may reach the lysosomes in which 
degradation occurs (see chapter I). 
The "masking" of specific recognition sites on molecules 
and cells is probably the most important role of sialic acids. 
For instance tumor cells seem to be protected against the 
immune defense system by the presence of highly sialylated 
surfaces, and sialylated glycoproteins are protected from 
breakdown by these sialic acid masks. A similar role of sialic 
acids can be found in erythrocytes. Removal of sialic acids 
leads to a rapid disappearance of the red cells from the blood 
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stream. 
Neuraminidases also have a key function in lysosomal 
degradation of sialic acid containing substances, since other 
lysosomal hydrolases can only perform their catalytic function 
after removal of the terminal NANA residues attached to the 
carbohydrate moieties of glycoproteins or gangliosides. 
The great pathophysiological importance of neuraminidases 
is indicated by their wide distribution in nature (from mi-
croorganisms to humans), and the biological importance of 
their potential substrates, glycosidically-bound N-acetylneu-
rarninic acids. This is also illustrated in man, by the exist-
ence of several severe genetic diseases associated with a 
neuraminidase deficiency (see chapter III). 
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Fig. II.l. Structure of the N-acetylneurarninic acid containing 
substrates of neuraminidase. R-, represent other carbohydrate 
residues, which are bound to the AGLYCON part. 
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II.2. SUBSTRATE SPECIFICITY 
The substrate specificity of neuraminidases is determined 
by several features of the substrate (for review see Corfield 
et al. 1981) (Fig. II.l.) 
-The structure of the neuraminic acid residue itself 
(N-acetyl, N-glycolyl, N-acyl, 0-acetyl derivatives). 
-The nature of neighbouring sugars {usually D-galactose, but 
also N-acetyl-D-galactosamine, N-acetyl-D-glucosamine or 
other neuraminic acid residues). 
-The type of linkage by which NANA is linked to neighbouring 
sugars (2-3, 2-4, 2-6 or 2-8). 
-The size of the carbohydrate portion (Keilich et al. 1979). 
-The structure of the aglycon part to which the neuraminic 
acid residues containing carbohydrate chains are linked. 
Knowledge about the substrate specificity may be import-
ant for the understanding of (patho) physiological functions 
(chapter II.l.). Experiments with different natural or synthe-
tic neuraminic acid residues have provided information on the 
parts of the neuraminic acid residue that are important for 
enzyme-substrate recognition, binding and eventually hydroly-
sis (for review see Drzeniek 1973, Corfield et al. 1981, 
Schauer 1982). Only ~-glycosides of neuraminic acid are 
cleaved. The only existing 6-glycoside of neuraminic acid 
exists in cytidine-monophosphate (CMP)-neuraminic acid, which 
is not a substrate for neuraminidase, independent of the 
source of the neuraminidase. Substrate specificity of neurami-
nidases was identical in different species independent of the 
neuraminic acid residue itself. The same holds for the a-
linkage specificity which is a general characteristic for all 
neuraminidases. After hydrolysis the a-anomer mutarotates in 
water to the 6-anorner (Friebolin et al. 1980). 
The naturally occurring neuraminic acids bear on C-atom 5 
an acetyl (N-acetylneuraminic acid, NANA) or glycolyl (N-gly-
colylneuraminic acid) residue; NANA is hydrolysed prefer-
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entia11y (Corfie1d et a1. 1980). Synthetic modification of N-
substitution with e.g. N-formyl or N-propionyl derivatives 
results in reduced cleavage rates (Brossmer and Nebelin 1969). 
Further important structural features for the hydrolysis 
of bound neuraminic acid residues by neurarninidases are the 
presence of a negative charge on C-atom 1 (Brossmer and 
Holmquist 1971), and a free OR-group on C-atorn 4, with excep-
tions for some viral neuraminidases (Schauer 1982). For ma-
ximum activity also the side chain (C7-C9) is important. 
Shortening leads to progressive decrease in the rate of hydro-
lysis (Veh et al. 1977}. When neuraminic acid residues are 
present at a terminal position of a carbohydrate side chain 
cleavage may not occur Oirectly because of steric hinOrance 
(for instance in GMl ganglioside} (Drzeniek 1973, Svennerholm 
1980}, but only after removal of the other carbohydrate chain. 
Neurarninidases are heterogeneous in their specificity 
towards the aglycon part. Viral ana bacterial neuraminidases 
appear to be rather unselective, in contrast to the mammalian 
neuraminidases which at this point are very selective. By 
using immobilized N-(4-nitrophenyl)-oxarnic recognition of 
substrates by neurarninidases was found to be influenced by a 
hydrophobic centre in the enzyme, distinct from the catalytic 
site (Brossmer et a1. 1977, Kei1ich et al. 1979). 
The next section of this chapter will mainly discuss 
mammalian neuraminidases. Substrate specificity studies of 
these enzymes have been hampered by the impurity of the neur-
aminidase preparations and accordingly reliable information is 
only scarcely available. The data obtained sofar will be 
discussed in the next section describing the evidence for the 
existence of different neuraminidases. 
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II.3. DIFFERENT NEURAMINIDASE$ 
In contrast with neuraminidases from microorganisms mam-
malian neuraminidases form a heterogeneous group. This is 
shown by the many forms of neuraminidase that have been found, 
with rather different substrate specificities concerning the 
aglycon part of the substrates, depending on species, tissue, 
or even subcellular localization. Whether all these neurarnini-
dases are genetically related or present different gene 
products remains still an open question. (for reviews see 
Cor field et al. 1981, Veh and Sander 1981). 
Mammalian neuraminidases have been studied in various 
species {rat, pig and cow) and tissues such as heart muscle 
{Tallman and Brady 1973), brain (Schengrund and Rosenberg 
1970, Carubelli and Tulsiani 1971, Venerando et al. 1975, 
1985; Cruz and Gurd 1981), liver (Aldaheff and Wolfe 1981, 
Michalski et al. 1982) spleen (Schengrund et al. 1979), kidney 
(Cohen-Forterre et al. 1984) , thyroid gland (Van Dessel et al. 
1984), placenta (McNamara et al. 1982), leucocytes (Nguyen 
Hong et al. 1980, Schauer et al. 1984), and cultured fibro-
blasts (Caimi et al. 1979, zeigler and Bach 1981). 
However, it has been hardly possible to obtain suffi-
ciently pure preparations allowing reliable studies on 
substrate specificity and genetic and molecular character-
ization. 
The neurarninidases are very heterogeneous in respect to 
their subcellular localization. Soluble and particulate forms 
of the enzyme have been found, but it cannot always be ex-
cluded that one form is derived from the other as a result of 
the experimental manipulation. Mammalian neurarninidases have 
been localized in the plasma membrane, microsomes, Golgi appa-
ratus, lysosornes and the cytosol (Tulsiani and Carubelli 1972, 
Visser and Ernrnelot 1973, Kishore et al. 1975, Venerando et al. 
1975). Different biochemical properties such as the Km value 
and sensitivity to certain treatments have been reported. 
These different neuraminidase activities may vary in relative 
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amounts among different species and tissues. 
Concerning the substrate specificity two groups of neur-
arninidases can be distinguished: 
-neuraminidases with specificity for sialoglycolipids 
(gangliosides). 
-neuraminidases with specificity for sialyl linkages in 
oligosaccharides and glycoproteins. 
Evidence has accumulated that these two groups of neur-
arninidases are derived from different gene products by the 
discovery of two different genetic diseases in man: Mucolipi-
dosis IV, a ganglioside specific neuraminidase deficiency, 
sialidosis, due to lysosomal oligosaccharide/glycoprotein 
specific neuraminidase deficiency (see chapter III) 
Neurarninidases of the first group seem to be primarily 
located in the plasma membrane of various cells of which brain 
tissue has been studied best. The highest specific activity 
has been found in the synaptosomal me~brane {Ohman et al. 
1970, Schengrund and Rosenberg 1970, Tettamanti et al. 1972, 
Yohe and Rosenberg 1977). However this ganglioside specific 
neuraminidase activity is also found in the cytosolic 
fractions of brain tissue and liver (Tulsiani and Carubelli 
1970 and 1972, Venerando et al. 1975 and 1978). 
Neuraminidases of the second group, acting on sialyl 
linkages in oligosaccharides and glycoproteins, seem to be 
primarily located in lysosomes (Mahadevan et al. 1967, Horvat 
and Touster 1968, Tulsiani and Carubelli 1970) Some activity 
has also been attributed to the plasma membrane (Visser and 
Emmelot 1973) Golgi (Kishore et al. 1975), and cytosol 
(Tulsiani and Carubelli 1970). It is not yet clear whether 
this is of physiological importance, or is due to experimental 
manipulation or contamination of the subcellular fractions. 
It is evident that reliable data about biochemical, mol-
ecular, physiological (substrate specificity}, and genetic 
characteristics of neurarninidases can only be obtained once 
sufficiently purified preparations are available. 
A main problem in the research of the past has been the 
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lack of a reliable and sensitive assay for neuraminidase. The 
most frequently used chromogenic assay is not only laborious, 
but also prone to misinterpretations, especially when used for 
crude preparations, with interfering substances. Recent 
methods enabled a more sensitive and reliable assay. The 
artificial fluorogenic substrates have been of great value in 
the (prenatal) diagnosis of genetic disease involving neurami-
nidase deficiency (Kleijer et al. 1979). In basic research 
these substrates have also been useful during purification 
procedures (Ngyuen Hong et al. 1980, McNamara et al. 1982, 
Spa1tro and A1daheff 1984, Van Dessel et al. 1984). Radio1a-
beled natural substrates or the use of adapted chromogenic 
procedures after removal of interfering substances have great-
ly improved studies on substrate specificity (Cohen-Forterre 
et a1. 1984). 
Recently, a cytosolic neuraminidase from rat liver has 
been purified to homogeneity (Miyagi and Tsuiki, 1985). This 
enzyme (molecular mass 43 kDa) appeared to be active towards 
sialyloligosaccharides, sialoglycoproteins as well as sialo-
glycolipids (gangliosides) , and shows a pH optimum around pH 
6.5, suggesting a physiological function in desialylation in 
extralysosomal compartments. This demonstrates that a classi-
fication in oligosaccharide/glycoprotein specific neuramini-
dases and ganglioside specific neuraminidases is not satisfac-
tory. Some neuraminidases apparently have activity towards 
both types of substrates whereas others have a higher specifi-
city. 
In cultured human fibroblasts at least two 
neuraminidases can be distinguished on the basis 
different 
of their 
subcellular localization and defined substrate specificity 
(Cantz and Messer 1979, Zeigler and Bach 1981, Mendla and 
Cantz 1984). First of all there is a lysosomal neuraminidase 
with an acid pH optimum around pH 4.0, probably membrane-bound 
and extremely labile and its activity primarily towards oligo-
saccharides and glycoproteins, although some investigators 
also reported some activity towards gangliosides (Chigorno et 
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al. 1986, Mancini et al. 1986a}. Secondly there is a neurami-
nidase probably located in the plasma membrane that acts ex-
clusively on gangliosides (Cantz and Messer 1979, Zeigler and 
Bach 1981). The linkage specificity (a2-3 or a2-6) suggested 
earlier (Strecker and Michalski 1978 ) seems not to exist 
(Mendla and Cantz 1984). 
The interest in different human neuraminidases has been 
stimulated by the discovery of several inherited human 
diseases associated with a neuraminidase deficiency. (see 
chapter III). At least two neurarninidases are involved in 
these diseases: one acting on oligosaccharides and glyco-
proteins and one acting on gangliosides. 
An exact characterization of mammalian (preferably human) 
neurarninidases is important both for a reliable prenatal diag-
nosis of the different diseases, and for a better under-
standing of the pathophysiological features in the different 
clinical variants of each of these diseases. On the other hand 
the study of human cell material with a neuraminidase defi-
ciency may be of great help in defining and characterizing the 
normal neuraminidases and for attributing specific physiologi-
cal functions to them. 
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CHAPTER III 
NEIJRAMINIDASE INVOLVEI!EIIT IN 
HUMAN GENETIC DISEASE 
III.l. CLINICAL AND GENETIC ASPECTS 
Research on neuraminidases has been stimulated by the 
discovery of different genetic disorders associated with a 
deficiency of neuraminidase activity. A neuraminidase defi-
ciency was first demonstrated in patients with an autosomal 
recessive disease originally described as 
(Spranger and Wiedemann 1968) by Cantz et al. 
et al. (1977) and Kelly and Graetz (1977). 
Mucolipidosis I 
(1977) , Spranger 
Biochemical investigations showed an accumulation of 
sialic acid containing compounds in cultured fibroblasts and 
leucocytes from these patients, excessive urinary excretion of 
sialyl oligosaccharides, and a profound deficiency of an acid 
neuraminidase which normally cleaves sialic acid residues from 
oligosaccharides (sialyllactose) and glycoproteins (fetuin). 
Clinically these patients exhibited features of a lysosomal 
storage disorder resembling Hurler disease, with an 
onset (signs of illness developed in the first year of 
In the same period some patients were described 
early 
life). 
with 
similar biochemical features, but with a milder clinical phe-
notype: absence of mental retardation and longer survival. 
These patients were described as new. types of Mucolipidosis I 
or as cherry-red spot-myoclonus syndrome (Strecker et al. 
1977, Durand et al. 1977, O;Brien 1977, Thomas et al. 1978, 
Rapin et al. 1978) . 
Several patients originally classified as atypical forms 
of GM1-gangliosidosis variants (Pinsky et al. 1974, Loonen et 
al. 1974, Galjaard et al. 1975, Suzuki et al. 1977, Andria et 
al. 1978) were later found to have a combined deficiency of 
lysosomal S-galactosidase and neuraminidase (Wenger et al. 
1978, Hoogeveen et al. 1980). Within each of these syndromes 
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the clinical heterogeneity is considerable. 
Since clinical manifestations have been used for classi-
fication without 
background, a lot 
considering the genetic 
of confusion about the 
and molecular 
nomenclature of 
disorders associated with neuraminidase deficiency was intro-
duced (Lowden and O'Brien 1979). 
At this moment the term Sialidosis (Durand et al. 1977) 
has been accepted for the category of patients with an iso-
lated neuraminidase deficiency (the former Mucolipidosis I and 
cherry-red spot-myoclonus syndrome), and patients with a com-
bined 6-galactosidase/neuraminidase deficiency are now classi-
fied as Galactosialidosis (Andria et al. 1980). Somatic cell 
hybridization studies demonstrated that these two syndromes 
are caused by mutations in different genes (see also chapter 
IV) (for reviews see Lowden and O'Brien 1979, Wiesmann and 
Herschkowitz 1980, Cantz 1980, in: Tettamanti et al. (eds) 
1981, O'Brien 1982, Ga1jaard et a1. l984a and 1984b, Cantz et 
al. 1984). 
Patients with Mucolipidosis II (I-cell disease) (Leroy 
and Spranger 1970), although presenting a severe neuraminidase 
deficiency, should not be classified among the Sialidoses, 
since the neuraminidase defect is only of one many lysosomal 
enzyme defects, all due to the same defective posttranslatio-
nal modification (Reitman et al. 1981, Hasilik et al. 1981). 
Two other types of neuraminidase deficiency associated 
disorders have been recognized, which also do not fit into the 
Sialidosis group, and which cannot be properly classified 
until the primary defect has been elucidated: Mucolipidosis IV 
with a supposed ganglioside-specific neuraminidase deficiency 
(Bach et al. 1979, Caimi et a1. 1982, Ben-Yoseph et a1. 1982) 
and some variants of Morquio disease type A with a partial 
oligosaccharide neuraminidase deficiency, which is probably a 
secondary effect of the primary defect N-acetylgalactosamine-
6-su1phate su1phatase (G1Bss1 et al. 1984). 
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III.2. SIALIDOSIS 
The Sialidoses can be divided into two main groups with 
distinct clinical phenotypes: 
1. A mild, normomorphic form. 
2. A severe, dysmorphic forrri. 
ad 1) The mild normomorphic form is characterized by the 
absence or a minimal mental retardation, cherry red spots, 
myoclonus and progressive blindness, and no dysrnorphic fea-
tures or bony involvement. 
In the past these patients have been classified as adult 
variants of Mucolipidosis I or cherry-red spot-myoclonus syn-
drome. A high proportion of these patients is of Italian 
ethnic origin. (for review see Lowden and O'Brien 1979). 
ad 2) The severe dysmorphic form is characterized by moderate 
to severe mental retardation, Hurler like facial features, 
kidney involvement, bony involvement, cherry-red spots, myo-
clonus and a rapidly progressive clinical course. 
Previously these patients were described as Mucolipidosis 
I or the Goldberg syndrome. 
Wiedeman 1970, Spranger 1981). 
(for review see Spranger and 
Biochemically all patients are characterized by elevated 
levels of bound N-acetylneuraminic acid in urine and cultured 
fibroblasts. The responsible protein defect was elucidated as 
an oligosaccharide/ glycoprotein specific lysosomal neuramini-
dase deficiency (Cantz et al. 1977, O'Brien, 1977). The normal 
enzyme cleaves a2-3 as well as a2-6 linkages but the mutant 
enzyme retains higher residual activity towards the former, 
resulting in preferential storage and urinary excretion of 
a2-6 linked oligosaccharides (Cantz et al. 1977, O'Brien 1982, 
Cantz et al. 1984). Further support for neuraminidase defi-
ciency as the primary gene defect was the observation of half-
normal enzyme activities in the parents of patients (gene-
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dosage effect) (for review see Lowden and O'Brien 1979). The 
neuraminidase acting on gangliosides is not affected (Cantz 
and Messer 1979, Cantz et al. 1984). 
Considerable clinical heterogeneity is found, not only 
between the two groups, but also within each of them (infan-
tile juvenile and adult forms) (Lowden and O'Brien 1979, 
Spranger 1981, Becket a1. 1984). This heterogeneity is prob-
ably due to different allelic mutations affecting the neurami-
nidase gene(s), which may lead to different residual activi-
ties in vivo. 
Recent gene localization studies (Mueller et al. 1986} 
suggest the presence of two genes essential for neuraminidase 
activity. This is in agreement with our studies presented in 
chapter IV, which provide evidence for the existence of two 
different neuraminidase subunits essential for its catalytic 
activity~ 
Molecular characterization of the defects and their alle-
lic variants will only be possible when purification and 
characterization of the neuraminidase involved has been per-
formed, and when antibodies become available (see chapter IV)~ 
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III.3. GALACTOSIALIDOSIS 
Several patients originally described as variant forms of 
GM1-gangliosidosis, were later found to have a combined defi-
ciency of an oligosaccharide neuraminidase and B-galactosi-
dase. These patients had earlier been classified as Sialidosis 
type 2, because of a supposed primary neuraminidase deficien-
cy. Somatic cell hybridization studies (see chapter IV) demon-
strated, however, that the combined B-galactosidase-neuramini-
dase deficiency was genetically unrelated to the isolated 
neuraminidase deficiency in Sialidosis. (for reviews see 
Andria et a1. 1981, Galjaard et al. 1984a, b). 
As in most other lysosomal storage diseases, different 
clinical phenotypes of Galactosialidosis have been recognized. 
Patients with the early-infantile form, show severe edema, 
ascites, skeletal dysplasia and ocular abnormalities, and die 
shortly after birth (Kleijer et al. 1979, Gravel et al. 1979). 
Patients with the late-infantile form present after 6-12 
months with dysmorphism, dysostosis and skeletal dysplasia, 
visceromegaly, macular cherry-red spot and mild mental retar-
dation (Pinsky et al. 1974, Andria et al. 1981, Strisciuglio 
et al. 1984). The largest number of patients, mainly of Japa-
nese origin are those with the juvenile/adult form where 
symptoms appear in late childhood or early adulthood. The 
major features are skeletal dysplasia, dysrnorphism, corneal 
clouding, macular cherry-red spot, angiokeratomata, neurologi-
cal manifestations and mental retardation (Loonen et al. 1974, 
1984; Suzuki et al. 1983, 1984). 
The responsible molecular defect in Galactosialidosis 
appeared to be a deficiency of a 32 KDa glycoprotein {d'Azzo 
1982, d'Azzo et al. 1982), subsequently shown to be required 
for the aggregation of 6-ga1actosidase monomers (see chapter 
IV}. The high molecular weight aggregate was found to be 
essential to protect the 6-galactosidase against rapid intra-
lysosomal proteolytic degradation. The explanation for the 
neuraminidase deficiency is discussed in chapter IV. 
Gene localization 
structural gene for this 
et aL 1985). 
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experiments 
32 kDa protein 
have assigned the 
on chromosome 22 (Sips 
Recently molecular characterization of the different 
variants of Galactosialidosis was performed by irnmunoprecipi-
tation studies of the 32 kDa protective protein and its 54 kDa 
precursor form (Palmeri et al. 1986, see also chapter IV). 
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III.4. MUCOLIPIDOSIS IV 
Mucolipidosis type IV is a lysosomal storage disorder, 
first recognized in 1974 (Berman et al. 1974), which 
clinically is characterized by congenital cloudy cornea and 
slow progressive, severe mental and motor deterioration, 
without visceral involvement. 
Patients reported until now are mainly of Jewish Ashkena-
zi origin and range in age from 6 months to the mid-twenties. 
Lysosomal storage of gangliosides, phospholipids and acid 
mucopolysaccharides has been found (for review see Bach and 
Zeigler 1981) • 
The neuraminidase active towards gangliosides has been 
reported to be partially deficient in cultured amniotic fluid 
cells and fibroblasts (Bach et al. 1979, Caimi et al. 1982). 
Other investigators, however, could not reproduce this finding 
(Sandhoff, personal communication). Ganglioside neuraminidases 
have been localized primarily in plasma membranes but a 
lysosomal localization cannot be ruled out completely (Zeigler 
and Bach 1985, Chigorno et a1. 1986). 
Recently evidence has been presented that subcellular 
distribution of the ganglioside neuraminidase is abnormal in 
fibroblasts from patients with Mucolipidosis IV (Zeigler and 
Bach 1985). 
Accurate 
sensitive and 
subcellular fractionation studies and a 
reliable assay for ganglioside neuraminidase 
are required before definite conclusions will be possible. 
Purification of ganglioside neuraminidase(s) will be the first 
essential step, followed by a molecular characterization in 
normal and mutant fibroblasts. 
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CHAPTER IV 
THE EXPERIMENTAL WORK 
IV.l. AIM OF THE WORK PRESENTED IN THIS THESIS 
Several autosomal recessive inheritable lysosomal storage 
disorders are known which are associated with a deficiency of 
lysosomal 6-galactosidase (GM1-gangliosidosis), a lysosomal 
neuraminidase {Sialidosis), or of both s-galactosidase and 
neuraminidase (Galactosialidosis) (see chapter III). Within 
each syndrome there are progressive infantile, somewhat later-
onset juvenile, and still milder adult forms. 
The aim of the work presented in this thesis was the 
elucidation of the genetic and biochemical background of the 
three syndromes mentioned above and their variant forms. 
The emphasis of the experimental work is on the molecular 
characterization of neuraminidase and on the clarification of 
its deficiency in combined 8-galactosidase/neuraminidase de-
ficiency (Galactosialidosis). 
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IV.2. DISCUSSION 
a. Genetic background 
Somatic cell hybridization studies on fibroblasts from 
classical infantile forms of GM1-gangliosidosis and cells from 
atypical patients at that time also classified as variant 
forms of GM1-gangliosidosis, showed that two different genes 
were involved in these two categories of diseases {Galjaard et 
al., 1975). Later, Wenger et al. (1978) found in another 
atypical patient with S-galactosidase deficiency a coexistent 
neuraminidase deficiency. 
Subsequently we have tested fibroblasts from different 
atypical patients (Pinsky et al. 1974, Loonen et al. 1974, 
Andria et al.. 1978, Kleijer et al. 1978) all of which were 
found to have a combined S-galactosidase and neuraminidase 
deficiency. 
Subsequently, somatic cell hybridization studies have 
been performed to elucidate the genetic background of this 
combined deficiency, the isolated neuraminidase deficiency in 
Sialidosis and the multiple lysosomal enzyme deficiency in "I-
cell disease". 
The results of these studies are reported in publica-
tion I. Restoration of neuraminidase activity was found in 
heterokaryons after fusion of cells from patients with differ-
ent clinical variants of Mucolipidosis I (Sialidosis) and 
cells from patients with different clinical variants of com-
bined B-galactosidase/neuraminidase deficiency. It was there-
fore concluded that the single neuraminidase deficiency in 
Sialidosis is caused by a mutation in a different gene than 
that involved in B-galactosidase/neuraminidase deficiency 
(Galactosialidosis). The results of these complementation ex-
periments have subsequently been confirmed using natural gly-
coprotein substrates (Swallow et al. 1981). 
Together with the earlier observations on B-galactosidase 
complementation (Galjaard et al. 1975) it could be concluded 
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that the three disorders associated with 6-galactosidase 
and/or neuraminidase deficiency are caused by mutations in 
three different genes. 
Recent gene-localization studies (Sips et al. 1985) have 
confirmed and extended this observation: the structural gene 
coding for B-galactosidase is on chromosome 3 and the gene 
coding for the 32 kDa protein, which is responsible for the 
combined S-galactosidase and neuraminidase deficiency is on 
chromosome 22. Genes coding for neuraminidase have been as-
signed to chromosome 10 and 20 (Mueller et al. 1986). 
No complementation was observed after somatic cell hybri-
dizatio~ of different variants within one disease, suggesting 
the involvement of different mutations within the same gene 
(allelic mutations) . 
Another important finding in publication I is the in-
crease of neuraminidase deficiency during cocultivation with 
neuraminidase deficient sialidosis cells. This was the first 
indication for the existence of a corrective factor. 
Finally publication I demonstrates that !-cell disease is 
genetically different from the other neuraminidase deficien-
cies. Subsequent biochemical analysis showed that I-cell 
disease is due to a defect in a posttranslational modification 
step (phosphorylation) , which is essential for a proper lyso-
somal compartmentalization of lysosomal proteins (see chapter 
I. 3). 
b. Biochemical background Galactosialidosis (a-gal-/neur-) 
and Sialidosis (neur ). 
d'Azzo et al. (1982) demonstrated that in normal human 
fibroblasts a-galactosidase is synthesized as a 85 kDa pre-
cursor form which is "processed 11 by a number of steps to a 
mature 64 kDa protein. a-Gal-/neur-fibroblasts were found to 
synthesize this 85 kDa precursor form normally, but mature 64 
kDa a-galactosidase is not or barely detectable. 
Turn-over studies of human a-galactosidase and uptake-
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experiments using bovine testis 6-galactosidase suggested 
rapid proteolytic degradation of B-galactosidase in Galacto-
sialidosis cells (van Diggelen et al. 1981, 1982). Studies by 
d'Azzo et al. {1982) provided evidence that this rapid degra-
dation is correlated with the deficiency of an until then 
unknown 32 kDa protein ("protective protein"). The reason for 
the neuraminidase deficiency in Galactosialidosis could not be 
clarified at that stage. A relation between 6-galactosidase, 
the protective protein and neuraminidase was, however, evi-
dent. 
1. Relation S-galactosidase-protective protein. 
The experimental work described in publication II clari-
fies the relation between the protective protein and a-ga-
lactosidase. Sucrose-density gradient studies revealed that in 
normal fibroblasts 80-90% of the a-galactosidase exists as 
high molecular weight multimer. The protective protein was 
found to play an essential role in the aggregation of mono-
meric a-galactosidase (64 kDa) into multimeric a-galactosidase 
(600-700 kDa). Because of the absence of protective protein 
molecules in Galactosialidosis, no multimers can be formed and 
apparently monomeric a-galactosidase is rapidly degraded by 
lysosomal cathepsins. This explains the observed a-galactosi-
dase deficiency. 
With ammonium chloride, secretion of the 54 kDa precursor 
of the protective protein can be stimulated (Hoogeveen et al. 
1981), enabling its partial purification. When this 54 kDa 
precursor is added to the medium above a-gal-/neur- cells a 
correction of a-galactosidase activity is found. This cor-
rection is accompanied by the formation of rnultimeric forms of 
a-galactosidase. Subsequent immuno-electron-microscopical 
studies indicated that this restoration of multimers also 
occurs in vivo (Willemsen et al. 1986). 
2. Relation a-galactosidase-protective protein-neuraminidase. 
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The relation between the 32 kDa protective protein and 
neuraminidase was still unclear. Addition of a concentrate of 
medium above human fibroblasts, to Galactosialidosis cells 
resulted in a restoration of both B-galactosidase and neurami-
nidase activity (Hoogeveen et al. 1981). The mechanism, how-
ever, remained unexplained, especially since ingested neurami-
nidase from bovine testis was not rapidly degraded by Galacto-
sialidosis cells (Verheijen, unpublished data). In experiments 
described in publication III it was demonstrated that in 
bovine testis lysosomal neuraminidase exists in a complex 
together with 6-galactosidase and the 32 kDa protein. Later, 
it could be demonstrated that this B-galactosidase-protective 
protein-neuraminidase complex is also present in other cell 
types like human fibroblasts (unpublished data), human leuco-
cytes {see publication VI), and human placenta (see 
publication IV). 
3. Purification of human lysosomal neuraminidase. 
In publication IV a start has been made with the purifi-
cation of the labile lysosomal human neuraminidase. This be-
came possible because part of the lysosomal neuraminidase 
activity in human placenta, present in a soluble inactive 
form, could be activated and stabilized by excessive con-
centration followed by preincubation at 37°C. Now, partial 
purification 
purification 
of human lysosomal neuraminidase analogous to the 
described for bovine testis 
cation III) could be performed, as well 
neuraminidase (publi-
as further studies on 
the relation between B-galactosidase and neuraminidase. 
Polyclonal antibodies raised against B-galactosidase and 
protective protein coprecipitate the neuraminidase activity. 
Sucrose density gradient centrifugation demonstrated that 
neuraminidase activity is exclusively present in high-density 
fractions associated with B-galactosidase. 
Monospecific antibodies against 64 kDa B-galactosidase 
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precipitate 6-galactosidase activity both in the monomeric 
fractions as in the multimeric fractions. However, purified 
monospecific antibodies against the 32 kDa protective protein 
precipitate only S-galactosidase present in rnultimeric forms. 
In addition they precipitate the neuraminidase activity asso-
ciated with the high-density multimeric form of a-galactosi-
dase. Since neuraminidase activity can be restored upon forma-
tion of high-density rnultimeric forms, evidence is obtained 
for a direct relation between neuraminidase activity and the 
presence of the 32 kDa protective protein. 
The direct relation between neuraminidase activity and 32 
kDa protective protein clarifies the deficiency of neuramini-
dase activity 
tective protein 
Additional 
in Galactosialidosis, where the 32 
is absent (d'Azzo et al. 1982), 
evidence for a direct role of 
kDa pro-
protein 
(Mendla 
cular 
in neuraminidase activity was obtained 
the protective 
by Cantz' group 
1983), who demonstrated 
factor essential for the 
the presence of a macromole-
oligosaccharide/glycoprotein 
specific neuraminidase activity from pig kidney. This factor 
could bind reversibly to the enzyme and showed characteristics 
of a protein. It is likely that this activating factor in pig 
kidney is identical with the protective protein in human 
tissues. 
The data in publication IV further suggest that associa-
tion of different subunits is essential for neuraminidase 
activity. One of these is the 32 kDa protective protein, but 
the others remained to be identified. 
In publication V the purification of these different 
neuraminidase subunits is described using a procedure based on 
the findings in publication IV. Activated and stabilized human 
placental neuraminidase is copurified with S-galactosidase 
using a-galactosidase specific affinity chromatography. Subse-
quently neuraminidase is dissociated from the S-galactosidase-
protective protein-neuraminidase complex by the chaotropic 
agent KSCN. The a-galactosidase specific affinity chromato-
graphy step is repeated to remove the a-galactosidase-pro-
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tective protein complex. The resulting inactive neuraminidase 
preparation was used to raise antibodies. Finally the 32 kDa 
protective protein was dissociated from the complex with 8-
galactosidase and purified to homogeneity. 
This experimental work shows that besides the 32 kDa 
subunit another neuraminidase subunit of 76 kDa is essential 
for the activity of lysosomal neuraminidase. This 76 kDa 
subunit is probably the clue to the elucidation of the bioche-
mical background of Sialidosis variants in which an isolated 
neuraminidase deficiency has been demonstrated. The antibodies 
against this subunit may provide a valuable tool to probe the 
nature of the molecular defect in Sialidosis. 
c. Biochemical diagnosis of neuraminidase related disorders 
When (Galacto)sialidosis is assumed on the basis of cli-
nical symptoms usually enzyme assays on total leucocytes or 
cultured skin fibroblasts are performed for a definite diagno-
sis. 
In publication VI it is, however, shown that a total 
leucocyte preparation contains two different types of lysoso-
mal neuraminidases both acting on the artificial substrate 4-
methylurnbelliferyl-N-acetylneuraminic acid (4 MU-NANA). Only 
one of which is genetically deficient in (Galacto)sialidoses. 
This makes a total leucocyte preparation an inadequate source 
of diagnostic material, because these cells from patients with 
(Galacto)sialidoses may show neuraminidase activities as high 
as 40% of normal values. In isolated lymphocytes, however, the 
lysosomal neuraminidase involved in genetic disease, comprises 
more than 85% of the total neuraminidase activity and these 
cells are therefore a reliable tool for diagnosis. 
Many investigators have tried to relate residual enzyme 
activity to the severity of the clinical features. In Siali-
doses and Galactosialidoses the heterogeneity can be summa-
rized as follows: 
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Sialidosis: 
- infantile, progressive forms neur. activity < 1% 
- milder forms without severe men-
tal retardation 1% < neur. act.< 10% 
Galactosialidosis: 
- early infantile forms B-gal.act. 5-15% neur. act. 5% 
- late infantile forms 8-gal.act. 5-15% neur. act. 1% 
juvenile/adult forms B-gal.act. 5-15% neur. act. 1% 
An attempt to relate clinical symptoms and residual (en-
zyme) protein activity is likely to be a simplification of a 
much more complex situation. First of all most biochemical 
assays are performed in vitro on homogenates of a selected 
cell type with an artificial substrate. Furthermore the clini-
cal symptoms reflect a complex disturbance in the pathophysio-
logy of different organs and cell types. A genetic (enzyme) 
protein deficiency may have very different consequences in 
different cell types and organs within one organism. In addi-
tion there may be considerable clinical and pathological hete-
rogeneity among different patients with the same genetic meta-
bolic disease. 
Publication VII reports on the molecular background of 
such clinical heterogeneity in patients with Galactosialido-
sis. 
In all three clinical phenotypes (see table above) the B-
galactosidase and neuraminidase deficiencies are secondary 
phenomena to the lack of the 32 kDa protective protein (see 
previous section b). We have therefore studied the biosynthe-
sis of this 32 kDa protein in the different clinical variants. 
In the early infantile form no 32 kDa protein can be detected 
and only very little of its 52 kDa precursor. 
Cells from patients with the late infantile form, how-
ever, do show an excessive amount of 52 kDa precursor and a 
small amount of 32 kDa protein. Different experiments demon-
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strated that in this clinical variant the mutation interferes 
with the posttranslational modification of the 52 kDa pre-
cursor. The small residual amount of 32 kDa protein is appa-
rently sufficient to yield a 1-5% neuraminidase activity, 
which could be stimulated by leupeptin treatment. This latter 
substance inhibits proteolytic degradation which explains the 
increase of the amount of 32 kDa protein. The experimental 
work described in publications IV and V demonstrated that this 
32 kDa protein is an essential part of neuraminidase. 
In the juvenile/adult form no 32 kDa protein can be 
detected, but the amount of 52 kDa precursor seems to be some-
what higher than in the early infantile form. Despite the 
further molecular characterization of the different clinical 
phenotypes we cannot yet provide an explanation for the mild 
clinical course of the juvenile/adult form. 
Further studies on the exact primary, secundary and ter-
tiary structure of the neuraminidase subunits and on the 
stoichiometry of the components of the lysosomal S-galactosi-
dase-protective protein-neuraminidase complex are now re-
quired. The results of such studies will contribute to the 
understanding of the mechanisms involved in the protection of 
lysosomal proteins against the hydrolytic activity of neigh-
bouring enzymes and they may provide a better insight in the 
pathogenesis of the clinical heterogeneity among the neurami-
nidase related disorders. 

51 
REFERENCES 
Andria, G., Del Giudice, E., Reuser, A.J.J. (1978). Atypical 
expression of S-galactosidase deficiency in a child with 
Hurler-like features but without neurological 
abnormalities. Clin. Genet. 14, 16-23. 
Andria, G., Strisciuglio, P., Pontarelli, G., Sly, W.S. and 
Dodson, W.E. (1981). Infantile neuraminidase and 
B-galactosidase deficiencies (galactosialidosis) with 
mild clinical courses. In: Sialidases and ialidoses. 
Perspectives in inherited metabolic diseases, Vol. 4 
(eds. Tettamanti, G., Durand, P. and DiDonato, S.) pp. 
379-395. Edi. Ermes, Milan. 
Appelmans, F., Wattiaux, R. and de Duve C. {1955). Tissue 
fractionation studies. 5. The association of acid 
phosphatase with a special class of cytoplasmic granules 
in rat liver. Biochem. J. 59, 438-445. 
Ashwell, G. and Morell, A. G. (1974). The role of surface 
carbohydrates in the hepatic recognition and transport of 
circulating glycoproteins. Adv. Enzymol. 41, 99-128. 
Bach, G., Zeigler, M., Schaap, T. and Kohn, G. (1979). 
Mucolipidosis type IV: ganglioside sialidase deficiency. 
Biochem. Biophys. Res. Commun. 90, 1341-1347. 
Bach, G. and Zeigler, M. (1981). Sialidase in mucolipidosis 
type IV: the deficiency of lysosomal ganglioside siali-
dase. In: Sialidases and Sialidoses. Perspectives in 
inherited metabolic diseases, Vol.4 (eds. Tettamanti, G., 
Durand, P. and Di Donato, S.) pp. 249-259. Edi.Ermes, 
Milan. 
Barranger, J.A. (1984). Marrow transplantation in genetic 
disease. New. Eng. J. Med. 311, 1629-1631. 
Barranger, J.A. and Brady, R.O. (eds.) (1984). Molecular basis 
of lysosomal storage disorders. Academic Press Inc. 
Barrett, A.J. and Heath, M.F. (1977). Lysosomal enzymes. In: 
Lysosomes, a laboratory handbook (ed. Dingle, J.T.) pp. 
19-146. Elsevier/North-Holland, Amsterdam. 
Beck, M., Bender, s.w., Reiter, H.-L., Otto, w., Bgssler, R., 
Dancygier, H. and Gebler, J. (1984). Neuraminidase 
deficiency presenting as non-immune hydrops fetalis. 
Eur. J. Pediatr. 143, 135-139. 
Ben-Yoseph, Y., Momoi, T., Hahn, L.C., Nadler, H.L. (1982). 
Catalytically defective ganglioside neuraminidase in 
mucolipidosis IV. Clin. Genet. 21, 374-381. 
Berman, E.R., Livni, N., Shapira, E., Merin, s. and Levij, 
J.S. (1974). Congenital corneal clouding with abnormal 
systemic storage bodies: a new variant of mucolipidosis. 
J. Pediatr. 84, 519-526. 
52 
Berthet, J. and de Duve, C. (1951) .Tissue fractionation 
studies. 1. The existence of a mitochondria-linked, 
enzymically inactive form of acid phosphatase in rat-
liver tissue. Biochern. J. 50, 174-181. 
Brambati, B., Simoni, G. and Fabre, S. {eds.) (1985). 
Chorionic villus sampling; fetal diagnosis of genetic 
diseases in the first trimester. Marcel Dekker Inc., New 
York. 
Brossrner, R. and Nebelin, E. (1969). Synthesis of N-forrnyl-
and N-succinyl-D-neuraminic acid. Febs Lett. 4, 335-336. 
Brossmer, R. and Holnquist, L. (1971). On the specificity of 
neuraminidase. Hoppe-Seyler's z. Physiol. Chern. 352, 
1715-1719. 
Brossmer, R .. , Ziegler, D. and Keilich, G. (1977). Selective 
isolation of vibrio cholerae neuraminidase using an 
immobilized 4-(Nitrophenyl) oxamic acid. Hoppe-Seyler's 
z. Physiol. Chern. 358, 397-400. 
Brown, M.S., Anderson, R.G.W. and Goldstein, J.L. (1983). 
Recycling receptors: the round-trip itinerary of migrant 
membrane proteins. Cell 32, 663-667. 
Brown, M.S. and Goldstein, J.L. (1986). A receptor-mediated 
pathway for cholesterol homeostasis (adapted from Nobel 
prize lecture dec. 1985). Science 232, 34-47. 
Caimi, L., Lombardo, A., Preti, A., Wiesmann, u. and 
Tettamanti, G. (1979). Optimal conditions for the assay 
of fibroblast neuraminidase with different nat~ral 
substrates. Biochim. Biophys. Acta 571, 137-146. 
Caimi, L., Tettarnanti, G., Berra, B., Omodeo, F., Borrone, C., 
Gatti, R., Durand, P., Martin, J .J. (1982). Mucolipidosis 
IV, a sialolipidosis due to ganglioside sialidase 
deficiency. J. Inher. Metab. Dis. 5, 218-224. 
Callahan, J.W. and Lowden, J.A. (eds.) (1981). Lysosomes and 
lysosomal storage diseases. Raven Press, New York. 
Cantz, M., Gebler, J. and Spranger, J. (1977}. Mucolipidosis 
I: Increased sialic acid content and deficiency of an 
a-N-acetylneurarninidase in cultured fibroblasts. Biochem. 
Biophys. Res. Commun. 74, 732-738. 
Cantz, M. and Messer, H. (1979}. Oligosaccharide and ganglio-
side neuraminidase activities of mucolipidosis I 
(sialidosis} and rnucolipidosis II (I-cell disease) 
fibroblasts. Eur. J. Biochem. 97, 113-118. 
Cantz, M. (1980). Neuraminidase studies in Sialidosis. In: 
Structure and function of gangliosides (eds. Svennerholrn, 
L., Mandel, P., Dreyfus, H. and Urban, P.F.) pp. 415-430. 
Plenum Press, New York. 
53 
Cantz, M., Mendla, K. and BaumkBtter, J. (1984). Sialidosis 
and related disorders: the nature of the sialidase 
defect. In: Recent progress in neurolipidoses and allied 
disorders (ed. Vanier, M.T.) pp. 137-145. Fondation 
Marcel Merieux, Lyon. 
Carubelli, R. and Tulsiani, D.R.P. (1971) .. Neuraminidase 
activity in brain and liver of rats during development. 
Biochim. Biophys. Acta 237, 78-87. 
Chigorno, v., Cardace, G., Pitto, M., Sonnino, S., Ghidoni, R. 
and Tettarnanti, G. (1986). A radiometric assay for 
ganglioside sialidase applied to the determination of the 
enzyme subcellular location in cultured human 
fibroblasts. Anal. Biochem. 153, 283-294. 
Cohen-Forterre, L., Mozere, G., Andre, J. and Sternberg, M. 
(1984). Cleavage of oligosaccharides by rat kidney 
sialidase. Influence of substrate structure. Febs. lett. 
173, 191-195. 
Conzelmann, E. and Sandhoff, K. (1978) .. AB variant of infan-
tile G~2-gangliosidosis: deficiency of a factor necessary for st~mulation of hexosaminidase A-catalysed degradation 
of GM2 and glycolipid GA2 . Proc. Natl. Acad. Sci. USA. 75, 3979-3983. 
Conzelmann, E. and Sandhoff, K. (1983-84). Partial enzyme 
deficiencies: residual activities and the development of 
neurological disorders. Dev. Neurosci. 6, 58-71. 
Corfield, A.P., Veh, R.W., Wember, M. and Schauer, R. (1980). 
Influence of sialic acid N-substitution on neuraminidase 
activity. Hoppe Seyler's Z. Physiol. Chern. 361, 231-232. 
Cor field, A.P .. , Michalski, J.-C. and Schauer, R. (1981) .. The 
substrate specificity of sialidases from microorganisms 
and mammals. In: Sialidases and Sialidoses. Perspectives 
in inherited metabolic diseases, Vol. 4 (eds .. Tettamanti, 
G., Durand, P. and DiDonato, S.) pp. 1-70. Edi.Ermes, 
Milan. 
Creek, K.E. and Sly, W.S. (1984). The role of the 
phosphomannosyl receptor in the transport of acid 
hydrolases to lysosomes .. In: Lysosomes in biology and 
pathology, Vol .. 7 (eds .. Dingle, J .. T., Dean, R .. T .. and Sly, 
W.) pp .. 63-82. Elsevier, Amsterdam, New York, Oxford. 
Cruz, T.F. and Gurd, J.W. (1981). The effects of development 
on activity, specificity and endogenous substrates of 
synaptic membrane sialidase. Biochim. Biophys. Acta 675, 
201-208. 
d~Azzo, A. (1982) .. Multiple lysosomal enzyme deficiency in 
man. Thesis, Erasmus University Rotterdam. 
54 
d'Azzo, A. Hoogeveen, A., Reuser, A.J.J., Robinson, D. and 
Galjaard, H. (1982). Molecular defect in combined 
S-galactosidase and neuraminidase deficiency in man. 
Proc. Nat1. Acad. Sci. USA. 79, 4535-4539. 
d'Azzo, A., Proia, R.L., Kolodny, E.H., Kaback, M.M. and 
Neufeld, E.F. (1984). Faulty association of a.- and 
8-subunits in some forms of S-hexosaminidases A deficien-
cy. J. Bio1. Chern. 259, 11070-11074. 
de Duve, C., Pressman, B.C., Gianetto, R., Wattiaux, R. and 
Appelmans, F. (1955). Tissue fractionation studies. 6. 
Intracellular distribution patterns of enzymes in rat-
liver tissue. Biochem. J. 60, 604-617. 
de Duve, C. (1969). The lysosome in retrospect. In: Lysosomes 
in biology and pathology, Vol.l (eds. Dingle, J.T., and 
Fell, H.B.) pp. 3-40, North Holland, Amsterdam. 
de Duve, C. {1983). Lysosomes revisited. Eur. J. Biochem. 137, 
391-397. 
Desnick, R.J. (ed.) (1980). Enzyme therapy in genetic 
diseases: Birth defects: original article series, Vol. 
XVI, Alan R. Liss, Inc. 
Dingle, J.T., Dean, R.T. and Sly, W. {eds.) (1984). Lysosomes 
in biology and pathology, Vol. 7. Elsevier, Amsterdam, 
New York, Oxford. 
Drzeniek, R. (1973). Substrate specificity of neuraminidases. 
Histochern. J. 5, 271-290. 
Durand, P., Gatti, R., Cavalieri, S., Borrone, c., Tondeur, 
M., Michalski, J.-c. and Strecker, G. (1977). Sialidosis 
(mucolipidosis I). Helv. Paediat. Acta 32, 391-400. 
Erickson, A.H., Conner, G.E. and Blobel, G. (1984). 
Biosynthesis of lysosomal enzymes. In: Molecular basis of 
lysosomal storage disorders (eds. Barranger, J.A. and 
Brady, R.O.) pp. 235-249. Academic Press Inc. 
Fraccaro, M., Simoni, G. and Brarnbati, B. (eds.} (1985). 
First-trimester fetal diagnosis. Springer Verlag, Berlin, 
New York. 
Friebolin, H., Brossmef, R., Keilich, G., Ziegler, D. and 
Supp, M. (1980). H-NMR-spektroskopischer nachweis der 
N-acetyl-a-D-neuraminsgure als prim~res spaltprodukt der 
neuraminidasen. Hoppe-Seyler's z. Physiol. Chern. 361, 
697-702. 
Fukushima, H., de Wet, J.R. and O'Brien, J.S. (1985). Molecular 
cloning of a eDNA for human a-L-fucosidase. Proc. Natl. 
Acad. Sci. USA. 82, 1262-1265. 
55 
Gahl, W.A., Bashan, N., Tietze, F., Bernardini, I. and 
Schulman, J.D. (1982). Cystine transport is defective in 
isolated leucocyte lysosomes from patients with 
cystinosis. Science 217, 1263-1265. 
Galjaard, H., Hoogeveen, A., Keijzer, W., de Wit-Verbeek, 
H.Aq Reuser, A.J.J., Mae Wan Ho, Robinson, D. (1975). 
Genetic heterogeneity in GM1-gangliosidosis. Nature 257, 60-62. 
Galjaard, H. (1980). Genetic metabolic disease, early diagno-
sis and prenatal analysis. Elsevier/North-Holland, 
Amsterdam. 
Galjaard, H. and Reuser, A,J.J. (1984}. Genetic aspects of 
lysosomal storage diseases. In: Lysosomes in biology and 
pathology, Vol. 7 (eds. Dingle, J.T., Dean, R.T. and Sly, 
W.) pp. 315-345. Elsevier, Amsterdam, New York, Oxford. 
Galjaard, H., d'Azzo, A., Hoogeveen, A. and Verheijen, F. 
(1984a). Combined 6-galactosidase-sialidase deficiency in 
man: genetic defect of a "protective protein 11 • In: 
Molecular Basis of Lysosomal Storage Disorders (eds. 
Barranger, J.A. and Brady, R.O.) pp. 113-132. Academic 
Press Inc. 
Galjaard, H., Hoogeveen, A., d'Azzo, A., Verheijen, F.W. and 
Reuser, A.J.J. (1984b). The genetic and molecular 
background of 6-galactosidase and neuraminidase 
deficiencies. In: Recent progress in neurolipidoses and 
allied disorders (ed. Vanier, M.T.) pp. 147-159. Fonda-
tion Marcel Merieux, Lyon. 
Galjaard, H. and Kleijer, W.J. (1986). Biochemical analysis of 
chorionic villi. In: Chorionic villus sampling; fetal 
diagnosis of genetic diseases in the first trimester. 
(eds. Brambati, B., Simoni, G. and Fabre, S.) pp.l31-152. 
Marcel Dekker Inc., New York. 
Geuze, H.J., Slot, J.W., Strous, G.J.A.M., Lodish, H.F. and 
Schwartz, A.L. (1983). Intracellular site of 
asialoglycoprotein receptor-ligand uncoupling: double-
label immunoelectron microscopy during receptor-mediated 
endocytosis. Cell 32, 277-287. 
Geuze, H.J., Slot, J.W., Strous, G.J.A.M., Hasilik, A. and Von 
Figura, K. (1985). Possible pathways for lysosomal enzyme 
delivery. J. Cell Biol. 101, 2253-2262. 
Ginns, E.I., Brady, R.O., Pirruccello, S., Moore, C., Sorrell, 
s., Furbisch, F.S., Murray, G.J., Tager, J. and 
Bar ranger, J. A. (1982). Mutations of glucocerebrosidase: 
discrimination of neurologic and non-neurologic pheno-
types of Gaucher disease. Proc. Natl. Acad. Sci. USA. 79, 
5607-5610. 
56 
Ginns, E.I., Choudary, P.V., Martin, B.M., Winfield, S., 
Stubblefield, B., Mayor, J., Merkle-Lehman, D., Murray, 
G.J., Bowers, L.A. and Barranger, J.A. (1984). Isolation 
of eDNA clones for human B-glucocerebrosidase using the 
lambda-gtll expression system. Biochern. Biophys. Res. 
Commun. 123, 574-580. 
Gl6ssl, J., Kresse, H., Mendla, K., Cantz, M. and Rosenkranz, 
W. (1984). Partial deficiency of glycoprotein neuramini-
dase in some patients with Morquio disease type A. 
Pediatr. Res. 18, 302-305. 
Goldberg, D., Gabel, C. and Kornfeld, S. (1984). Processing of 
lysosomal enzyme oligosaccharide units. In: Lysosomes in 
biology and pathology, Vol. 7 (eds. Dingle, J.T., Dean, 
R.T. and Sly, W.) pp. 45-62. Elsevier, Amsterdam, New 
York, Oxford. 
Goldstein, J.L., Anderson, R.G. and Brown, M.S. (1979). Coated 
pits, coated vesicles, and receptor-mediated endocytosis. 
Nature 279, 679-685. 
Gottschalk, A. (1956). The linkage of sialic acid in 
mucoprotein. Biochim. Biophys. Acta 20, 560-561. 
Gottschalk, A. (1957). Neuraminidase, the specific enzyme of 
influenza virus and vibrio cholerae. Biochim. Biophys. 
Acta 23, 645-646. 
Gottschalk, A. and Bhargava, A.S. (1971). Neuraminidases. In: 
The Enzymes, Vol. 5 (ed. Boyer, P.D.) pp. 321-342. 
Academic Press, New York. 
Gottschalk, A. and Drzeniek, R. (1972). Neuraminidase as a 
tool in structural analysis. In: Glycoproteins: their 
composition, structure and function, BBA library, Vol. 5 
(ed. Gottschalk, A.) pp. 381-402. Elsevier, Amsterdam. 
Gravel, R.A., Lowden, J.A., Callahan, J.W., Wolfe, L.S. and Ng 
Yin Kin, N.M.K. (1979). Infantile Sialidosis: a phenocopy 
of type 1 GM1-gangliosidosis distinguished by genetic 
complementat1on and urinary oligosaccharides. Am. J. Hum. 
Genet. 31, 669-679. 
Harford, J., Klausner, R.D. and Ashwell, G. (1984). Inhibition 
of the endocytic pathway for asialoglycoprotein 
catabolism. Biol. Cell 51, 173-180. 
Hasilik, A. and Neufeld, E.F. (1980). Biosynthesis of lysoso-
mal enzymes in fibroblasts. Phosphorylation of mannose 
residues. J. Biol. Chern. 255, 4946-4950. 
Basilik, A., Waheed, A. and Von Figura, K. (1981). Enzymatic 
phosphorylation of lysosomal enzymes in the presence of 
UDP-N-acetylglucosarnine. Absence of the activity in I-
cell fibroblasts. Biochem. Biophys. Res. Commun. 98, 761-
767. 
57 
Hasilik, A. and Von Figura, K. (1984). Processing of lysosomal 
enzymes in fibroblasts. In: Lysosomes in biology and 
pathology, Vol. 7 (eds. Dingle, J .. T .. , Dean, R.T .. and Sly, 
W .. ) pp .. 3-16 .. Elsevier, Amsterdam, New York, Oxford. 
Hers, H.G. (1965). Inborn lysosomal diseases. Gastroenterology 
48' 625-633. 
Hers, H. G. and van Hoof, F. {eds.) (1973). Lysosomes and 
storage diseases. Academic Press, New York and London. 
Hers, H. G. (1973). The concept of inborn lysosomal disease. 
In: Lysosomes and storage diseases (eds. Hers, H.G. and 
van Hoof, F.) pp. 147-171. Academic Press, New York and 
London. 
Hoflack, B. and Kornfeld, S. (1985a). Lysosomal enzyme binding 
to mouse P 388Dl macrophage membranes lacking the 215-kDa 
mannose 6-phosphate receptor: evidence for the existence 
of a second mannose 6-phosphate receptor. Proc. Natl. 
Acad. Sci. USA. 82, 4428-4432. 
Hoflack, B. and Kornfeld, S. (1985b). Purification ·and 
characterization of a cation-dependent mannose 6-
phosphate receptor from murine P 388Dl macrophages and 
bovine liver. J. Bio1. Chern. 260, 12008-12014. 
Holtzman, E. (1976). Lysosomes: a survey. Springer-Verlag, 
Wien, New York. 
Hoogeveen, A.T., Verheijen, F.W., d'Azzo, A. and Galjaard, H. 
(1980}. Genetic heterogeneity in human neuraminidase 
deficiency. Nature 285, 500-502. 
Hoogeveen, A., d'Azzo, A., Brossmer, R. and Galjaard, H. 
(1981). Correction of combined S-ga1actosidase/ 
neuraminidase deficiency in human fibroblasts. Biochem. 
Biophys. Res. Commun. 103, 292-299. 
Hoogeveen, A.T., Verheijen, F.W. and Galjaard, H. (1983). The 
relation between human lysosomal B-galactosidase and its 
protective protein J. Bio1. Chern. 258, 12143-12146. 
Hoogeveen, A.T., Reuser, A.J.J., Kroos, M. and Galjaard, H. 
(1986). GM1-gang1iosidosis: defective recognition site on 
s-ga1actos1dase precursor. J. Bio1. Chern. 261, 5702-5704. 
Horvat, A. and Touster, 0. {1968). On the lysosomal 
occurence and the properties of the neuraminidase of rat 
liver and of Ehrlich ascites tumor cells. J. Biol. Chern. 
243, 4380-4390. 
Kaback, M.M. (1977). Tay-Sachs disease: screening and 
prevention. Alan R. Liss, New York. 
58 
Kaback, M.M. {1981). Heterozygote screening and prenatal 
diagnosis in Tay-Sachs disease: a worldwide update. 
In: Lysosomes and lysosomal storage diseases (eds. 
Callahan, J.W. and Lowden, A.J.) pp. 331-342. Raven 
Press, New York. 
Keilich, G., Ziegler, D. andBrossmer, R. (1979). Viral, 
Bacterial and mammalian neuraminidases: a comparison of 
their substrate specificities. Hoppe-Seyler's Z. Physiol. 
Chern. 360, 1161-1162. 
Keilich, G., Ziegler, D. and Brossmer, R .. (1979) .. 
Glycoconjugates containing N-acetyl-D-neuraminic acid 
constituents as subtrates for neuraminidases. In: 
Glycoconjugates (eds. Schauer, R., Boer, P., Buddecke, 
E., Kramer, M .. F., Vliegenthart, J.F.G. and Wiegandt, H.) 
pp. 346-347. Georg Thieme Publishers, Stuttgart. 
Kelly, T.E. and Graetz, G. (1977). Isolated acid neuraminidase 
deficiency: a distinct lysosomal storage disease. Amer. 
J. Med. Genet. 1, 31-46. 
Kishore, G.S., Tulsiani, D.R.P., Bhavanandan, V.P. and 
Carubelli, R. {1975). Membrane-bound neurarninidases of 
rat liver. Neuraminidase activity in Golgi apparatus. J. 
Biol. Chern. 250, 2655-2659. 
Kleijer, W.J., Hoogeveen, A., Verheijen, F.W., Niermeijer, 
M.F., Galjaard, H., O'Brien, J.S. and Warner, T.G. 
(1979). Prenatal diagnosis of sialidosis with combined 
neuraminidase and 8-galactosidase deficiency. Clin. 
Genet. 16, 60-61. 
Kleijer, W.J. (1986). First-trimester diagnosis of genetic 
metabolic disorders. Contr. Gynec. Obstet. 15, in press. 
Konings, A., Hupkes, P., Versteeg, R., Grosveld, G., Reuser, 
A. and Galjaard, H. (1984). Cloning a eDNA for the lyso-
somal a-glucosidase. Biochem. Biophys. Res. Comm. 119, 
252-258. 
Kornfeld, S. (1986). Trafficking of lysosomal enzymes in 
normal and disease states. J. Clin. Invest. 77, 1-6. 
Kuhn, R. and Brossmer, R. (1958). Die Konstitution der 
lactaminsgurelactose, a-ketosidase wirkung von viren der 
influenza-gruppe. Angew. Chern. 70, 25. 
Lerner, U. (1980). Relationship between bone resorption and 
lysosomal enzyme release as demonstrated by the effect of 
1-a-hydroxy-vitarnin D-3 in an organ culture system. 
Biochirn. Biophys. Acta 632, 204-213. 
Leroy, J.G. and Spranger, J.W. (1970). I-cell disease. New 
Engl. J. Med. 283, 598-599. 
59 
Li, Y.T. and Li, S.C. (1984). Activator proteins related to 
the hydrolysis of glycosphingolipids catalyzed by 
lysosomal glycosidases. In: Lysosornes in biology and 
pathology, Vol.? (eds. Dingle, J.T., Dean, R.T. and Sly, 
W.) pp.99-117. Elsevier, Amsterdam, New York, Oxford. 
Loonen, M.C.B., Lugt, L. van de, Franke, C.L. {1974). 
Angiokeratoma corporis diffusum and lysosomal enzyme 
deficiency. Lancet ii, 785. 
Loonen, M.C.B., Reuser, A.J.J., Visser, P. and Arts, W.F.M. 
(1984). Combined sialidase (neuraminidase) and 
S-galactosidase deficiency. Clinical, morphological and 
enzymological observations in a patient. Clin. Genet. 26, 
139-149. 
Lowden, J.A. and o'Brien, J.S. (1979). Sialidosis: a review of 
human sialidase deficiency. Am. J. Hum. Genet. 31, 1-18. 
Mahadevan, S., Nduaguba, J.C. and Tappel, A.L. (1967). 
Sialidase of rat liver and kidney. J. Biol. Chern. 242, 
4409-4413. 
Mancini, G.M.S., Hoogeveen, A.T., Galjaard, H., Mansson, J.E. 
and Svennerholm, L. (1986a). Ganglioside GMl metabolism 
in living human fibroblasts with 6-galactosldase 
deficiency. Hum. Genet. 73, 35-38. 
Mancini, G.M.S., Verheijen, F.W. and Galjaard, H. (1986b). 
Free N-acetylneuraminic acid (NANA) storage disorders: 
evidence for defective NANA transport across the 
lysosomal membrane. Hum. Genet. in press. 
McKusick, V.A. and Neufeld, E.F. (1983). The mucopolysaccha-
ride storage diseases. In: The metabolic basis of in-
herited disease (eds. Stanbury, J.B., Wyngaarden, J.B., 
Frederickson, D.S., Goldstein, J.L. and Brown, M.S.) 
pp. 751-777. McGraw-Hill Book Company, New York. 
McNamara, D., Beauregard, G., Nguyen, H.V., Yan, D.L.S., 
Belisle, M. and Potier, M. (1982). Characterization of 
human placental neurarninidases (stability, substrate 
specificity and molecular weight). Biochem. J. 205, 
345-351. 
Mendla, K. (1983). Characterisierung einer 
oligosaccharid-spezifischen sialidase aus der 
Schweine-niere. Thesis, Westf~lischen Wilhelms-
Universitgt, MUnster. 
Mendla, K. and Cantz, M. (1984). Specificity studies on the 
oligosaccharide neuraminidase of human fibroblasts. 
Biochem. J. 218, 625-628. 
Michalski, J.-c., Corfield, A.P. and Schauer, R. (1982). 
Solubilization and affinity chromatography of a sialidase 
from human liver. Hoppe-Seyler's z. Physiol. Chern. 363, 
1097-1102. 
60 
Milunsky, A. (ed.) (1979) .. Genetic disorders and the fetus .. 
Plenum Press, New York. 
Miyagi, T. and Tsuiki, S. (1984). Rat-liver lysosomal 
sialidase. Solubilization, substrate specificity and 
comparison with the cytosolic sialidase. Eur. J. Biochem. 
141' 75-81. 
Miyagi, T. and Tsuiki, s. (1985) .. Purification and 
characterization of cytosolic sialidase from rat liver. 
J. Biol. Chern. 260, 6710-6716. 
Mostov, K.E .. and Sirnister, N .. E. (1985). Transcytosis. Cell 43, 
389-390. 
Mueller, O.T .. , Henry, W .. M., Haley, L.L .. , Byers, M.G., Eddy, 
R.L .. and Shows, T.B. (1986). Sialidosis and 
Galactosialidosis: chromosomal assignment of two genes 
associated with neuraminidase-deficiency disorders. Proc. 
Natl. Acad. Sci. USA 83, 1817-1821. 
Myerowitz, R. and Proia, R.L. {1984). eDNA clone for the a-
chain of human e-hexosaminidase: deficiency of a-chain 
rnRNA in Ashkenazi Tay-Sachs fibroblasts. Proc. Natl. 
Acad. Sci. USA 81, 5394-5398. 
Myers, R.w., Lee, R.T., Lee, Y.C., Thomas, G.H., Reynolds, 
L.W. and Uchida, Y. (1980). The synthesis of 
4-methylumbelliferyl a-ketoside of N-acetylneuraminic 
acid and its use in a fluorometric assay for 
neuraminidase. Anal. Biochem. 101, 166-174. 
Neufeld, E.F., Lim, T.W. and Shapiro, L.J. (1975). Inherited 
disorders of lysosomal metabolism. Ann. Rev. Biochem. 44, 
357-376. 
Neufeld, E.F. (1981). Recognition and processing of lysosomal 
enzymes in cultured fibroblasts. In: Lysosomes and 
lysosomal storage diseases (eds. Callahan, J.W. and 
Lowden, J.A.) pp. 115-130. Raven Press, New York. 
Neurath, H. and Walsh, K.A. (1976). Role of proteolytic 
enzymes in biological regulation {a review). Proc. Natl. 
Acad. Sci. USA. 73, 3825-3832. 
Nguyen Hong, v., Beauregard, G., Potier, M., Belisle, M., 
Mameli, L., Gatti, R. and Durand, P. (1980). Studies on 
the Sialidoses. Properties of human leucocyte 
neuraminidases. Biochim. Biophys. Acta 616, 259-270. 
Novikoff, A.B. (1973). Lysosomes: a personal account. In: 
Lysosomes and storage diseases (eds. Hers. H.G. and van 
Hoof, F.) pp 1-41. Academic Press, New York and London. 
O'Brien, J.S. (1977). Neuraminidase deficiency in the cherry 
red spot-myclonus syndrome. Biochem. Biophys. Res. 
Commun. 79, 1136-1141. 
61 
O'Brien, J.S. (1982). Sialidosis. In: Genetic errors of 
glycoprotein metabolism (eds. Durand, P. and O'Brien, 
J.S.) pp. 33-48. Springer-Verlag, Berlin, Heidelberg, New 
York. 
O'Brien, J.S., de Wet, J., Fukushima, H., Wilcox, E., Dewji, 
N., McGee, J., Warner, T., Yoshida, A., Fluharty, A., 
Hill, F. and Helinsky, D. (1984). Cloning of lysosomal 
genes. In: The molecular basis of lysosomal storage 
disorders. (eds. Barranger, J.A. and Brady, R.O.) pp. 
387-404. 
Ohman, R., Rosenberg, A. and Svennerholm, L. (1970). Human 
brain sialidase. Biochem. 9, 3774-3782. 
Palmeri, s., Hoogeveen, A.T., Verheijen, F.W. and Galjaard, H. 
(1986). Galactosialidosis: Molecular heterogeneity among 
distinct clinical phenotypes. Am. J. Hum. Genet. 38, 
137-148. 
Paschke, E. and Kresse, H. (1982). Morquio disease type B: 
activation of GM1-s-galactosidase by GM1-activator protein. Biochem. Biophys. Res. Commun. 109, 568-575. 
Pastan, I. and Willingham, M.C. (1983). Receptor-mediated 
endocytosis: coated pits, receptosomes and the golgi. 
Trends Biochem. Sci. 8, 250-254. 
Pastan, I. and Willingham, M.C. (1985). Endocytosis. Plenum 
Press, New york and London. 
Pinsky, L., Miller, J., Stanfield, B., Watters, G., Wolfe, L. 
(1974). GM1-gangliosidosis in skin fibroblast culture: 
enzymatic differences between types 1 and 3 and 
observations in a third variant. Amer. J. Hum. Genet. 26, 
563-577. 
Potier, M., Mameli, L., Belisle, M., Dallaire, L. and 
Melan~on, S.B. (1979). Fluorometric assay of neuramini-
dase with a sodium (4-methylumbelliferyl-a-D-N-acetyl-
neuraminate) substrate. Anal. Biochem. 94, 287-296. 
Proia, R.L. and Neufeld, E.F. (1982). Synthesis of 
B-hexosaminidase in cell-free translation and in intact 
fibroblasts: an insoluble precursor a-chain in a rare 
form of Tay-Sachs disease. Proc. Natl. Acad. Sci. USA. 
79, 6360-6364. 
Rahmann, H., R~ssner, H. and Breer, H. (1976). A functional 
model of sialo-glyco-macromolecules in synaptic 
transmission and memory formation. J. theor. Biol. 57, 
231-237. 
Rapin, I., Goldfischer, S., Katzman, R., Engel, J. and 
O'Brien, J.S. (1978). The cherry-red spot-myoclonus 
syndrome. Ann. Neurol. 3, 234-242. 
62 
Reitman, M.L., Varki, A. and Kornfeld, S., (1981). Fibroblasts 
from patients with I-cell disease and pseudo-Hurler 
polydystrophy are deficient in uridine 
5'-diphosphate-N-acetylglucosarnine: glycoprotein 
N-acetylglucosaminylphosphotransferase activity. J. Clin. 
Invest. 67, 1574-1579. 
Renlund, M., Kovanen, P.T., Raivio, K.O., Aula, P., Gahmberg, 
C.G. and Ehnholm, C. (1986). Studies on the defect under-
lying the lysosomal storage of sialic acid in Salla 
disease. J. Clin. Invest. 77, 568-574. 
Reuser, A.J.J. (1984). Genetic heterogeneity in lysosomal 
storage disorders studied by somatic cell hybridization. 
In: Molecular basis of lysosomal storage disorders (eds. 
Barranger, J.A. and Brady, R.O.) pp. 235-249. Academic 
Press. Inc .. 
Reuser, A .. J.J., Kroes, M .. , Oude Elferink, R.P.J. and Tager, 
J.M. {1985). Defects in synthesis, phosphorylation and 
maturation of acid a-glucosidase in glucogenosis type II. 
J. Biol. Chern. 260, 8336-8341. 
Reutter, W., KBttgen, E., Bauer, C .. and Gerok, W. {1982). 
Biological significance of sialic acids. In: Sialic 
acids. Chemistry, metabolism and function .. {ed. Schauer, 
R.) pp. 263-305. Springer-Verlag, Wien, New York. 
Rosenberg, A. and Schengrund, c .. -L .. (1976). Biological roles 
of sialic acid. Plenum Press, New York, London. 
Sandhoff, K. and Conzelmann, E. {1979). Activation of lysoso-
mal hydrolysis of complex glycolipids by non-enzymic 
proteins. Trends Biochem. Sci. 4, 231-233. 
Schauer, R. (ed.) (1982). Sialic acids. Chemistry, metabolism 
and function. Springer-Verlag, Wien, New York. 
Schauer, R .. , Wember, M. and Tschesche, H .. (1984). Isolation 
and characterization of an oligosaccharide- and 
glycoprotein-specific sialidase from human leucocytes. 
Hoppe-Seyler's Z. Physiol. Chern. 365, 419-426. 
Schauer, R .. (1985). Sialic acids and their role as biological 
masks. Trends Biochem .. Sci. 10, 357-360. 
Schengrund, C.-L. and Rosenberg, A. (1970). Intracellular 
location and properties of bovine brain sialidase. J. 
Biol. Chern. 245, 6196-6200. 
Schengrund, c.-L. I Repman, M.A. and Nelson, J .T. (1979). 
Distribution in spleen subcellular organelles of siali-
dase active towards natural sialoglycolipid and 
sialoglycoprotein substrates. Biochirn. Biophys. Acta 568, 
377-385. 
63 
Sips, H.J., de Wit-Verbeek, H.A., Westerveld, A. and Galjaard, 
H. (1985). The chromosomal localization of human 
S-galactosidase revisited: a locus for 8-galactosidase on 
human chromosome 3 and for its protective protein on 
human chromosome 22. Hum. Genet. 69, 340-344. 
Skudlarek, M.D., Novak, E.K. and Swank, R.T. (1984). 
Processing of lysosomal enzymes in macrophages and 
kidney. In: Lysosomes in biology and pathology, Vol. 7. 
(eds. Dingle, J.T., Dean, R.T. and Sly, W.) pp. 17-43. 
Elsevier, Amsterdam, New York, Oxford. 
Spaltro, J. and Aldaheff, J.A. (1984). Solubilization, 
stabilization and isoelectric focusing of human liver 
neuraminidase activity. Biochim. Biophys. Acta 800, 
159-165. 
Spranger, J~ and Wiedemann, H.R. (1970). The genetic 
mucolipidoses. Hum. Genet. 9, 113-139. 
Spranger, J., Gebler, J. and Cantz, M. {1977). Mucolipidosis 
I-a sialidosis. Amer. J. Med. Genet. 1, 21-29. 
Spranger, J. (1981). Mucolipidosis I: phenotype and nosology. 
In: Sialidases and Sialidoses. Perspectives in inherited 
metabolic diseases, Vol. 4 {eds. Tettamanti, G., Durand, 
P. and Di Donato, S.) pp. 303-315. Edi. Ermes, Milan. 
Stahl, P. and Schwartz, A.L. (1986). Receptor-mediated 
endocytosis. J. Clin. Invest. 77, 657-662. 
Stanbury, J.B., Wyngaarden, J.B., Frederickson, D.S., 
Goldstein, J.L. and Brown, M.S. (eds.) (1983). The 
metabolic basis of inherited disease. McGraw-Hill Book 
Company, New York. 
Steckel, F., Gieselmann, V., Waheed, A., Hasilik, A., Von 
Figura, K., Oude Elferink, R., Kalsbeek, R. and Tager, 
J .M. {1982). Biosynthesis of acid a.-glucosidase in late-
onset forms of glycogenesis type II (Pompe's disease). 
Febs lett. 150, 69-76. 
Strecker, G., Peers, M.C., Michalski, J.-c., Hondi-Assah, T., 
Fournet, B., Spik, G., Montreuil, J., Farriaux, J.P., 
Maroteaux, P. and Durand, P. (1977). Structure of nine 
sialyl-oligosaccharides accumulated in urine of eleven 
patients with three different types of sialidosis, 
mucolipidosis II and two new types of rnucolipidosis. Eur. 
J. Biochem. 75, 391-403. 
Strecker, G. and Michalski, J .-c. (1978). Biochemical basis of 
six different types of sialidosis. Febs lett. 85, 20-23. 
Strisciuglio, P., Creek, K.E. and Sly, W. (1984). 
Complementation, cross reaction, and drug correction 
studies of combined a-galactosidase neuraminidase 
deficiency in human fibroblasts. Pediatr. Res. 18, 167-
171. 
64 
Suzuki, Y., Nakamura, H., Fukuoka, K., Shimada, Y., Uono, M. 
(1977). S-Galactosidase deficiency in juvenile and adult 
patients. Hum. Genet. 36, 219-229. 
Suzuki, Y. Sakuraba, H. Yamanaka, T. Ko, Y-M. and Okamura, Y. 
(1983). Galactosialidosis (B-galactosidase-neuraminidase 
deficiency): a new hereditary metabolic disease with 
abnormal degradation of enzyme molecules. Acta Paediatr. 
Jpn. 25, 31-37. 
Suzuki, Y., Sakuraba, H., Yamanaka, T. et al. (1984). 
Galactosialidosis: a comparative study of clinical and 
biochemical data on 22 patients. In: The developing brain 
and its disorders (ed. Arima, M.) pp. 161-175. 
Univ. of Tokyo Press. 
Svennerholrn, L .. (1980) .. Gangliosides and synaptic 
transmission. In: Structure and function of gangliosides 
(eds. Svennerholm, L., Mandel, P., Dreyfus, H. and Urban, 
P.F.) pp. 533-544. Plenum Pess, New York. 
Swallow, D.M., Hoogeveen, A.T., Verheijen, F.W. and Galjaard, 
H. (1981). Complementation analysis of human sialidase 
deficiency using natural substrates. Ann. Hum. Genet. 45, 
105-112. 
Tager, J.M., Hamers, M., Schram, A.W., van den Bergh, 
F.A.J.T.M., Rietra, P.J.G.M., Loonen, M., Koster, J.F. 
and Slee, R. (1980). An appraisal of human trials in 
enzyme replacement therapy of genetic diseases. In: 
Enzyme therapy in genetic diseases. Birth defects: ori-
ginal article series, Vol. XVI, pp. 343-359 (ed. Des-
nick, R.J.) Alan, R. Liss, Inc. 
Tager, J.M. (1985). Biosynthesis and deficiency of lysosomal 
enzymes. Trends Biochem. Sci. 10, 324-326. 
Tallman, J.F. and Brady, R.O. (1973). The purification and 
properties of a mammalian neuraminidase (sialidase). 
Biochim. Biophys. Acta 293, 434-443. 
Tettamanti, G., Morgan, I.G., Gombos, G., Vincendon, G. and 
Mandel, P. (1972). Sub-synaptosomal localization of brain 
particulate neuraminidase. Brain Res. 47, 515-518. 
Tettamanti, G., Durand, P. and DiDonato, S, (eds.} (1981}. 
Sialidases and Sialidoses. Perspectives in inherited 
metabolic diseases, Vol. 4. Edi. Ermes, Milan. 
Thomas, G.H., Tipton, R.E., Ch'ien, T., Reynolds, L.W. and 
Miller, C.S. (1978). Sialidase (a-N-acetyl neuraminidase) 
deficiency: the enzyme defect in an adult with macular 
cherry-red spots and myoclonus without dementia. Clin. 
Genet. 13, 369-379. 
Tulsiani, D.R.P., Carubelli. R. (1970). Studies on the soluble 
and lysosomal neuraminidases of rat liver. J. Biol. Chern. 
245, 1821-1827. 
65 
Tulsiani, D.R.P. and Carubelli, R. (1972). Soluble and 
lysosomal neuraminidases in the liver of developing 
chicks. Biochim. Biophys. Acta 284, 257-267. 
Vaes, G. (1973). Digestive capacity of lysosomes. In: 
Lysosornes and storage diseases (eds. Hers, H.G. and van 
Hoof, F.) pp. 43-77. Academic Press, New York and London. 
van der Horst, G.T.J., Kleijer, W.J., Hoogeveen, A.T., 
Huijmans, J.G.M .. , Blom, W. and van Diggelen, O .. P. (1983) .. 
Morquio B syndrome: a primary defect in 8-galactosidase. 
Am. J. Med. Genet. 16, 261-275. 
van Dessel, G., de Wolf, M., Lagrou, A., Hilderson, H. and 
Dierick, w. (1984) .. Characterization, purification and 
subcellular localization of bovine thyroid sialidase. J. 
Biochem. 96, 937-947. 
van Diggelen, O.P., Schram, A.W., Sinnott, M.L., Smith, P.J. 
Robinson, D. and Galjaard, H. (1981). Turnover of 
B-galactosidase in fibroblasts from patients with 
genetically different types of B-galactosidase 
deficiency. Biochem. J. 200, 143-151. 
van Diggelen, O.P., Hoogeveen, A.T., Smith, P.J., Reuser, 
A.J .J. and Galjaard, H. (1982). Enhanced proteolytic 
degradation of normal B-galactosidase in the lysosomal 
storage disease with combined B-galactosidase and 
neuraminidase deficiency. Biochim. Biophys. Acta 703, 69-
76. 
van Dongen, J.M., Barneveld, R.A., Geuze, H.J. and Galjaard, 
H. (1984). Immunochemistry of lysosomal hydrolases and 
their precursor forms in normal and mutant human cells. 
Histochem. J. 16, 941-954. 
Varki, A., Reitman, M.L., Vannier, A., Kornfeld, S., Grubb, 
J.H. and Sly, w.s. (1982). Demonstration of the 
heterozygous state for I-cell disease and pseudo-Hurler 
polydystrophy by assay of N-acetylglucosaminyl-phospho-
transferase in white blood cells and fibroblasts. Am. J. 
Hum. Genet. 34, 717-729. 
Veh, R.W., Corfield, A.P., Sander, M. and Schauer, R. (1977). 
Neuraminic acid-specific modification and tritium 
labeling of gangliosides. Biochim. Biophys. Acta 486, 
145-160. 
Veh, R.W. and Sander, M. (1981). Differentiation between 
ganglioside and sialyllactose sialidases in human 
tissues. In: Sialidases and Sialidoses. Perspectives in 
inherited metabolic diseases, Vol. 4 (eds. Tettamanti, 
G., Durand, P. and DiDonato, S.) pp. 71-109. 
Edi.Ermes, Milan. 
66 
Venerando, B., Tettamanti, G., Cestaro, B. and Zambotti, V. 
(1975). Studies on brain cytosol neuraminidase. I. 
Isolation and partial characterization of two forms of 
the enzyme from pig brain. Biochim. Biophys. Acta 403, 
461-472. 
Venerando, B., Preti, A., Lombardo, A., Cestaro, B. and 
Tettamanti, G. (1978). Studies on brain cytosol 
neuraminidase. II. Extractability, solubility and 
intraneuronal distribution of the enzyme in pig brain. 
Biochim. Biophys. Acta 527, 17-30. 
Venerando, B., Fiorilli, A., Masserini, M., Giuliani, A. and 
Tettamanti, G. (1985). Interactions of pig brain 
cytosolic sialidase with gangliosides. Formation of cata-
lytically inactive enzyme-ganglioside complexes. Biochim. 
Biophys. Acta 833, 82-92. 
Verheijen, F.W., Palmeri, S., Hoogeveen, A.T. and Galjaard, H. 
(1985). Human placental neuraminidase. Activation, 
stabilization and association with 6-galactosidase and 
its protective protein. Eur. J. Biochem. 149, 315-321. 
Visser, A. and Ernmelot, P. (1973). Studies on plasma 
membranes. XX. sialidase in hepatic plasma membranes. J. 
Membr. Biol. 14, 73-84. 
Waheed, A., Hasilik, A. and Von Figura, K. (1982). Enhanced 
breakdown of arylsulfatase A in multiple sulfatase 
deficiency. Eur. J. Biochem. 123, 317-321. 
Walker, P.G. (1952). The preparation and properties of 
a-glucuronidase. 3. Fractionation and activity of 
homogenates in isotonic media. Biochem. J. 51, 223-232. 
Warner, T.G. and O'Brien, J.S. (1979). Synthesis of 
2'-{4-rnethylumbelliferyl)-a-D-N-acetylneuraminic acid and 
detection of skin fibroblast neuraminidase in normal 
humans and in Sialidosis. Biochem. 18, 2783-2787. 
Wenger, D.A., Tarby, T.J. and Wharton, C. (1978). Macular 
cherry-red spots and myoclonus with dementia: Co-existent 
neuraminidase and a-galactosidase deficiencies. Biochem. 
Biophys. Res. Commun. 82, 589-595. 
Wiesmann, U.N. and Herschkowitz, N. (1980). Sialidases 
(Mucolipidoses) , clinical pictures. In: Structure and 
function of gangliosides (eds. Svennerholm, L., Mandel, 
P., Dreyfus, H. and Urban, P.F. ) pp. 385-399. Plenum 
Press, New York. 
Wileman, T., Harding, C. and Stahl, P. (1985). Receptor-
mediated endocytosis. Biochem. J. 232, 1-14. 
67 
Willemsen, R., Hoogeveen, A.T., Sips, H.J., van Dongen, J.M. 
and Galjaard, H. (1986). Immunoelectron microscopical 
localization of lysosomal B-galactosidase and its 
precursor forms in normal and mutant human fibroblasts. 
Eur. J. Cell Biol. 40, 9-15. 
Williams, D.A. and Orkin, S.H. (1986). Somatic gene therapy. 
Current status and future prospects. J. Clin. Invest. 77, 
1053-1056. 
Willingham, M.C. and Pastan, I. (1985). Receptosomes, 
endosomes, CURL: different terms for the same organelle 
system. Trends Biochem. Sci. 10, 190-191. 
Yohe, H.C. and Rosenberg, A. (1977). Action of intrinsic 
sialidase of rat brain synaptic membranes on membrane 
sialolipid and sialoprotein components in situ. J. Biol. 
Chern. 252, 2412-2418. 
Zeigler, M. and Bach, G. (1981). Cellular localization of 
neuraminidases in cultured human fibroblasts. Biochem. J. 
198, 505-508. 
Zeigler, M. and Bach, G. (1985). Ganglioside distribution in 
mucolipidosis type IV cultured fibroblasts. Arch. 
Biochem. Biophys. 241, 602-607. 
68 
SUMMARY 
Since the discovery of the lysosome as a distinct subcel-
lular compartment important for intracellular digestion, by 
the group of De Duve in 1955, more than 70 lysosomal hydro-
lases have been described. A genetically determined deficiency 
of one of these enzymes may result in the intralysosomal 
accumulation of cellular constituents or extracellular 
products. Depending on the function of the enzyme, the rate of 
accumulation and the interference with the cellular metabo-
lism, a variety of clinical and pathological manifestations 
will occur. Up to now more than 30 lysosomal storage disorders 
are known, nearly all of which are of autosomal recessive 
inheritance. 
This thesis deals with the genetic and molecular cha-
racterization of genetic diseases associated with a deficiency 
of lysosomal neuraminidase. 
Neuraminidases (EC 3.2.1.18, sialidase, N-acetyl-neurami-
nosyl glycohydrolase) catalyze the hydrolysis of neuraminic 
acid residues (sialic acids) from a variety of neuraminic acid 
- containing compounds. These enzymes are widely distributed 
in nature and in mammalian cells they form a heterogeneous 
group as far as their subcellular localization and substrate 
specificity are concerned. Our experimental work has focussed 
on the lysosomal neuraminidases which catalyze the cleavage of 
N-acetylneurarninic acid residues from glycoproteins, oligosac-
charides and glycopeptides. The availability of an artificial 
fluorogenic substrate (4-rnethylumbelliferyl-N-acetyl-neurami-
nic acid) permitting a sensitive and reliable enzyme assay, 
has greatly facilitated both the diagnostic work and the 
research described in this thesis. 
Patients with the lysosomal storage disease Sialidosis 
have a generalized deficiency of neuraminidase which can be 
reliably demonstrated in cultured skin fibroblasts or in iso-
lated blood lymphocytes. Patients excrete increased amounts of 
oligosaccharide-bound N-acetylneuraminic acid in urine which 
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compound is also elevated in (cultured) fibroblasts and other 
cell types. Clinically, two forms are being distinguished: 
- a severe, dysmorphic form characterized by severe men-
tal retardation, skeletal deformities, Hurler-like facial 
features, macular cherry-red spot, myoclonus, kidney involve-
ment and a rapidly progressive clinical course. 
- a milder, norrnomorphic form with a later onset, mild 
mental retardation or normal mental development, macular cher-
ry-red spot, progressive visual impairment, and myoclonus. 
Patients with Galactosialidosis are characterized by a 
combined deficiency of lysosomal neuraminidase and a-galacto-
sidase and urinary excretion of sialyloligosaccharides. Clini-
cally three different forms have been reported: 
an early infantile form with severe edema, ascites, 
skeletal dysplasia and ocular abnormalities where pa-
tients die shortly after birth. 
a late infantile form where symptoms occur after 6-12 
months such as dysmorphic facial features, skeletal 
dysplasia, visceromegaly, macular cherry-red spot and 
mild mental retardation. 
- a juvenile/adult form where clinical features occur 
during late childhood or early adulthood; the major 
symptoms are skeletal dysplasia, dysmorphism, corneal 
clouding, macular cherry-red spot, angiokeratomata, 
neurological manifestations and mental retardation. 
In addition there are different types of patients with 
GM1-gangliosidosis who are characterized by an isolated defi-
ciency of 6-galactosidase resulting in intralysosornal ac-
cumulation of GM1-ganglioside and a variety of physical abnor-
malities and mental retardation. 
One of the aims of the experimental work in our group is 
a better understanding of the molecular basis of clinical 
heterogeneity within certain lysosomal storage disorders. In 
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this context it is important to realize that gene mutations 
may interfere with a variety of molecular processes involved 
in the biosynthesis, modification and functioning of a lysoso-
mal (enzyme) protein. Mutations may interfere with the synthe-
sis of the precursor (enzyme) protein, they may block one of 
the many steps involved in the translocation, the phosphoryla-
tion and the correct compartmentalization into the lysosome. 
Furthermore, mutations may interfere with the correct aggrega-
tion of subunits or with other proteins, within the lysosome 
and also the molecular structure of the mature enzyme may be 
altered in such a way that the catalytic site does not 
function properly. Finally, lysosomal disorders are known 
where the defect concerns the interaction between enzyme and 
substrate (defective activator protein) or impairment of the 
lysosomal release of metabolites (such as N-acetylneuraminic 
acid storage disorders). 
One approach towards the elucidation of the genetic back-
ground of different disorders or of different clinical va-
riants of the same disorder is complementation analysis after 
hybridization of two mutant fibroblast strains. Such experi-
ments are described in publication I for different neuramini-
dase related diseases. It was shown that the neuraminidase 
deficiencies in Sialidosis, Galactosialidosis and "I-cell" 
disease are based on mutations in different genes. The clini-
cal variants within these diseases seem to be caused by dif-
ferent mutations within the same gene (allelic mutations}. 
Previous work by our group has revealed that the combined 
deficiencies of a-galactosidase and neuraminidase in Galacto-
sialidosis are caused by the lack of a 32 kDa glycoprotein 
which normally seems to be required for the protection of a-
galactosidase against rapid intralysosomal proteolytic degra-
dation. In publication II we show the molecular basis for this 
protection. In normal fibroblasts a-galactosidase exists main-
ly as a high density multimer (600-700 kDa) of B-galactosidase 
monomers (64 kDa). The 32 kDa "protective protein" was found 
to be essential for the aggregation of a-galactosidase mono-
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mers. The absence of the 32 kDa protein in Galactosialidosis 
results in rapid proteolytic degradation of normally synthe-
sized 64 kDa S-galactosidase monomers. 
The neuraminidase deficiency in Galactosialidosis re-
mained, however, unexplained and this was elucidated by the 
experimental work in publications III, IV and V. First (publi-
cation III) it was found for bovine testis that lysosomal 
neuraminidase exists in a complex together with 6-galactosi-
dase and the 32 kDa protective protein. A similar complex was 
later found in human placenta, cultured fibroblasts and leuco-
cytes. 
The purification and characterization of human neuramini-
dases had so far been hampered by the extreme lability of this 
membrane-bound enzyme. In publication IV a method is described 
which enabled us to purify neuraminidase. Inactive neuramini-
dase present in the soluble fraction of homogenized human 
placenta could be activated and stabilized by excessive con-
centration and 90 min. incubation at 37°C. Monospecific anti-
bodies against the 32 kDa protein were prepared and their use 
together with sucrose-density gradient centrifugation showed 
that this active neuraminidase and the 32 kDa protein are 
present only in a fraction containing high density 6-galacto-
sidase multimer. These results suggested that the 32 kDa 
protective protein also is essential for the catalytic activi-
ty of lysosomal neuraminidase. 
In publication V we report the purification and partial 
characterization of human lysosomal neuraminidase. The results 
indicate that in addition to the 32 kDa protein another 
subunit (76 kDa) is associated with neuraminidase activity. 
Antibodies reacting with this subunit have been prepared. 
These results not only explain the neuraminidase defi-
ciency in Galactosialidosis but also form the basis for future 
studies aimed at the elucidation of. the exact molecular defect 
in different variants of Sialidosis. 
The importance of selecting the correct cell material for 
biochemical diagnosis of neuraminidase related disorders is 
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illustrated by observations described in publication VI. A 
total leucocyte preparation (granulocytes and lymphocytes) was 
found to contain two types of lysosomal neuraminidase, only 
one of which is genetically deficient. As a consequence such 
cell material is not an adequate source for diagnostic 
purposes in contrast with fibroblasts and isolated blood lym-
phocytes, which mainly contain the neuraminidase defective in 
(Galacto)sialidosis. 
Several investigators have attempted to relate the se-
verity of clinical features and the residual enzyme activity 
in selected cell types from patients with different variants 
of the same genetic disease. Such attempts are complicated by 
the fact that clinical features are the result of complex 
interactions of pathophysiological processes in a variety of 
organ systems and cells. Also, 
out on a homogenate of one 
substrate(s). The difficulty in 
most enzyme 
cell type 
explaining 
assays are carried 
using artificial 
the clinical hete-
rogeneity is illustrated by the work on different variants of 
Galactosialidosis, described in publication VII. 
I~~unoprecipitation studies on fibroblasts from patients 
with the early infantile form and the juvenile/adult form show 
an absence of the 32 kDa protective protein and a small amount 
of its 52 kDa precursor. The milder clinical course in the 
juvenile/adult form cannot yet be explained on the basis of 
these molecular studies. In cells from patients with the late 
infantile form, however, an excessive amount of this 52 kDa 
precursor was found which appeared to be due to a defective 
processing into the 32 kDa protein. In the latter patients the 
small residual amount of 32 kDa protein is apparently suffi-
cient to yield 1-5% neuraminidase. 
The experimental work reported in this thesis has led to 
the explanation of the neuraminidase deficiency in the lysoso-
mal storage disorder Galactosialidosis. It has also contri-
buted to our understanding of the relationships in normal and 
mutant cells of the 6-galactosidase, neuraminidase and the 32 
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kDa protective protein complex. Further studies on the prima-
ry, secundary and tertiary structure of these components, as 
well as their stoichiometry, will hopefully lead to a better 
understanding of the normal protective mechanism of (enzyme) 
protein in the lysosome and of the exact molecular defects in 
the different variants of Sialidoses. 
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SAMENVATTING 
Sinds de Duve's groep in 1955 het voor intracellulaire 
afbraakprocessen belangrijke celorganel, het lysosoom, ontdek-
te, zijn meer dan 70 lysosomale hydrolases beschreven. Een 
erfelijk bepaalde defici~ntie van een van deze enzymen kan tot 
gevolg hebben dat allerlei intra- of extracellulaire com-
ponenten in de lysosornen ophopen. Afhankelijk van de funktie 
van bet enzyrn, mate van ophoping en de invloed op bet cel-
lulaire metabolisme, zullen een groot aantal verschillende 
klinische en pathologische syrnptomen optreden. Tot nu toe zijn 
meer dan 30 lysosomale stapelingsziekten bekend, die bijna 
allernaal autosomaal recessief overerven. 
Dit proefschrift beschrijft de genetische en moleculaire 
karakterisering van erfelijk bepaalde ziekten met een defi-
ci~ntie van lysosomaal neuraminidase. 
Neuraminidases (EC 3.2.1.18, sialidase, N-acetylneura-
minosyl-glycohydrolase) katalyseren de hydrolyse van neurami-
nezuur (siaalzuur) residuen van een groot aantal neuramine-
zuur-bevattende stoffen. Deze enzymen zijn wijd verbreid in de 
natuur en vormen in zoogdiercellen wat betreft hun subcel-
lulaire localisatie en substraat specificiteit een heterogene 
groep. Ons experimentele werk heeft zich toegespitst op de 
lysosomale neurarninidases die de splitsing van N-acetylneura-
minezuur residuen van glycoprote!nen, oligosacchariden en 
glycopeptiden katalyseren. Bet beschikbaar kornen van een 
kunstrnatig fluorogeen substraat (4-methylumbelliferyl-N-ace-
tylneuraminezuur) heeft een gevoelige en betrouwbare enzyrn 
activiteits bepalingsmethode mogelijk gernaakt en heeft diag-
nostisch werk en bet onderzoek beschreven in dit proefschrift 
vergernakkelijkt. 
Pati~nten met de lysosomale stapelingsziekte Sialidose 
hebben een gegeneraliseerde defici~ntie van bet enzyrn neurami-
nidase, die bepaald kan worden in gekweekte huidfibroblasten 
of in uit het bloed ge!soleerde lymfocyten. De pati~nten 
scheiden grote hoeveelheden gebonden N-acetylneuraminezuur in 
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de urine uit en vertonen ook een verhoging van 
(gekweekte) huidfibroblasten en andere celtypen. 
deze stof in 
klinische verschijnselen kunnen twee vormen van 
Gebaseerd op 
de ziekte 
worden onderscheiden: 
- een ernstige, dysmorfe vorm, gekarakteriseerd door 
ernstige mentale retardatie, skeletafwijkingen, ge-
laatstrekken zoals bij het syndroom van Hurler, "Cher-
ry-red spots" op de macula, myoclonie~n, nierafwij-
kingen en een snel progressief verloop. 
- Een mildere, normomorfe vorrn, gekenmerkt door later 
optredende symptomen, een normale mentale ontwikkeling 
of een milde retardatie, "cherry-red spots" op de ma-
cula, progressief visuele afwijkingen en rnyoclonie~n. 
Pati~nten met Galactosialidose zijn biochemisch geken-
merkt door een samengestelde defici~ntie van de lysosomale 
enzymen neuraminidase en a-galactosidase en door de uitschei-
ding in de urine van sialyloligosacchariden. Gebaseerd op 
klinische verschijnselen kunnen drie verschillende vormen 
worden onderscheiden: 
- Een vroeg-infantile vorm, met ernstig oedeem, ascites 
en oogafwijkingen. De pati~nten overlijden kort na de 
geboorte. 
Een laat infantiele vorm waarin de verschijnselen op-
treden tussen 6 en 12 maanden na de geboorte; zoals 
vervormde gelaatstrekken, skeletafwijkingen, viscerome-
galie, "cherry-red spots" op de macula en milde mentale 
retardatie. 
- Een juveniele/adulte vorm waarin de klinische 
verschijnselen optreden in de adolescentie periode; de 
belangrijkste symptomen zijn skeletafwijkingen, dysmor-
fiegn, vertroebeling van de cornea, "cherry-red spots" 
op de macula, angiokeratomata, neurologische ver-
schijnselen vaak gepaard gaande met rnentale retardatie. 
Een andere categorie pati~nten. bestaat, met de ziekte 
GMl-gangliosidose, gekenmerkt door een enkelvoudige defici~n-
tie van a-galactosidase, die resulteert in lysosomale stape-
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ling van GMl-ganglioside en een aantal verschillende fysieke 
en mentale afwijkingen. 
Een van de doelstellingen van het experimentele werk 
binnen onze groep is het verkrijgen van een breder inzicht in 
de moleculaire achtergrond van de klinische heterogeniteit 
binnen bepaalde lysosomale stapelingsziekten. In dit verband 
is bet belangrijk om zich te realiseren dat genmutaties in-
vloed kunnen hebben op een groot aantal verschillende mole-
culaire processen die betrokken zijn bij de biosynthese, rnodi-
ficatie en werking van een lysosomaal enzyrn (eiwit). Mutaties 
kunnen invloed hebben op de synthese van het precursor (enzym) 
eiwit, of kunnen een van de vele stappen blokkeren die tijdens 
de translocatie, glycosylering en fosforylering, en uiteinde-
lijke lysosomale bestemming van een nieuw gesynthetiseerd 
(enzym) eiwit plaatsvinden. Mutaties kunnen bovendien in het 
lysosoorn zelf nog invloed hebben op de correcte associatie van 
subeenheden, of andere eiwitten, en mutaties kunnen een zoda-
nige verandering van de moleculaire structuur teweegbrengen, 
dat de plaats op het enzym betrokken bij de katalyse ("cataly-
tic site") niet goed rneer functioneert. Andere lysosornale 
stapelingsziekten zijn bekend waarin de interactie tussen 
enzym en substraat niet goed plaatsvindt (activator defici~n­
ties), of waarin de enzymatische afbraakprocessen wel normaal 
verlopen, maar de ontstane metabolieten het lysosoorn niet 
kunnen verlaten (zeals in vrij N-acetyl-neuraminezuur stape-
lingsziekten). 
Een benaderingswijze voor de opheldering van de gene-
tische achtergrond van verschillende ziekten of verschillende 
klinische varianten van een ziekte is de cornplementatie ana-
lyse. Zulke experimenten voor de verschillende met neuramini-
dase geassocie~rde ziektebeelden zijn beschreven in publika-
tie I. Hierin wordt aangetoond dat de neuraminidase defici~n­
tie in Sialidose, Galactosialidose en "I-cell disease" wordt 
veroorzaakt door mutaties in verschillende genen. De klinische 
varianten binnen een ziekte daarentegen worden waarschijnlijk 
veroorzaakt door verschillende mutaties binnen hetzelfde gen 
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(allele mutaties) . 
Uit eerder werk van onze groep is gebleken, dat de gecom-
bineerde a-galactosidase en neuraminidase defici~ntie in ga-
lactosialidose wordt veroorzaakt door het ontbreken van een 32 
kDa glycoprote!ne dat essentieel is voor de bescherming van B-
galactosidase tegen snelle intralysosomale proteolytische 
afbraak. In publikatie II wordt getoond hoe deze bescherming 
op moleculair niveau plaatsvindt. In normale fibroblasten 
bestaat 8-galactosidase hoofdzakelijk als een multimeer van B-
galactosidase (64 kDa) rnonomeren met een hoge dichtheid (600-
700 kDa). Het 32 kDa "beschermend eiwit" bleek essentie~l voor 
aggregatie van B-galactosidase monorneren. De afwezigheid van 
het 32 kDa eiwit leidt tot versnelde proteolytische afbraak 
van de normaal gesynthetiseerde 64 kDa B-galactosidase mono-
meren. 
De neuraminidase defici~ntie in Galactosialidosis bleef 
echter onbegrepen tot het experimentele werk in publika-
tie III, IV env. Ten eerste (publikatie III) werd gevonden dat 
lysosomaal neuraminidase uit rundertestis zich in een complex 
bevindt samen met a-galactosidase en het 32 kDa beschermend 
eiwit. Later kon zo'n zelfde complex worden aangetoond in 
menselijke leucocyten, fibroblasten en placenta. 
Zuivering en karakterisering van menselijke neuramini-
dases was tot nu to niet mogelijk door de extreme labiliteit 
van dit membraan-gebonden enzym. In publicatie IV beschrijven 
we· een methode die ons in staat stelde om met de zuivering van 
neuraminidase te beginnen. Een inactieve vorm van neuramini-
dase, die aanwezig is in de oplosbare fractie van gehomogeni-
seerde menselijke placenta's, kon worden omgezet in een ac-
tieve en stabiele vorm d.rn.v. sterke concentrering gevolgd 
door een incubatie bij 37°C. Monospecifieke antilichamen tegen 
het 32 kDa eiwit konden worden gemaakt en gebruikt in cornbina-
tie met sucrose-gradient experimenten, om aan te tonen dat 
actief neuraminidase en het 32 kDa eiwit alleen aanwezig zijn 
in een fractie van B-galactosidase multirneren met een hoge 
dichtheid. Deze resultaten suggereerden dat het 32 kDa be-
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schermend eiwit ook nodig is voor de katalytische activiteit 
van lysosomaal neuraminidase. 
In publikatie V wordt gerapporteerd over de zuivering en 
karakterisering van lysosornaal neuraminidase van de mens. De 
resultaten laten zien dat naast het 32 kDa eiwit nog een 
andere subeenheid (76 kDa) is betrokken bij bet tot stand 
komen van neuraminidase activiteit. Vervolgens konden antili-
chamen tegen deze subeenheid worden gemaakt. 
Deze resultaten verklaren niet alleen de neuraminidase 
defici~ntie in Galactosialidose, maar vorrnen ook een beginpunt 
voor verdere studies naar de preciese moleculaire achtergrond 
in de verschillende varianten van Sialidose. 
Alvorens een biochemische diagnose wordt uitgevoerd, is 
een goede celrnateriaal keuze van belang, hetgeen gelllustreerd 
wordt door waarnemingen in publikatie VI. Leukocyten (een 
mengsel van granulocyten en lymfocyten) bevatten twee ver-
schillende neurarninidases, waarvan er slechts een defici~nt is 
in sialidose. Dit celrnateriaal is dan ook geen geschikte bron 
voor diagnostische doeleinden. Dit in tegenstelling met fibro-
blasten en uit leukocyten geisoleerde lyrnfocyten die hoofd-
zakelijk die neuraminidase bevatten, die defici~nt is in (Ga-
lacto)sialidose. 
Verscheidene onderzoekers hebben geprobeerd om relaties 
te leggen tussen de ernst van de klinische verschijnselen en 
de residuele enzymactiviteit, gevonden in bepaalde cellen van 
pati~nten met verschillende variante vormen van dezelfde gene-
tische ziekte. Zulke pogingen worden gecompliceerd door het 
feit dat de klinische symptornen een gevolg zijn van complexe 
interacties van pathofysiologische processen in verscheidene 
organen en cellen. Bovendien worden de meeste enzymbepalingen 
uitgevoerd met artifici~le substraten op homogenaten gemaakt 
van slechts een celtype. De moeilijkheid in bet verklaren van 
de genetische heterogeniteit is geillustreerd door bet werk 
met Galactosialidose varianten beschreven in publikatie VII. 
Imrnunoprecipitatie studies met fibroblasten van pati~nten 
met de vroege-infantiele vorm en de juveniele/adulte vorm 
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toonden aan dat het 32 kDa beschermend eiwit afwezig is en dat 
slechts een zeer geringe hoeveelheid van de 52 kDa "precursor" 
aanwezig is. Het mildere klinisch verloop in de juve-
niele/adulte vorm kan op basis van deze moleculaire studies 
nog niet worden verklaard. In cellen van pati~nten met de 
laat-infantiele vorm werd een verhoogde hoeveelheid 52 kDa 
"precursor" gevonden, welke veroorzaakt lijkt te worden door 
een defect in de "processing" naar de 32 kDa vorm. Blijkbaar 
is de kleine hoeveelheid 32 kDa eiwit genoeg om te zorgen voor 
geringe neuraminidase activiteit (1-5%). 
Het in 
heeft geleid 
ci~ntie in 
dit proefschrift beschreven experirnentele werk 
tot een verklaring van de neuraminidase defi-
de lysosornale stapelingsziekte Galactosialidose. 
Bovendien heeft dit werk bijgedragen tot een beter begrip van 
bet B-galactosidase, neuraminidase, 32 kDa bescherrnend eiwit 
complex in normale- en rnutante cellen. Toekomstige studies aan 
de primaire, secundaire en tertiaire structuur van deze compo-
nenten en aan de stoichiometrie van het complex zullen hope-
lijk kunnen leiden tot een beter begrip van het normale be-
scherrningsmechanisrne van lysosomale (enzyrn) eiwitten en van de 
preciese rnoleculaire defecten in de verschillende Sialidose 
varianten. 
80 
NAWOORD 
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Allereerst wil ik mijn ouders bedanken voor de 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 13 februari 
1956 te Rotterdam geboren. In 1974 werd het diploma Atheneum B 
behaald aan het Franciscuscollege te Rotterdam. In datzelfde 
jaar werd, na uitloting voor de studie diergeneeskunde, begon-
nen met de studie biologie aan de Gemeente Universiteit van 
~msterdam. Na het Kandidaatsexamen medische biologie (B1 ') in 
september 1977 werd op 18 juni 1980 "Cum laude" bet doc-
toraalexamen afgelegd, met als hoofdvak celbiologie (Prof. Dr. 
H. Galjaard, Rotterdam) en als bijvakken biochemie (Prof. Dr. 
J.M. Tager, Amsterdam) en immunologie (Prof. Dr .• K.W. Pondrnan, 
Amsterdam) • 
Van 1 juli 1980 tot 31 december 1985 is hij in dienst 
geweest als wetenschappelijk assistent op de afdeling Celbio-
logie en Genetica (Prof. Dr. H. Galjaard) van de Erasmus 
Universiteit te Rotterdam. In deze periode werd het in dit 
proefschrift beschreven onderzoek verricht en werd practicum 
onderwijs in de celbiologie en histologie gegeven aan le jaars 
studenten geneeskunde. 
Op 1 januari 1986 volgde een aanstelling als wetenschap-
pelijk onderzoeker bij bovengenoemde afdeling. 
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Genetic heterogeneity in 
human neuraminidase deficiency 
A. T. Hoo~evecn, F. W. Verheijen, A. d'Azzo & 
H. Gnljaard 
Department of Cell Biology and Genetic,, Era,mu~ Univen.ity. 
Rouerdam, The Nethcrhmd> 
There is u deficiency of human :t-!V-ncety!neuraminidnsc in 
several inherited diseases. In patients with mucolipidosis I (refs 
1.2) and in adult<; with a variant form without bony 
abnormalities and mental rctardntion·'-•, both also classified as 
sinlidoses•, it io; the only deficient enzyme. In muco!ipidosis II 
('I.-cell' di.••;ca.•>c) neur:aminida..<;e i-; one of many deficient 
lywsomal hydrolnscs,_' and a third manifestation combines 
deficiency of neuraminidase and P·t::alactosida._<;e•.•. We have 
investigated the genetic background of 1hcse various 
neuraminidase deficiencies by somatic edl hybddi1.ation and eo-
cultivation. The principal conclusions from work on mutant 
fibroblasts, reported here. are that at least three gene mutation.-. 
are involved and tlmt the combined P-1-!alaetosida:.e/ 
neur.uninida•;e deficiency is likely to be due to defective post· 
transla.rional modification or these enzymes. 
Table l summarizes the neuraminic acid content and the 
activities of {)-galactosidase and neuraminidase in the different 
mutant fibroblasts and 4 days after fusion of each cell type 
with itself (parental fusion). The activity of neuraminidase was 
measured with N-acctylneuraminosyl-o-lactosc and with 4--
methylumbc\liferyl-o:-2-N-acetylneuraminic acid (provided by 
Dr J. S. O'Brien). and similar results were obtained with both 
substrates. Because of its simplicity and high sensitivity, we 
have used principally the fluorometric ;:t,_"..;;ay, the results of 
which are reported here. As Table 1 shows, the neuraminidase 
activity in fibrobla.-.ts from a severely mentally retarded 11-yr-
old girl with the classical form of mucolipidosis 1 (ML 1). also 
classified as sialidosis 2 (ref. 4}, was 1% of control values. Cells 
from a patient with a variant form described by Durand t:t 
Table 2 Cell hybridiT.mion and co-cultivation of ncuraminidase-
dcflcienl human flbrobla.~t' 
Combination of cell 'train~ 
!..:ell andcla.". ML l 
1-eell and variant MLJ 
!..:ell and adult P·.,:al· /neur· 
!..:ell and infantile 
P-gal· /neur· 
Cla."'· MLl and variant ML I 
Adult P-r;;J' /neur· and 
infant. P-gal· jneur· 
Cla>s. ML I and adult 
P-gal- jneur· 
Cla,s. ML l and infant. 
t}-p.l'/neur· 
Variant ML I and adult 
P·gJJ.l '/neur· 
Variant MLI and inf:.~nt. 
fi-t:al' /neur· 
Neuraminidase activity 
{ x w-Q mot per h permgprotein) 
Hybridization Co-cultivation 
6.::! 0.5 
9.6 1.::! 
3.5 0.6 
58 0.::! 
1.6 1.::! 
O.B 1.0 
9.9 3.7 
5.0 3.0 
7.0 9.0 
'·' 
9.9 
Value are the means of three to ,ix independent expenments. 
Hybridi7.ation wa.' carried out with polyethylene glycol a~ before'> 
adapted for human fibrobta.~l' in monolayer. 106 cells of both eel\ 
,tr..tin' were mixed 4 da)'1> before fu,ion and cultivated in Ham's FlO 
medium with 10% fetal calf ,.;rum. The medium wa.~ changed after 3 
days and 1 day !mer cells were rin»<:d twice with medium without 
,erum. and after removal of the medium. hybridization was carried out 
a' fo\\o.....s: 1 ml of 4::!% polyethylene glyeol (PEG) molecular wei.,:ht 
1,000 (Koch-Light) in Ham's FlO with 15% DMSO wa.~ ::.dded. The 
mixtu.re was rocked for :!min, I ml ::!5% PEG in Ham's FlO was 
added. the mixture wa.~ rocked a.,:ain and Sml Ham\ FlO wa' added 
twice. After rockin~;. the medium wa,; removed, the eel\, nn:.ed with 
Ham's FlO and then Ham·, FlO with 10% fetal calf 'erum wa.~ added. 
After 4 day> of cultivation in the ~ame medium, the heterokaryon 
population wa.> eo\\ccted and :maly~ed for neuraminidase activity 
u"ng 4-methylumbe\\iferyl a' sub\.trate. Miero~py of stain<..d 
preparation~ after eel\ fusion revealed that 70-W/,, of the eells 
cont:>ined more than one nuelcm, and autoradiography after 
incorpomtion of 'H-thymidinc showed that nearly all multinucleate 
cdb were heterokaryon,. 
Table t Acuvitie>. of P-galaetosidase and neuraminidase. and neuraminic acid content in mutant human fibrobla.,ts and efTect ol''cel\ fusion 
Neurammida.-.c 
Total neuraminic acid P-Galacto"da.-.e Unfu:.ed After parental 
Cell type oo~~mol per mg) fu~ion 
I -Cell* 
"' 
9 0.3 0.::! 
Cla.-;sical ML l* 
" 
730 L3 0.7 
Variant ML J• ., 850 
'·' 
3.9 
Adiitt P-f!:al- /neur· 60 95 L3 1.5 
Infantile {J-gJJ.l. jneur· 59 98 06 0.7 
Heterozygous mother 
" 
579 
" Heterozygous father 17 6::!7 ]9
Control flbrobtasts 
M~o ::!::! 6]0 82 
Range 15-31 350-1,050 43-129 
[n-= 17) (n=36) {n= 17) 
Aetivitie> are expressed JS nmol per h per mg protein and the values given are the means of three to six independent experiments on each 
mutant strain and on a large number ofeontrol fibroblasts. In all instances flbroblasts were cultured in Ham's FlO medium with 10/,, fetal calf 
serum and they were collected by trypsmization, rinsed in saline and centrifuged. Cells were disrupted by addition of bidistillcd water tO the pellet, 
and after shaking. the homogenate was used directly f<;~r biochemi~al analysis. Neumminida": activity wa.~ determmed wnh methytumbc\\iferyl 
substr:J.te (provided by Drs T. Warner and J. S. O'Brien. >ee ref. 20 for ~ynthe,is). Cell homo.,:enatc O)!JJ was incubmed with 2J.J-I ZmM substrate 
in 0.::!5 M Na-acetate bufTer. pH4.3. for 1-2 h at 37 oC; the fluorescence of the liberated mcthylumbelliferone wa.' measured :.~fter addition of 500 J.J-1 
0.5 M sodium carbonate bufTer. pH !0.7. at 448nm. The activity of .8-.,:alaetosida..e y;as also mea.~ured with methylumbelliferyt substrate a.~ before• 
Total neuraminic acid content w:J.S measured after hydrolysis of the cells for l h at sooc in 0.1 N H~SO.,. according to Warren'' 
•Cultured fibroblasts from :1 patient with mucolipidosis I were provided by Dr H. D. Bak~cr; thosc from a patient with a variant form (De PF 
in rd. 3) by Dr P. Durand. and those from a patient with 1-cel\ d~'<C115e by Dr A. Boue. 
a/.3• and sometimes classified as sialidosis I (ref. 4). had a 
residual activity_ of 4-5',%',. This higher residual activity is 
probably responsible for the lower neuraminic acid content in 
these fibroblasts. 
Fibroblasts from a mentally retarded adult male with 
myoclonus and ataxia10 and from a 2-yr-old boy with Hurler-
like features but no neurological abnormalities'' had a 
profound neuraminidase deficiency in addition to a 10% 
residual activity of ,B-galactosidase (Table 1). These two 
patients had previously been classified as variant forms of 
G"wgangliosidosis' z or ,B-galactosidasc deficiency13 on the 
basis of complementation after fusion with fibroblasts from 
patients with a primary defect of .B·galactosidase. Fibroblasts 
from both parents of the patient with infantile p. 
galactosidase/neuraminidase deficiency (p..gai-/neur·) had 
normal activity of .B·galaetosidase but neuraminidase activity 
was about half the mean control value (Table I). This makes it 
unlikely that ,6-ga!aetosidase deficiency is the primary defect in 
this condition.· One of our patients with P..gal-(neur· has 
recently been classified as sialidosis II (ref. 4). Because the 
primary defect in this condition has not yet been resolved and 
the syndromes included in the category sialidosis 2 are so 
different clinically, biochemic::Uly and even genetically. such 
classification seems somewhat premature: 
We have studied the genetic background of the various 
neuraminidase deficiencies by complementation analysis after 
somatic cell hybridization. The results of enzyme assays 4 days 
after fusion of each cell strain with itself (parental fusion in 
Table I) indicate that the polyethylene glycol (PEG) method 
of hybridization 14 does not affect neuraminidase activity. The 
results of fusions of different mutant cell strains arc 
summarized in the second column of Table 2. Compared with 
parental fusions. there was 4--15 times as much neuraminidase 
activity after fusion of I-cells with each of the other mutant 
fibroblasts. The activities after co-cultivation (third column of 
Table 2) were not higher than the average values for each pair 
of parental cells. The complementation observed after fusion of 
I-cells with each of the other mutant fibroblasts i.<> most 
probably due to a correction of the post-translational defect in 
!-cell disease 7• The rapid generation of neuraminidase activity 
and of other lysosomal hydrola:>es after fusion of l-ce\ls with 
various other mutant fibroblasts 15 would agree with a 
normalization of the processing and(or activation of preformed 
glycosidascs. 
The fusions of classical M L I x variant M L I did not result 
in complementation and these conditions probably represent 
different mutations within one gene. The ~me is true for the 
adult type and infantile type of p-gal~ (neur- deficiency. 
Fusions of each of the MLI strJ.ins with eaell of the 
,B-gal-/neur~ deficient fibroblasts, however. resulted in a clear 
increase in neuraminidase activity (3-9 times the values after 
parental fusion). This indicates that tWO different gene 
mutations are involved in the neuraminidase deficiency of 
sialidosis I and the combined ,B-gal- jncur·. The res.toration of 
neuraminidase activity after fusion of ML I cells with 
.8-S'al" /neur- fibroblasts might result because one cell type. 
most probably ML I. is deficient in the structural part of the 
enzyme and the other is defective in a modifying enzyme or a 
regulatory factor. Another explanation could be that 
neurJ.minidase is made up of different subunits which must be 
normal for the expression of its activity. 
Neuraminidase activity also increased after co-cultivation of 
the different types of MLI cells with each of the ,B-gal" (ncur· 
fibroblasts (compare last column Table 2 with average values 
of both parental strains in Table I). This partial restoration of 
neurJ.minidase activity was investigated further by labelling the 
mutant fibroblasts with fluorescent pol)l'>tyrcne beads.. followed 
by co-cultiv:.ttion for 3 days, separation of the two cell 
populations by two-colour flow sorting (FACS II) according 
to Jongkind er 1:1/. "' and assay of neuraminidase. Table 3 
shows a marked incre-J.se in neuraminidase activity in the 
combined .8-gal-(neur· fibroblasts whereas the MLI cells 
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remain deficient. We could find no neuraminidase activity in 
the culture medium above the mutant cells and the labelling 
did not a!Tect the enzyme activity. These experiments suggest 
the transfer of an unknown factor from MLI cells to 
fibroblasts with a combined ,B-gal- (ncur- deficiency, a factor 
which can increase the neuraminidase activity in the latter cells 
four- to sevenfold. Normal human fibroblasts also secrete this 
'correction factor·. We found no evidence of an activator "that 
could act in vitro. for mixing of homogenates of the two kinds 
of cells did not affect enzyme activity. The correction observed 
after hybridization (Table 2) and after co-cultivation (Table 3) 
may represent a normalization of the post-translational 
Table 3 Co-cultivation of different neuraminidase-deficient cdl 
str.Uns and enzyme assays after two-colour now sorting (FACS II) 
Neuramini~ activity 
( x 10·• mol per h permgprotcin) 
Before Arter Jd 
Cell type 
C!a.<..~ical ML I 
Infantile P-gal-(neur-
Mixed cell population 
eo-cultivation 
0.7 
co-cultivation 
0.7 
0.8 5.3 
0.7 29 
Red polystyrene beads were added to the culture medium above 
classical MLI cell~ ldt for 2 days. and cell~ were eolle<;:ted by 
trypsinization, rinsed and centrifuged (I,OOOr.p.m. for 5-IOmin). The 
same wa.~ done with green beads for P-gal" /neur· fibrobla.stl.. About 2 
x 10~ cells of each labelled type were seeded and co-cultivated in 
eonfluency for 3 days. The two labelled cell populations were then 
separated and collected with a FACS II cell sorter according to 
Jongkind ct a/. 10 and neuraminida.«e activity wa.~ mea.~ured as 
described in Table l. The value~ given are the mean of three 
independent experiments which pve very similar values. 
processing of neuraminidase and {J-galactosidase. It remains to 
be seen how neuraminidase is related to these processes.. for 
neuraminidase deficiency can also occur without p. 
galactosidase deficiency. N-acctylneuraminic acid is. however, 
a common component of glycoprotcins. certain 
glycosaminoglycans and gangliosides.' 7 • '~. and different 
neuraminida..;;es have a role in the degradation of these 
compoundsn. 10• A better understanding of the nature of the 
neuraminidase deficiency in the various mutant cells might 
resolve the interrelationship with ,B-galactosidase deficiency. 
Further charactcri7.ation of the correction factor is in progress: 
its heat lability. affinity for concanavalin A and the fact that l· 
cells cannot provide it (co-cultivation studies in Table 2) 
suggest that it is a glycoprotein. 
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The Relation between Human 
Lysosomal ~-Galactosidase and Its 
Protective Protein* 
(Recciwd for publication, May 2, 1983) 
AndrO:· T. Hoogevccn, Frnn,; W. Verhcijcn, and 
Hans Galjaurd:l: 
From the Dcp<~rtmrnt of Cell BioWcy and c,.!U'tic>~, 
Erasmu.s Uni~.~<:rsity, Rottadam. tW Nrt/u:rlaruis 
Cultured skin fibroblasts from patients with the ly-
sosomal storage disease galactosialidosis lack a 54-kDa 
protein which is a precursor of 32-kDa and 20-kDa 
proteins. which immunoprecipitate with human anti-
.8-~actosida....e- antiserum. The lack of a 32-kDa .. pro-
tective protein .. results in a combined deficiency of {j-
galactosida.~ and sialidase. The mechanism of protec-
tion of lysosomal .B-galactosidase against proteolytic 
degradation is elucidated by sucrose density gradient 
centrifugation and immunoprccipitation studies. In 
normal fibroblasts at the low intralysosomal pH, more 
than 85% of ,8-galactosidasc exists as a high molecular 
weight (600-700 kDa) multimer and about 10% as a 
monomer of64-kDa. In mutant cells from galactosiali-
dosis patients. the residual enzyme activity, about 10%. 
is pre:<~ent as a monomer and no multimer exists. After 
addition of the 54-kDa precursor form of the protective 
protein, the density pattern of .8-galactosidasc in gal-
actosialidosi.s cells is normalized. Immunoprecipitation 
studies after sucrose density gradient centrifugation 
on homogenate and on purified P-galactosidase from 
normal fibroblasts show that the protective protein is 
associated only with the multimeric form of .8-galac-
tosida..:;e. We propose that intralysosomal protection 
against proteolysis of .8-galactosidasc and sialidase is 
accomplished by aggregation into a high molecular 
weight complex consisting of multimeric .8-galactosid-
ase. sialidase, and protective protein. The genetic de-
ficiency of the latter. as in galactosialidosis. results in 
a rapid degradation of monomeric .8-galactosidasc and 
a loss of sialida._.:;e activity. 
The lysosomal enzyme P-n-gnlactosidase {EC 3.2.1.23) cat-
alyzes the hydrolysis of the /3-D-galilctosyl moiety from Gr-w 
pnglioside.' nsialo-Gr-n ·ganglioside, galactose containing gly-
cosaminog"!ycans, and a variety of synthetic substrates {1, 2). 
Genetic deficiencies in man involving /J-galactosidnse have 
been found in patients with different' types of lyso...:;omal 
storage disease; biochemical and genetic studies of cultured 
skin fibroblasts from such patients have contributed to our 
• The cost~ of publication of thiR article were defrayed in part by 
tho: payment of paf:"<: charf:"e~. ThiR article mUIIt therefore be hereby 
marked "advertisement" in accordance with 18 U.S.C. Section 1734 
~olely to indicuto: this fact. 
:j: To whom reprint request~ should be addre~Red at, Do:partment 
of CeU Biology and G~netie><. Erm<mus University, P. 0. Box 1738. 
3000 DR Rotterdam, the Netho:rlund.~. 
1 Tho: trivial name used is: G"h N-a~tylncuruminylf:"anglio· 
tetruglyco~ylceramido:. 
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understandin~ of both the normal and mutant enzyme {for 
reviews. see Refs. 2-4). 
In normal human tissues and cultured cells, nctive lysoso-
mal ,6-galactosidase exists as a monomeric form with a molec-
ular mass of 64-kDu unci a high molecular mass aggregate of 
the 88.me polypeptide of approximately 700-kDa {5, 6). In 
purified preparutions from human placenta {7) and porcine 
~<pleen (8), additional proteins with a molecular mass of 31-
kDu and 21-kDa have been desi;;nated as contaminD.nts. Re-
cently, d'Azzo et aL {9) reported the absence of these latter 
proteins in cells from patients with galactosialidosis, an au-
tosomal recessive inherited lysosomal storage disease which 
is associuted with a coexistent deficiency of ,6-galactosidaSe 
and sialidnse {10, 11). The same investigutors also showed 
that the lack of these 32-kDa and 20-kDa proteins lends to 
enhanced intralysosomol degradntion of p-galactosidase. It 
was postulated that in normal cells a 32-kDa protective pro-
tein i8 required to protect P-galacto8idnse against the action 
of intralysosomal proteases (9). 
The purpose of the present study wa8 to investigate the 
relationship between the protective protein{s) and the absence 
of the high molecular weight form of ,6-galactosidase which 
was previously found in cells from galactosialidosis patients 
(6). Using sucro8e density p-adient centrifugation followed by 
immunoprecipitation studies with anti-}3-galactosidn..'l{' anti-
serum, we 8how that the 32·kDa and 20-kDa protective pro-
tein::: are derived from a 54-kDa precursor protein and that 
these proteins are essential for the aggregation of monomeric 
il·gnlactosidase. When !l-galactosidnse is not aggregated into 
a high molecular weight form, it is rapidly degraded by lyso-
somal cathepsins. The functional si;;nificance of this obser-
vation is discussed. 
E."XPERIMENTAL PROCEDURES 
Prcpq.ratWn of CcU Matcrial.,-Human skin fibrobiust.q from a 
normal individual and from a patient with galuctosialidoRis det<Cribed 
by Kleiier ct aL {12) wt•re obtained from the Rotterdam Cell &posi-
tory (Dr. M. F. Niermeijer). The cell~ were cultivated in Ham's FlO 
medium {Flow Laboratories, McLean, VA) supplemented with 10% 
fetal calf t<erum and antibiotiC!< (Gibco). Early pllSSU~ of the cell 
Htra.ins wero: grown in 75 em~ Falcon flasks to a density of 1 to 2 ID!:" 
of protein/f"l;.llik. The cells from one fla~k were harvested by trypsin-
ization, rinRCd in saline, and centrifuged (10 min at 90 x g) as reported 
('arli~r (13). The cell pellet waB lyRCd by suspending in 100 ;J of 20 
mM Ka phosphate. pH 6.0. containing 100 mM NaCI and 1~ (w/v) 
Zwitterionic detergent 3-12 (Ca.lbiochem) (Buffer A). This oo.mple is 
centrifuged at 10,000 rpm during 10 min at 4 ·e: Tbe supernatant 
wo.~ ut«"d for funho:r ~tudieR. 
Sw:ro~e Density Grrui.i.cn.t Ccn.trifu,;at.Wn-SucrO!M: d~nsity r:radient 
centrifugation wo.<, performed by the method of Martin and Ames 
{14). Lino:ur r:radients of 20 to 40% (w/v) sucrose in Buffer A were 
prepared in a total volume of 5 ml. Samplctl of 100 ;J of supernatant 
were layered on to the top of the gradient and centrifut;ation was 
carried out at 40,000 rpm for 15 h at 4 ·c in a Beckman LS-65 
ultraco:ntrifuge with an SW 50·1 rotor. After centrifugation. 175-~<l 
fraction~ were collected and S-galuetosido.RC o.~says with 1 mM 4· 
methylumbelliferyi-S·O·f:"alactopyrnno~de as a substrate were per· 
formed on 10·~<1 samplCK o.~ described earlier (13). 
Immu.noprccipitat.ion of RadWactWe S-Gaklctosidasc-This immu· 
noprecipitation was perlormed nc<:ording to procedures described 
earlier (9, 15). At 3-4 days before labeling, the Ham's FlO medium 
was r.:placed bv Dulbecco'R modification of Eagle's medium (Flow 
LaborutoriCK) s~pplerncnted with 10% fetal calf t<erurn nnd antibiot· 
ics. One hour prior to labeling. this medium was replaced by Dulbec· 
co's medium free of l~ucine. SubRCquently, replacement by 6 ml of 
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thi~ t<Ume medium ~upplcml'ntcd with 0.2 ml of dialyzed fetnl calf 
serum and 0.2 ml of L-[4,5-'H]l<;>ucine i~ performed (0.2 mCi, 135 Ci/ 
mmol, Amernhum Rndiochcmicul C('ntl'e). The cell~ weN' 170wn for 
48 h in the presence of this labe!('d medium. Aft<>r incubation. the 
cdh< were harvl.'l<ted and centrifuged Ill\ d<'OCribed clll'lier (15). 
Thl' cdl )>l'llet wa" eithl'r lysed in Buffer A and directly layered on 
th(' sucrosl' gTadicnt, or th~ulactol!idusc in the lvsak' wus first purificd 
UNinr: uffinity chromnto!:l"aphy (16) before ,;uCroso;- d"'nsity grudiC'nt 
centrifugation. For this lutt('r purpolle, thl' cell p('ll('t from one or two 
Falcon flwkH ww lyst:'d in 500 .,1 of 20 mM Na acetate, pH ,:i.2, 
containing 0.1 M NnCI, 1% (wjv) Zwitl.('rionic detergent and 0.2% 
(w/v) bovine !Ierum albumin {Buffer B). ThiB HD.mpl!O' wa.<; nppli!O'd to 
n 60-~tl p-aminophenylthi()f:alnctosid!O'-CH-S!O'phnro>'l' affinity matrix 
(16). Th!O' column was w.ushed with 600 .,J of Buffer B supp!!O'm!O'nkd 
with 0.5 M NaCt and eluowd in buffer B ~upplem!O'nkd with 0.1 M ..,. 
gnl.actonoloctone. Tho;- eluate wa~ dinlvzed aR.(Iinst buffer A ~upple­
m('nted with 0.2% (w/v) bovine l!Crum ~lbumin. according to Peno;-fski 
(li). 
Pooled fraction" were mixed with exce~K of conventional onti-):i-
gnlncto~idn.~!O' :mti~!O'rum rnio<l'd ngninllt human plac!O'ntnl enzyme (9) 
and incubakd for 1 h nt20 ·c followed by 15 h nt4 ·c. Polyacrylamide 
g!O'l l'l('Ctrophon>~is in th!O' pre><!O'ncc of Hodium dod('Cyl sulfnt<> wu.~ 
performed on 12% Hlnb gel~ according to Laemmli (18) with modifi-
cations described by HaHilik and Neufeld (15). Fluorography wall 
carried out according to Bonner and LLiflkey (25) and the ["C]mcthyl-
lnb!O'led protein molecular w.;-ig-ht ~tnndnrd~ (phosphorylas!O' b. 92,000; 
bovin!O' ><erum albumin. 6-5.000; IJ:(;. 55.000; ovalbumin, 46,000; car-
bonic anhydl-ao<l'. 30,000 (Am!O'rsham)) w!O're Ul!Cd.. Visuali7..ution ofth!O' 
labcl!O'd proti'iw w;;rn potlllibl!' after 1~2 weeks of exposur!O' to X-Omat 
Kodak film. 
Corr!O'ction of the combined p-galacto~ida>'l' and n!O'uraminid.ru<e 
ddici.;-ncy in galacto~ialido~iB fibroblru;t.H wu.~ studii'd in two way~. 
Fin<tly. the intralyNosomal proteolytic do;-17adation of the \y:;osomal 
enzym"" wu.~ inhibited by addition to the medium of Ieupeptin 
(Sif<!ll.a) ut u final concentration of0.02 mM for 4 daY!' prior to sucrose 
denillty grudicnt Ci'ntrifuga.tion. $('(;ondlv. th!O' ~corrective factorM (19) 
and 54-kDu id<:ntificd glycoprowin (9) 'was preparo;-d by addition of 
10 mM NH.CI to the medium above Gr>wl:"anglio,;idosiH fibrobla~!.H 
durin).; 2 day:; followOO by concentration on an Amicon PMlO filkr 
to a final volum!O' of 1 ml u.~ descrilx>d before (9, 19). An aliquot of 40 
.,1 of thll,; concentrate was added per 1 ml of the Ham·~ FlO medium 
abov!' Rfi]a<:tosialidosiB fibrobla.'<t.~ durin).; 4 day~ and then sucro~.;­
dewity gradi<:nt eentrifugation was performed to ;;tudy the p-gnlac-
tosid.ru<e pnttern in thC' mutant c!O'!k 
Finnlly, radioactively JabelOO corrective factor wa~ prepart•d in tht• 
Harne way but after addition of both j'H]Ieucine (s<'<' above) and 
NH,Cl during 2 day~ prior to prcparution of the concC'ntrnte. The 
rodiolabelOO concentrat<> WUII diulyzOO aguim<t Ham's FlO medium 
adde-d to gnlactosi::tlido~i~ fibrobla..~t>; for 4 day~ and subo<l'QUC'ntly 
immunoprecipitation studies with anti-{.i'-g-olucto~idn.w .antiserum 
were <:arriOO out to identify the "corrective proteinM and it» fat\' after 
being- taken up by the mutant fibroblwlt>;. 
RESIJLTS AND DISCUSSION 
Proteetive Protein for {3-Galactosidase-In previous ,:;tudiC<S 
(9). it wa,:; shown that galactosia.lido,:;is fibroblasts lack n 32-
kDa protein which precipitated with an antiserum against 
human {3-galnctosida,:;e but which did not show any hydrolytic 
activity. In all other human cells tested. including those with 
a p-galnctosida,:;e deficiency, this 32-kDa protein is pre:>ent. 
On the basis of pulse-chase experiments and the absence of a 
54-kDa glycoprotein in ammonium chloride-stimulated me-
dium above galactosinlidosis fibroblasts. d'Azzo et al. (9) pos-
tulated that the 54-kDa protein is the preeursor of the 32-kDa 
protective protein.~ In immunopreeipitation studies summa-
rized in Fig. 1. experimental evidence is presented for this 
hypothesis. Ammonium chloride-stimulated and ["H]Jeucine-
labeled medium nbove control fibroblasts contains the 85-
kDa precursor of {3-galactosida,:;e and a 54-kDa glycoprotein 
(Fig. lb). When this medium is given to galactosialidosis cell,:;. 
a 32-kDa and 20-kDa protein band becomes apparent (Fig. 
ld). This is not the cnse when NH4 Cl-stimulatcd and rndio-
labeled medium derived from gnlnctosialidosis cells (Fig. lc), 
which lacks the 54-kDa protein. is added (Fig. lc). These 
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FIG. 1. Polyacrylamide g-el electrophoresis of immunopre-
cipitated lh~alnctosidv.se. a, Standardfl. b, NH.Cl-stimulakd mi'-
d.ium above control fibroblasts. c, NH.Cl-stimulakd. mOOium above 
l:"lliactoBialido~il< ():i-ga.IM/neurM) ce\1\1. d. Ga\actosialidol!is fibrobiMtl! 
after addition of mOOium m!'nt.ionOO und.;-r b. c. Galactosialidosi~ 
fibrobkrntl! aft<:-r uddition of medium m!'ntioned undo;-r c. 
re:>ults t~how that the 54-kDn protein is the precursor fonn of 
the 32-kDa und 20-kDn protein,:;; the ,:;tronger 32-kDa protein 
is thought to be required to protect P'-gulacto,:;idase ngainst 
intralywsomal proteolytic degradation (9). 
Sucro:::c Den..~ity Gro.dicnt Centrifugation-The relation,:;hip 
between the 32-kDa protective protein and P'-galactosidase 
was further investigated with sucrose density gradient cen-
trifugation. In a lysate in buffer A of control fibroblasts, two 
peaks are demonstrated at pH 6.0 (Fig. 2a). About 15% of the 
total activity i." present as a monomer and 85% as a high 
molecular weight multimer. Previous studiC<S using gel filtra-
tion hnd already ,:;hown that ,13-gn.lactosidnse exists in two 
form,:; i.e. n monomer of about 64kDa and a high moleculnr 
weight aggregate of about 600 to 700kDn (5-S). In contrast to 
previous observation,:;, we find that mo,:;t of the enzyme exist& 
a,:; n multimer which might be due to the experimental con-
ditions used in this study. When the cell sample was homog-
enized by sonication or freeze-thawing, nearly all enzyme was 
found to occur as a monomer. The ratio monomer:multimer 
is also pH-dependent because. under our conditions avoiding 
sonicntion or fr~ze-thawing and using Zwittergcnt as a de-
tergent. all p-galnctosidase nctivity exists as a multimer at pH 
4.0. In the in uiuo situation within the lysosome where the pH 
i,:; in the order of 5.0 (20). most of the P-ga!Dcto,:;ida,:;epresum-
ably exists as a high moleculnr weight aggregate. 
N; i,:; shown in Fig. 2b. n lysate from n patient with galac-
tosialidosis only shows the monomer peak after sucrose den-
,:;ity gradient centrifugation. This finding is in agreement with 
earlier gel filtration studies, which indicated a marked de-
crease of high molecular weight P'-gulactosidase in gu.lactosi-
a.lidosi.< cells (6). This figure also shows that when these 
mutant cells are treated. with leupeptin. which inhibits intra-
lyt~osomal cathepsins. the P-galactosidase activity rises but 
the density pattern remains unchanged (Fig. 2b). The in-
crea,:;ed activity seems thus to be due to an increase in mon-
omeric {3-galactosidase. When cells with other types of {3-
galn.cto,:;id..use deficiency t~uch as those derived from patients 
with G:-.wgangliot~ido,:;is are treated with leupeptin, there is 
no ,:;ignificant rise of P'-gulactosidase activity (data not 
shown). 
Addition to go.lacto,:;ialidosis fibrobla,:;ts of XH4-,:;timulated 
medium from control fibrobla,:;ts known to contain the 54-
kDn precursor of the 32-kDa protective protein results in a 
normalization of the density pattern of /3-galactosidase in the 
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F1C. 2. Sucrose den~ity ,::radient centrifugation of lysoso-
mal,B-g-nlaetosida..;;c in normal and mutant human fibroblasts. 
a. DcnBity pattern of .6-gnla.ctosidasc in normal fibroblasts (0---0); 
and ... indicate the re11pectivc indict's of the linear sucrose gradient 
from 20 to 40% in 20 mM Nn phosphate. pH 6.0, containinl:" 100 mM 
NoCll.l!ld 1% (w/v) Zwinerionic dete~nt. b. Pattern in gnla.cto~iuli­
do~i,;ceJlll (x-x) andofthc samccl'lls niter inhibition oflvsooomnl 
cothcpRinB by lmpcptin (A-- -A). c. Pattern in gnlo.ctosialidoois cclli; 
before (X-X) nnd after nddition of NH.Cl-stimulnted medium 
contnining the 54-kDu pre<:ui'ROr of the prot<:'ctive protein (0-- -0). 
muUlnt cell$ (Fig. 2c). After 4 dnys administration of this 
~corrective factor~. about two-thirds of the enzyme appears 
us a high molecular weight multimer. These results suggest 
that the 54-kDa precursor nnd the 32-kDa protein derived 
from it is required for the nggregation of monomeric P-galac-
tosidase into n high molecular weight form. This observation 
eA-ploins previous results by Hoeksema et aL (6), who found a 
normalization of the gel filtration pattem of P-galactosidase 
after somatic cell hybridization of P-r;alactosidase-deficient 
GMt-gangliosidosis fibroblasts and galactosialidosis cells. The 
former cells will synthesize the 32-kDa and 20-kDa proteins 
wherens the nucleus of the galactosialidosis cells will code for 
normal P-gnlactosidase polypeptide chains. 
Jmmu.noprccipitation-A lysate of [aH]leucine-labeled con-
trol fibroblasts was exposed to sucrose density gradient cen-
trifugation. Fractions 1-1, 5-11. and 14-20, corresponding to 
the pattem illustrated in Fig. 2, were pooled and treated voith 
conventional antiserum against human P-galactosidase. After 
immunoprecipitation, polyacrylamide gel electrophoresis was 
carried out under denaturing conditions and the results arc 
shown in Fig. 3. In the fractions 1--4, no ;3-galactosidase and 
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FIG. 3. Polyacrylamide gel electrophoresis of immunopre-
cipituted P-galaetosida!<e in pooled fractions after sucrose den· 
sity gradient centrifugation. a. Standards. b, Immunopn><:ipitat<' 
of the total lY~Utte of control fibroblasts. c, Cell lysat<.' after Bucrooe 
density gradient centrifugation; pooled fractions 5-ll. d. The Nnme: 
pooled frnctions 14-20. c, Purified P-~etosidnsc from control fibro· 
bll'4~ta: pool <Xi frnctions 5-11. f. Thl' same; pooled fractions 14-20 . .r:. 
Immunopn><:ipitate of the unrctaincd material of thi' nffinitv column 
used for the purificntion of $-~:alncto>ridn~e. · 
minor quantities of the 32-kDa and 20-kDa proteins ar~ 
present. The frnctions 5-11 corresponding with the monomer 
(Fig. 2) contain the ~xpected amount of 64-kDn ,8-galactosid-
ase accompanied by large quantities of the 32-kDa and 20-
kDa proteins (Fig. 3, lane c). The frnctions 14-20 correspond-
ing with the multimeric form contain the majority of the 64-
kDa !}-galactosidase and nbout equal amounts of the 32-kDa 
protein and only truces of the 20-kDa protein (Fig. 3, lane d). 
Similar immunoprecipitation studies were performed after 
purification of ,8-galactosida.."C from control fibroblasts. using 
affinity column chromatography. When the eluate of the 
column is exposed to sucrose density gradient centrifugntion, 
a similar pattern of ,8-galactosidnse nctivity with two peaks 
(Fig. 2) is obtained. The results of immunoprecipitation stud-
ies on the pooled fractions 5-11 and 14-20 are shown in the 
right-hand part of Fig. 3. Hardly any bands are visible in the 
fractions 1-4. In fractions 5-11, again a faint 64-kDa {J-
galactosidase band is seen, but contrary to the studies on total 
cell l)'Mte, hardly any 32-kDa and no 20-kDa proteins are 
present in this purified preparntion (Fig. 3, lane e). In the 
fractions 14-20, most of the 64-kDa !}-galactosidase and the 
32-kDa protein nnd minor quantities of the 20-kDa protein 
are present (Fig. 3lan.e f). When immunoprecipitation studies 
were performed on the unretained mnterial of the affinity 
column used for purification of /}-galactosidase, most of the 
32-kDa and 20-kDa proteins were found there (Fig. 3, lane g). 
These immunoprecipitation studies suggest that the 32-
kDa component found in the low density fraction of cell lysate 
is not bound to the {J-galactosidase monomer nnd the latter is 
easily separated from it using affinity chromatography. On 
the other hand, affinity chromatography of the P-galactosid-
ase in the high density fraction copurifies apparently equal 
amounts of the 32-kDa protein. This strongly suggests that 
these two components nrc intimately bound in the high mo-
lecular weight nggre):;.lte. 
CONCLUSION 
We have shown that in normal human fibroblasts a 54-kDa 
precursor protein is processed into a 32-kDa glycoprotein, 
which in tum is required for the aggregation of monomeric 
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(64-kDa) !)-galactosidase into a high molecular mass multimer 
of 600 to 700-kDa. There seems to be an excess amount of 
32-kDa protein in proportion to the amount of il-galactosidase 
monomer. Thitl has also been observed for the microsomal 
accessory protein egngyn which binds j'j-glucuronidase to the 
endoplasmic reticulum in mouse (21). 
We have found for human fibroblasts that at the low 
intralysosomal pH, most of the #-galactosidase exists as a 600 
to 700-kDa multimer and that the 32-kDa protective protein 
is firmly bound to this high molecular mass aggregate. Pre-
viou:,~ ::~tudies of human plncenta (7) and porcine spleen {8) 
have nlso demonstruted the pre!icncc of low molecular weight 
proteing together with the high molecular weight fraction of 
.8-:;alactosidase but these have wrongly been considered as 
conUlminantfl. Verheijen ct al. (22) recently showed that sial-
id::tse and the high molecular weight form of P-galactogidase 
exist us a complex. It is likely th::~t this complex ifl membrane-
bound. Cheetham and Dance (23} suggested emlicr that the 
high molecular weight form of P-galactosidase consists of low 
molecular weight enzyme bound to small frapnents of the 
lysosom::~l membmne. 
d'Azzo et al. (9} have recently shown that the autosomal 
recessive lysosomal storage discnse galactosialidosis is asso-
ciated with the absence of the 54-kD::~ precursor protein of 
the 32-kDa and 20-kDa glycoproteins mentioned above. They 
explained the combined deficiency of p-galactosidase and 
sialidase as beinr; due to enhanced degradation of }3-galacto-
sidase whereas the protective protein would also be required 
to activate sialidase. 
In the present study, we have shown that the protection of 
}3-galactosidase is realized by aggregation of monomers into 
high molecular weig-ht multimers. Thi::< is supported by the 
observation that the sUlbility of ,13-galactosidase increases with 
conditions favoring the formation of multimers (24). When 
the ::~ggregation of monomers cannot take place, us in gulac-
tosialidosis. /)-galactosidase remains in its monomeric form 
which apparently is very sensitive to intralysosomal proteo-
lytic degrad::ttion. It seems likely that sialidase needs to be 
incorporated into a membrane-bound high molecular weight 
complex with /)-galactosidase in order to become active (22). 
If no such complex enn be formed. as in galactosialidosig, 
sialidase remains inDctive (9. 22). 
Further studies arc now under way to investigate the role 
of monomeric p-galactosid::tse and of the high molecular 
weight complexes of multimeric {3-galnctosidase, protective 
protein(s), and sialida:;e in the hvdrolvsis of various sub-
strates. 
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The isolation of an acid neuraminidase from bovine testis is 
described. Under all experimental conditions this neuraminidase 
copurifies with acid a-galactosidase, but not with other lysosomal 
hydrolases. Immunotitration with an antiserum raised against puri-
fied human placental B-galactosidase results in the coprecipita-
tion of both enzyme activities. Our data indicate that acid neura-
minidase and a-galactosidase are present as an enzyme complex. The 
possible physiological relevance is discussed. 
INTRODUCTION 
Neuraminidases catalyze the hydrolysis of sialic acid resi-
dues n-ketosidically bound to oligosaccharides, glycoproteins, 
glycopeptides and glycolipids. They are widely distributed in 
eukaryotic and prokaryotic cells (1). 
The neurarninidases of prokaryotic cells are very well studied 
(1,2), but relatively little information is available on eukaryo-
tic neuraminidases {3-6) • 
In the last few years a number of different genetic defects 
of -lysosomal acid neuraminidase have been found in man {for reviews 
see 7,8). Especially interesting are patients ~ho have a aombined 
deficiency of two lysosomal enzymes, neuraminidase and e-galacto-
sidase {9,10). To understand the possible relationship between 
neuraminidase and e-galactosidase, it is necessary to have more 
information about the structure and properties of the different 
molecular forms of mammalian neuraminidases. Such information will 
also help to elucidate the molecular nature of genetic diseases 
associated with a neuraminidase deficiency. 
Despite the recent availability of sensitive assay procedures 
with methylumbelliferyl substrate, the lability and strongly 
membr~ne bound character of the enzyme hampered studies on mamma-
lian neuraminidases (3,4) {for review, see 6). 
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In the present report we describe the copurification of a 
bovine testis acid neuraminidase with lysosomal 8-galactosidase 
throughout the isolation procedure developed for the latter 
enzyme. Evidence is presented that 6-galactosidase and neuramini-
dase molecules exist as an enzyme complex. 
MATERIALS AND METHODS 
Purification procedure 
All purification steps were carried out at 4°C, unless other-
wise noted. The procedure used is a modification of the isolation 
method developed for bovine testis S-galactosidase as described 
earlier (ll). 
Bovine testes were obtained at the local slaughterhouse and 
kept frozen at -70°C until use. Testes devoid of epididyrnes 
(0.5 kg) were homogenized in 2 vel. distilled water in a Waring 
blender for 3 min. The homogenate was brought to pH 4.0 by drop-
wise addition of 2N HCl. After 30 min stirring the acid homogenate 
was centrifuged at 25000 x g for 30 min. The clear supernatant was 
adjusted to pH 6.2 with 2N NaOH. This supernatant was applied to 
a Concanavalin A-Sepharose column (60 ml bed volume) (Pharmacia) 
that was previously equilibrated with 50 mM sodium phosphate 
buffer pH 6.2. After loading, the column was washed overnight with 
equilibration buffer containing 100 rnM sodium chloride. The column 
was brought to room temperature and washed with equilibration 
buffer containing 1M sodium chloride ana eluted with the same 
buffer with 1M ~-methylglucoside added to it. The eluate was con-
centrated on an Arnicon Hollow Fiber Concentrator and dialysed 
overnight against 10 vol. of 20 mM sodium acetate buffer pH 5.2 
containing 100 rnM sodium chloride. This preparation was applied 
to a 2 ml p-arninophenyl-thiogalactoside-CH-Sepharose column 
(prepared as described earlier (12)), equilibrated with the same 
buffer as used for dialysis. The column was then washed extensive-
ly with 10 times the bed volume of equilibration buffer and sub-
sequently with the same volume of equilibration buffer containing 
1M sodium chloride. S-Galactosidase and neuraminidase were eluted 
by adding 100 mM ~-galactonolacton to the last buffer. The eluate 
was concentrated and dialysed in an Amicon Ultrafiltration cell 
with a PM-10 filter. Dialysis was against 25 mM sodium acetate 
~~;f~~o~~~t:~~i~~o;~~ ~ :~~6~ chloride. The final preparation 
Assav of protein and enzvme activitY 
Protein was measured by the method of Lowry (13). 
The activity of neuraminidase and the other en7.ymes was 
measured with 4-methylumbelliferyl substrates, according to pro-
cedures described earlier (8,10). One unit of activity is defined 
as the amount of0enzyrne forming 1 ~mol of 4-methylumbelliferone per minute at 37 C. 
SDS-Polyacrylamide gel electrophoresis 
Electrophoresis was carried out on a 12% polyacrylamide slab 
gel as described by Laemmli (14), with a modified acrylbisacryl 
ratio of 30 : 0.315. 
Gel filtration 
A 1 x 95 em column of Sephadex G-200 (Pharmacia) was equi-
librated at 4°C with 25 mM sodium acetate buffer pH 5.2 containing 
100 mM sodium chloride. 2 mg of the purified enzyme preparation 
was mixed with glycerol (final cone. 10%) and applied to the 
column. The column was run overnight and fractions of 1 ml were 
collected. All fractions were assayed for both neuraminidase and 
~-galactosidase. 
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Immunotitr.:ttion 
10 ~1 Concanavalin A-Sepharose eluate containing 6.03 mU ~­
galactosidase and 0.066 mU neuraminidase was added to 10 ~l 1M 
sodium phosphate buffer pH 6.0 containing 1M sodium chloride and 
5% bovine serum albumin. An increasing amount of an IgG prepara-
tion (5-100 Ill) (prepared from an antiserum raised against puri-
fied human placental S-galactosidase (15) using Protein A-
Sepharose) was added to this mixture. 20 mM sodium phosphate 
~~ffer pH 6.0 containing 100 mM sodium.chlori~e was agded to a 
~lnal volume of 120 ~1. After 3 hours ~ncubat10n at 4 C 20 111 of 
a 1 : 1 protein A-Sepharose suspension in 20 mM sodium phosphate 
buffer pH 6.0 containing 100 mM sodium chloride was added. After 
2 hours all tubes were centrifuged at 10,000 x g for 1 minute. 
Supernatants were assayed for both neuraminidase and 6-galacto-
sidase. 
RESULTS AND DISCUSSION 
In our initial attempts to purify active acid neuraminidase 
from a mammalian source, we observed that bovine testis contains 
large amounts of acid neuraminidase. We also found a considerable 
~curaminidase activity in the 25000 x g supernatant after acid 
precipitation, which enabled us to purify an active mammalian 
neuraminidase. This neuraminidase has a pH optimum around 4.5 and 
a Km value of 3 rnM using the 4-methylumbelliferyl-N-acetylneura-
~inic acid substrate. 
In the course of studies on the molecular properties of 6-
gala-::tosidase we found that neuraminidase copurified during puri-
fication of bovine testicular 6-galactosidase, after two sub-
sequent affinity chromatography steps. The purification and recov-
ery of neuraminidase and 13-galactosidase at different stages of 
a representative purification is summarized in table 1. 
Chromatography on Concanavalin .?.-Sepharose yields a prepara-
tion in which neuraminidase and a-galactosidase arc purified 25-
and 30-fold respectively. 
After p-aminophenylthiogalactoside-CH-Sepharose affinity 
chromatography, whi.ch seemed to be specific for 6-galactosidase 
purification, not only a 512-fold purification of a-galactosidase 
was achieved, but also a 316-fold purification of neuraminidase. 
Neuraminidase had a somewhat lower overall recovery (17%) than e-
galactosidasc (28%). However, no neuraminidase activity was pres-
ent in the unretained material and no residual neuraminidase could 
be detected on the column after elution. The lower recovery of 
neur~inidase is therefore probably due to a more pronounced de-
naturation during the last affinity chromatography step. The 
activity of neuraminidase is measured with a substrate concentra-
tion below the Km, since higher substrate concentrations result 
in high blancs, which disturb accurate measurements. The specific 
Table 1 
Copurification of Neuraminidase {Neur) and ~-Galactosidase (Gal). 
Results are for 500 g wet weight testes. 
Step Volume Protein Activity Specific activity Activity Purification Yield 
Neur, Gal. Neur. Gal. Neur/Gal Neur. Gal. Neur. Gal. 
-
ml mg mu• mU/mg xlo- 2 -fold % 
"' 
"' 
25000 xg 
supernat. pH4 730 5542 2008 99604 0. 36 18. 0 2.0 1 1 100 100 
Con A 
Sepharose 5. 0 87.5 796 47033 9. 10 537.5 1.7 25 30 40 47 
PAPS-gal-
Sepharoseb 2. 5 3.05 34 7 28083 11 3. 8 9208 1.2 316 512 17 28 
--
arunol 4-methylumbelliferone released/min. 
bPAPS-gal-Sepharose: p-aminophenylthiogalactoside-CH-Sepharose. 
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Table 2 
Lysosomal hydrolase activities in the purified 
bovine testicular neuraminidase preparation 
25000 xg Supernatant Purified Purification 
mU/mg mU(mg factor 
Neur<ll!linidasc 0.36 113.8 
" 
316 
a-Galactosidase 18.0 9208 
" 
512 
B-Glucuronidasc 5.7 13.8 
" 
2 
~-Galactosidase 2.4 17.4 
" 
7 
B-Glucosidase 2. 6 13.8 
" 
5 
8-Kexosaminidasc 204 562 
" 
3 
a.-Gluccsidase 1. 6 1.1 
" 
1 
a-M.J.nnosl.dase 1.2 1.5 
" 
1 
activities of neuraminidase are therefore an underestimation of 
the real values. 
Table 2 demonstrates that only 6-galactosidase and neuramini-
dase are copurifying during our procedure: none of the other 
hydrolas~s tested were substantially purified. The overall yield 
of these othe~ acid hydrolases varied from 0.02% to 1%. This indi-
cates that the copurification is specific for neuraminidase and 
a-galactosidase. 
Both neuraminidase and a-galactosidase elute in the void vol-
ume of a Sephadex G-200 column (Fig. 1), suggesting that both en-
zymes are present as a high molecular weight aggregate <)300 kd). 
This observation prompted us to try and separate the two en-
zymes via a variety of separation techniques, e.g. sucrose gradi-
ents, aceton fractionation, r.ellogel electrophoresis and hydro-
phobic chromatography. However, under all conditions tested, a-
galactosidase and neuraminidase could not be separated, which fits 
the assumption, that both enzymes are present as a complex. 
Additional evidence for the existence of an enzyme complex 
was derived from immunotitration experiments (Fig. 2). In the 
presence of antibodies raised against purified human placental a-
galactosidase, both neuraminidase and a-galactosidase activities 
were precipitated. The precipitation curves for both enzyme activ-
ities are identical, which indicates the simultaneous removal of 
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both enzymes and that B-galactosidase and neuraminidase react with 
the same antibody population. 
Polyacrylamide gel electrophoresis of the purified preparation 
in the presence of SDS shows three major protein bands with mol-
ecular weights of 64 kd; 32 kd and 22 kd (Fig. 3}. Since bovine 
testis a-galactosidase monomer has a molecular weight of 64 kd, it 
is likely that the neuraminidase activity in our purified prepara-
tion is associated with the 32 kd and/or 22 kd protein band(s). 
Distler et al. (16) also reported a 64 kd band for bovine testis 
a-galactosidase, but did not mention any other components. In 
human liver, Norden et al. {17), and human fibroblasts, Hoeksema 
et al. (18) a-galactosidase monomer (64 kd) and high molecular 
weight aggregates (600-700 kd) were found. Recently our group 
(d'Azzo et al., 15) using immunoprecipitation, discovered that 
mature a-galactosidase (64 kd) is for.med from a precursor (85 kd) 
and that in addition a protective glycoprotein (32 kd) is required 
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to prevent excessive intralysosomal proteolytic degradation. This 
protective protein and its 54 kd precursor are deficient in fibro-
blasts from patients with combined a-galactosidase and neuramini-
dase deficiency. 
Preliminary experiments on solubilized neuraminidase from 
normal human fibroblasts (to be published) also point to the pres-
ence of e-galactosidase and neuraminidase in an enzyme complex. 
We are currently studying the relationshi? between these two en-
zymes and the 32 kd protective protein. 
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Human placental neuraminidase 
Activation, stabilization and association with P-galactosidase and its 'protective' protein 
Frans W. VERHE!JEN. Silvia PALMERI. AndrC T. HOOGEVEEN and Hans GAUAARD 
Department of Cell Biolor.y and Genetics. Erasmus University Rotterdam: and 
Institute ofNcuro!ogical Sciences. Medical School. University of Siena 
(Received November 30. 1984(February 11. 1985) ~ EJB 841259 
Supernatant of homogenized human placenta hardly contains lysosomal neuraminidase activity. It is. however, 
possible to generate remarkably high activity by concentration of a partially purified glycoprotein fraction. This 
activity is labile to dilution, but can be stabilized by incubation at 3T'C and acid pH. 
Using jJ-galactosidase specific affinity chromatography and immunotitration, we show that the activated and 
stabilized human lysosomal neuraminidase exists in a complex with P-galactosidase. Sucrose density gradient 
centrifugation experiments demonstrate that the neuraminidase activity is exclusively present in a high density 
multimeric form of j3-galactosidase. 
The formation of multimeric forms of j3-galactosidase is known to require a 32000-M,. 'protective' protein. 
Monospecific antibodies against this 'protective' protein were purified from a conventional antiserum containing 
a mixture of antibodies against the 64000-M, j3-galactosidase protein and against the 32000-M, 'protective' 
protein. using a nitrocellulose blot immunoaffinity purification procedure. Immunotitration experiments with 
these antibodies show that the 32000-M,. ·protective' protein is present both in association with the P-galactosidase 
multimer and with the high-density multimeric form together with neuraminidase. 
Our data further suggest that association of the 32000-M, 'protective' protein and another yet unidentified 
subunit is essential for the catalytic activity of lysosomal neurnminidase. These results explain the absence of 
neuraminidase activity in the autosomal recessive human lysosomal storage disorder galactosialidosis. where the 
32000-M, 'protective' protein is known to be absent. 
A lysosomal glycoprotein and oligosaccharide substrate 
specific neuraminidase is known to be deficient in the human 
inherited lysosomal storage disorders. sialidosis and 
galactosialidosis. In sialidosis it is the only deficient enzyme, 
whereas in galactosialidosis there is a combined deficiency 
of lysosomal neuraminidase and j3-galactosidase [1-4]. The 
latter disease was found to be due to a deficiency of a protein 
with a relative molecular mass of32000. which function is to 
protect j3-galactosida.se from rnpid proteolytic degradation 
[SJ. Recently it was shown that this is realized by aggregation 
of monomeric P-galactosidase into high molecular mass 
complexes. which apparently are less sensitive to intralyso-
somal proteases [6}. 
Very little is. however. known about the molecular 
background of the neuraminidase deficiency in galac-
tosialidosis. One of the major reasons is that the lability and 
membrane-bound character of human lysosomal neuraminid-
ase have complicated its purification and characterization [7-
9] .. 
Our earlier observation that a lysosomal neuraminidase 
from bovine testis copurifies with lysosomal .8-galactosidase 
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sodium dodecyl sulphate; ConA. concanavalin A. 
En=ymes. Neuraminidase (EC 3.2.1.18): ,8-ga\actosidase (EC 
3.2.1.23). 
[10]. pointed to a complex of these two enzymes. On the basis 
of this observation and of studies on normal and mutant 
fibroblasts we have suggested a close relationship between 
64000-M, mature ,8-galactosidase, its 32000-M,. 'protective' 
protein and lysosomal neuraminidase [5, 6. 10). 
In the present study we demonstrate that it is possible 
to generate and stabilize: considernble neuraminidase activity 
which enabled us the partial purification of neuraminidase 
from human placenta. Furthermore the relationship of human 
lysosomal neuraminidase with ft-galactosidase and its 32000-
M, ·protective' protein could be investigated. 
EXPERIMENTAL PROCEDURES 
Partial purification 
All steps were carried out at 4 '-C. unless otherwise noted. 
Frozen human placenta was obtained from a local hospitaL 
About 5 kg placenta was homogenized in 7 l distilled water in 
a Waring Blendor for 3 min. The homogenate was centrifuged 
at 25000 xg for 30 min. The clear supernatant was collected. 
set to pH 6.3 with 1 M sodium phosphate buffer and mixed 
with 200 ml packed Concanavalin-A-Sepharose (Phar-
macia). The mixture was stirred overnight. The ConA-
Sepharose beads were collected on a glass fliter and washed 
at room temperature with 2 I sodium phosphate buffer pH 6.3 
containing 100 mM NaCL Afterwards the beads were washed 
with 2 I of the last buffer containing 1 M NaCL Glycoproteins 
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were eluted with 2 1 of buffer containing 1 M NaCl and 1 M 
methyl cc·O¥glucopyranosidc. The eluate was concentrated and 
dialyscd on an Amicon Hollow Fiber Concentrator. Dialysis 
was against 20 mM sodium phosphate buffer containing 
100 mM NaCI, pH 5.2. The final volume was about 160m!. 
Activation and stahilization of partly purifh•d neuraminidase' 
The glycoprotein prepar<J.tion was further concentrated in 
an Amicon Ultrafiltration Cell, using a PM 10 filter. 
Concentration was continued to a protein concentration of 
about 60 mg!ml. This preparation was incubated at 37"C 
for 90 min to stabilize neuraminidase activity (sec Results). 
Afterwards the preparation was frozen and stored at ~ 70QC. 
Affinity purification 
Affinity chromatography using p-aminophcnylthio-
galactosidc-CH-Scpharosc was performed as described earlier 
[10]. Experiments were performed with activated and 
stabilized glycoprotein preparations derived from about 5 kg 
placenta. 
Polyacrylamide gel electrophoresis 
Polyacrylamide gel electrophoresis of the affinity purified 
enzyme preparation was performed in the presence of sodium 
dodecyl sulphate (SDS-PAGE) as described by Lacmmli [11]. 
About 30 IJ.g of protein was applied to the slot. 
Jmmunotitration using antibodies against /1-galactosidase 
A sample of the ConA-Scpharosc eluate, activated and 
stabilized for neuraminidase, was diluted tenfold in 20 mM 
sodium phosphate buffer pH 6, containing 100 mM NaCL 
20 1-1-l from this dilution, containing about 0.1 mU 
neuraminidase and 4 mU ,6-galactosida.~c. was mixed with 
10 vJ of the same buffer containing 2 mgjml bovine serum 
albumin. and 0 ~ 20 1-1-l of an IgG preparation (prepared from 
an antiserum raised against purified human placental (J-ga-
lactosidase, using protein-A-Sepharosc [5)) was added. The 
final volume was made 50 )11 by thcadditionof20 mM sodium 
phosphate buffer pH 6, containing 100 mM NaCL After 2 h 
incubation at 4°C, 10 vJ protein-A-Scpharose suspension 
(1: 1) in the last buffer was added. After 2 hgentle rotation all 
tubes were centrifuged at 3000 xg for 1 min. The supernatants 
were assayed for both neuraminidase and ,6-galactosidase 
activity. 
fmmunotitration using monospeciflc antibodies 
After sucrose density gradient centrifugation of an 
activated and stabilized glycoprotein preparation the top 
fractions from peak I and II were diluted with 40 mM sodium 
phosphate buffer pH 6. containing 200 mM NaCl and 1 mgj 
ml bovine serum albumin. About 0.25 mU ,6-galactosidase 
was used for each immunoprccipitation. The immuno-
precipitation was performed as described above. 
Immunoprecipitation of neuraminidase activity was per-
formed using an activated and stabilized glycoprotein prepa· 
ration. This was diluted appropriately as described for peak 
I and II. In these experiments about 0.01 mU neuraminidase 
and about 0.3 mU p~galactosidasc were used. 
Sucrose den.1·ity gradient centrifugation 
Sucrose density gradient centrifugation was performed as 
described by Martin and Ames [12]. Linear gradients of20-
40% (wjv) sucrose in 20 mM sodium acetate buffer pH 5.2. 
containing 100 mM NaCl were prepared in a total volume of 
5 mi. 100 IJ.l sample was applied. Centrifugation was carried 
out at 40000 rpm for 15 h at 4"C in a Beckman L5-65 
ultracentrifuge with a SW-50 rotor. Fractions of 200 )11 were 
collected and assays were performed on 5-)11 samples. 
Nitrocdlu.lose blo
1
! affinity purification of antibodies 
Specific antibodies were purified from a conventional 
/3-galactosidase antiserum, using a slightly modified method 
of Smith ct al. [13]. 30-50 ).lg of the affinity purified prepara-
tion containing /3-ga\actosidasc, neuraminidase and 'protec-
tive· protein was appli<."d to each slot of a 10% slab gel. After 
SDS-PAGE the protein was transferred to a nitrocellulose 
filter by the electro blotting method of Towbin ct al. [14]. A 
strip of the nitrocellulose was cut and stained for protein using 
0.1% ami do black in 45% methanol and 10% acetic acid. 
Using the stained strip as comparison, unstained regions of 
the nitrocellulose containing the 32 000-M, and 64000-M, pro-
tein bands were cut. transferred to separate tubes and in-
cubated for 1 h with P1/NaCI containing 100 mg/ml bovine 
serum albumin. Thereafter the tubes were drained and 
conventional antiserum diluted in P,/NaCJ containing 0.5% 
Tween 20 was added to each of the tubes. The tubes were 
rotated at room temperature for l-3 h. The antiserum was 
removed and the nitrocellulose pieces were washed 3 times 
15 min with PdNaCl containing 0.5% Tween 20. Monospe-
cific antibodies were eluted from the appropriate 
nitrocellulose piece by washing 3 times 30 s with 100 )115 mM 
glycine-HCl pH 2.3. containing 0.5% Tween 20 and 100 1-1-g/ 
ml bovine serum albumin. The eluates were neutralized 
immediately with 20 1J.I1 M sodium phosphate buffer pH 6. 
Assays 
Protein was measured by the method described by Lowry 
[15]. Neuraminidase and fJ-galactosidase activities were mea-
sured with the appropriate 4-mcthylumbellifcryl substrates as 
reported earlier [16]. (4-Mcthylumbelliferyl-N-acctyl-
ncuraminic acid was a generous gift of Prof. R. Brossmcr. 
Dept. of Biochemistry, University of Heidelberg, FRG). One 
unit of activity is defined as the amount of enzyme releasing 
1 ).!mol of 4-mcthylumbcllifcronc/min at 37''C. 
RESULTS 
Activation of partly purified neuraminidase by concentration 
When frozen human placenta is homogenized in water and 
the homogenate is centrifuged at 25000 xg. /1-galactosidasc 
activity is present in the supernatant. but neuraminidase 
activity is below detection (Table 1). When the glycoprotcins 
from the supernatant were purified using ConA-Sepharosc 
affinity chromatography. the specific activity of {3-ga-
lactosidase had increased. but still hardly any neuraminidase 
activity could be measured. Neuraminidase activity can. how-
ever. be generated through concentration of the glycoprotein 
fraction (Fig. 1 A). For every twofold concentration. the 
neuraminidase activity increases about fourfold, whereas the 
increase of ft-galactosidase activity is linear with concentra-
tion as expected. The process of neuraminidase activation 
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Fig. 1. Act/l"alion and stabifi::arion of neuraminidase in a parr!y purificdg6·coprorcin preparation from human placenta. {A) Effect of conccntr..ltion 
of the preparation on ncuraminida~e (Neur.) and P-galactosidasc (,8-Gul.) activity. (B) Effect of dilution after concentration. (C) The same. 
but before dilution the preparation was incubated Ul 3TC and pH 5.2 for 90 min. For experimental dctails. sec text 
Table 1. Portia{ puri/icarion of {3-galoctosidase and neuraminidase 
5 kg frozen human placenta was homogenized and centrifuged at 25000xg. The glycoprotcins from the supernatant were purified using 
Conc::mavalin-A-Sepharose. The concentrution and ~tabili7..ation treatments were perfonned as described in the text. All data shown are 
derived from a representative experiment. n.d. = not detectable. Neur .. neuraminidase: P-GaL. ,6-galactosidase. Neuruminidasc recovery 
cannot be calculated because of b.ck of initial activity 
Preparu tion 
25000 xg supernatant 
Glycoprotein preparation 
Glycoprotein preparation after concentration 
The same but after stabili7..ation 
of ncur::tminidasc activity 
Total activity 
Ncur. 
u 
n.d. 
0.26 
1.6 
3.0 
seems to be reversible. since dilution of the concentrate leads 
to a loss of the neuraminidase activity, while that of P-
galactosidase remains constant (Fig. 1 B). 
Stabilization of the generated neuraminidase activity can 
be achieved by incubation of the concentrated glycoprotein 
fraction at 37~C and pH 5.2. During this stabiliz::ttion a fur-
ther increase in activity is observed. and after this treatment 
the neuraminidase activity is no longer lost upon dilution 
(Fig. 1 C). The activity thus obtained appears to be very stable. 
The preparation can even be sonicated for long periods and 
Spedfic activity Recovery 
.6-Gal. 
P-Gal. Neur. P-Gal. 
mUfmg protcin % 
293 n.d. 0.5 100 
127 0.13 63.3 43 
109 0.83 55.0 37 
115 1.50 58.3 39 
can be frozen without any loss of activity. The activities during 
the various steps described abow are summarized in Table 1. 
The relation of neuraminidase and (J-galactosUia.~e 
To investigate the relationship betwecn this neuraminidase 
and (J-galactosid.ase the concentrated and stabilized gly-
coprotcin preparation was chromatographcd on a p-amino-
phenylthiogalactoside-CH-Sepharose affinity column. This 
experiment is summarized in Table 2. In the preparation 
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Table 2. Copurification of fJ-xalactosidase and neuraminidase durin!< P·xafactosidase speciju: affmity chromatography 
A glycoprotein preparation purified from human placenta was treated us described in the text. to activate and stabilize neuraminidase activity. 
Afterwards the preparation was chromatographcd on a p-aminophcnylthiogalactosidc-CH-Sepharosc column. which is an affinity column 
specific for jJ-galactosidase. Ncur .• neuraminidase; P-Ga!.. ,8-ga\actosidase 
Preparation Total activity Specific activity Recovery 
Ncur. P-GaL Neur. P-Gal. Ncur. fJ-Gal. 
Before affinity chromatogmphy 
After affinity chromatography 
" ~;;; 
~~ " "-
r~ 
,ul lgG add .. d 
u 
4.35 
1.00 
70.4 
40.7 
Fig. 2. !mmunotitration of activated and srabili::ed human p!accrllal 
ncuraminidrJsc (Ncur.) and p..galactosida..w: (fJ·Gaf.). A glycoprotein 
preparation from human placenta was concentrated to a protein 
concentration of about 60 mgjml, and was incubated at 3TC pH 5.2 
for90 min. This fully neuraminida:;e-activated and 5tabilized prepara-
tion was titrated with anti {.8-galactosidase) IgG. The antibodies were 
raised against a fi-galactosidase preparation that was purified under 
such conditions that neuraminidase did not copurify 
obtained after this p.ga.Jactosidase specific affinity chro-
matography the specific activities of both .B·ga.lactosidasc and 
neuraminidase had increased dramatically. Furthennore no 
neuraminidase activity could be eluted prior to the specific 
elution together with .B·galactosida..~. This points to copuri-
fication of both enzymes. presumably because they are present 
as a complex. 
Additional evidence for the exlstence of such a complex 
was derived from immunotitration experiments. using anti-
bodies raised against purified .B·gaJactosidase. The activities of 
,8-galactosidasc and neuraminidase were found to precipitate 
simultaneously (Fig. 2). 
Polyacrylamide gel electrophoresis of the affinity purified 
preparation in the presence of sodium dodecyl sulphate 
showed three major protein bands (Fig. 3): a protein with a 
M, of about 64000. a protein with aM, around 30000 and a 
protein with a M, around 20000. Some rriinor bands are 
visible. 
Since ,8-galactosidase is known to exlst in different molec-
ular forms. we used sucrose density gradient centrifugation 
to study the exact relationship between· .B-gaJactosidasc and 
neuraminidase. In the partially purified glycoprotein prepara-
tion ,8-galactosidase activity is mainly present in the 64000· 
M, monomeric fonn. and neuraminidase activity was 
undetectable (Fig. 4a). In the same preparation after activa. 
tion and stabilization of neuraminidase. P-galactosidase 
mU/mg protein 
3.0 48.3 
555 22600 
KOa 
94_ 
-67-
-
43_ .... 
30w-
20_ -
14-
a 
% 
100 
23 
·-
-
b 
100 
58 
Fig. 3. Sodium dodi!eyf sulphatefpolyacryfamidi! gd dccrrophorcsis of 
the affmity purified P-galactosidascf'protcetive ·protein/neuraminidase 
preparation. Before affinity chromatography the glycoprotein prepa-
ration was treated as described in the text to activate and stabilize 
neuraminidase. Lunea: marker proteins. Lune b: purified preparJ.-
tion 
activity was found both in the monomeric fonn (about 30%). 
and in a high molecular ma.-.s multimeric fonn (about 60%). 
In addition ,8-galactosidase activity is present in a second 
multimeric fonn of still higher density. All neuraminidase 
activity was found to be present in this latter multimeric 
peak (Fig. 4b). When a concentrated preparation was not 
stabilized. p-galactosidase activity was present in two peaks 
of activity. one monomeric ::md one multimeric. The higher 
density multimeric form was not present under these 
conditions and neuraminidase activity was absent (Fig. 4c). 
Since without stabilization treatment neuraminidase activity 
is lost upon dilution (Fig. 1 b) ::md sucrose density gradient 
centrifugation implies dilution, the loss of neuraminidase 
activity can be explained. 
From these experiments we conclude that the presence of 
lysosomal neuraminidase in a complex with the high density 
multimeric form of ,8-galactosidase is essential for its stability 
and catalytic activity. at least in vitro. 
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The relationship between neuraminidase 
and the 32000-M, 'protective'protein 
For the multimeriz:l.tion of JJ-galactosidasc a 32000-M, 
'protective' protein is required, as was demonstrated for 
human fibroblasts [6]. Fig. 3 shows that this protein is also 
pr.esent in the affinity column eluate when the placental 
glycoprotein preparation is applied to the column after induc-
tion of complex formation. The apparent M, of this protein 
seems to be slightly different from the M, of the protein in 
human fibroblasts. However. since this protein is a 
glycoprotein. the observed difference is not significant. 
Therefore. to avoid confusion with the previous literature [5. 
6]. we maintain the established terminology as a 32000-M, 
?rotein. 
To investigate whether the 32000-M, protein was also 
iJre:>cnt in the complex of the high density multimer of 
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Fig. 5. Jmmunoprecipiration of different molecular forms of {J-ga-
facrosidasc ({J-Gal.) usin~; monospccific antibodies. Sucrose density 
gradient centrifugation of {J-galactosidase (A), was followed by 
immunotitmtion of the fi-galactosida.-.e monomeric form I (B) and of 
the fl-gabctosida~ multimerie form II (C), with anti- (ft-ga· 
bctosidase) specific lgG (8----8) and with :mti-('protective' pro-
tein) specific lgG ( 8--e ). These specific lgG preparntions were 
extrneted from an conventional anti-(fl-galactosida~) antiserum 
containing a mixture of antibodies ag:.tinst fi-galactosidasc and "pro-
tective' protein. using a nitrocellulose-blot afl"inity-purification proce-
dure. a_~ described in the text 
/3-galactosidase and neuraminidase. immunoprccipitation 
studies were carried out. For this purpose, specific antibodies 
against the 32000-M, protein and against the 64000-M, pro-
tein were extracted from a rabbit antiserum containing both 
types of antibodies, as described under Experimental Proce-
dure. With immunoblotting it was verified that the anti-
(32000-M, protein) antibodies did not cross-react with the 
64000-M, protein band, and vice versa (results not shown). 
Fig. 5 illustrates the reactivity of both types of monospe-
cific antibodies with peak I and pe:lk II of /3-galactosidase 
activity. Antibodies against the 64000-M, protein band are 
able to precipitate both the monomeric (peak I) and the 
multimeric (peak II) form of /3-galaetosidase, whereas anti-
(32000-M, protein) antibodies only precipitate the high mo-
lecular mass form ~f .8-galactosidase (peak II). 
As is shown in Fig. 6. neuraminidase and /3-galactosidasc 
activity coprecipitate with both the anti-(32000-M, protein) 
and the anti-(64000-M, protein) antibodies. No precipitation 
was observed with monospecific antibodies against a 50000-
M, protein contaminant which were extracted from the same 
rabbit antiserum. This demonstrates the specificity of the im-
munological method used. and it shows the stability of 
neuraminidase during the immunoprecipitation. 
From these results we conclude that the 32000-M, 'protec-
tive' protein is not only closely associated with the j3-ga-
lactosidase multimer, but also with the neuraminidase associ-
ated high density multimer of /3-galactosidasc. 
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Fig. 6.Jmmunotitrarion of pfaunraf neuraminidm·r:and {J-galacrosidasc 
with differ<•nr nirroccllulosc-btor affinit}~purifl('d antibodies. An 
activated and stabilized glycoprotein fraction from human placenta 
containing neuruminidase activity (0--0) and fi-guluctosidasc 
activity (D~---0) was treated with im;reasing amounts of 
nitrocellulose-blot affinity-purified monospecific IgG preparations 
against the 32000-M, protein band. the 64000-M, protein band and 
a 50000-M, protein band contaminant. After incubation asd~b<:d 
in the text the activities remaining in the supernatants were mcawrcd 
DISCUSSION 
Although lysosomal neuraminidase is known as a 
membrane-bound enzyme [3. 7-9. 17], our data show that 
neuraminidase is also present in the supernatant of human 
placental tissue though in an inactive form. Its activity can 
be generated by concentration. The activity increases 
quadratically with concentration. which suggests that the 
aggregation of at least two subunits is essential for 
neuraminida..~e activity. The stabilization of the generated 
activity by incubation at 37'C and acid pH probably shifts the 
existing equilibrium between inactive. not aggregated subunits 
and active aggregated subunits towards the latter. This 
equilibrium apparently shifts easily by freezing and 
homogcni7..ation to the inactive not aggregated subunits. 
which explains the well-known lability ofncuraminida$e and 
the absence of activity in frozen and homogenized prep-
arations [3, 8, 17, 18]. 
Using affinity chromatography and immunotitration we 
provide evidence that the existence of neuraminidase in a 
complex with j3-galactosidase is quite a general phenomenon. 
since it was found in human placenta (Fig. 4 and Table 2) in 
addition to bovine testis [10], human fibroblasts (unpublished 
results) and human leucocytes [19]. 
The 32000-M, protein. which is present in the final prepa-
ration of /3-galactosidase and neuraminidnsc, is a prerequisite 
for the formation of the high molecular mass enzyme 
complexes. In fibroblasts from patients vtith a genetically 
determined deficiency of the 32000-M, protein (gal-
actosidosis). j3-galactosidase remains in the monomeric form 
which is sensitive to degradation by lysosomal proteases [6]. 
The deficiency of neuraminidase in galactosialidosis points to 
a further relation between this enzyme and the 32000-M, 
'protective' protein. In the present studies we have demon-
strated. in vitro. the association of lysosomal neur..tminidase 
with a high density multimeric /3-galactosidase. 
Using monospccific anti-(32000-M, protein) antibodies 
it was shown that the 32000-M, 'protective' protein is also 
associated with this high density multimeric /3-galactosidase 
together with neuraminidase. The simultaneous dis-
appearance of this high density /3-galactosidase multimer and 
neuraminidase activity. as observed in Fig. 4c, supports the 
hypothesis that the 32000-M, protein is a common subunit 
of lysosomal JJ-galactosida.."C and neuraminidase. It prevents 
intralysosomal degmdation of /3-galactosidase. but at the 
same time it is essential for the expression of neuraminidase 
activity. 
Since cells from patients with GM 1-gangliosidosis have a 
normal neuraminidase activity despite the absence of 
/3-galactosidase molecules [20]. the complex of neuraminidase 
with /3-galactosidase is not essential for its activity. at least in 
vivo. 
In addition to the 32000-M,subunit. another yet unknown 
subunit seems to be required -for neuraminidase activity. The 
20000-M, protein. which is present in the purified enzyme 
preparation. is not likely to be the unknown subunit of 
neuraminidase. This cleavage product formed during pro-
teolytic processing of the 'protective' protein [6] is present 
vtith the 32000-M, protein in the multimeric form of /J-ga-
lactosidase (peak II), where no neumminidase activity was 
found. With the identification of the unknown subunit it must 
be taken into account that the present studies have been 
performed on soluble neuraminidase, whereas most of this 
enzyme is membrane-bound. 
The method which we developed to generate neur-
aminidase activity in >'itro will be useful for the further puri-
fication and characteri7..ation of the different neuraminidase 
subunits. Information about the subunit structure of 
neuraminidase is essential for the understanding of the molec-
ular nature of human disorders associated with neumminidase 
deficiency. 
We thank Dr A. J. J. Rcuser for helprtJI disctJssions '-!nd Ms 
M. J. C. H. van Woensel ror preparation or the mantJscript. 
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SUMMARY 
Lysosomal neuraminidase and B-galactosidase are present 
in a complex together with a 32 kDa protective protein. This 
complex has been purified and the different components have 
been dissociated using potassium isothiocyanate (KSCN) treat-
ment. 6-Galactosidase remains catalytically active, but neura-
minidase loses its activity upon dissociation. The inactive 
dissociated neuraminidase was purified by removing the remain-
ing non-dissociated B-galactosidase/protective protein complex 
using 8-galactosidase specific affinity chromatography. The 
dissociated neuraminidase material shows two major polypep-
tides on SDS-PAGE with an apparent molecular mass of 76000 and 
66000. Subsequently the 32 kDa protective protein was disso-
ciated from the 6-galactosidase/protective protein complex, 
and purified. 
Antibodies raised against the dissociated inactive neura-
minidase preparation specifically immunoprecipitate the active 
neuraminidase present in the complex with 6-galactosidase and 
protective protein. 
By imrnunoblotting evidence is provided that the 76 kDa 
protein is a subunit of neuraminidase which, in association 
with the 32 kDa protective protein, is essential for neurami-
nidase activity. 
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INTRODUCTION 
Studies on neuraminidase (EC 3.2.1.18) from bacterial, 
viral and eukaryotic sources have provided information on the 
substrate specificity of this enzyme. Substrates may be either 
sialylated glycoproteins and oligosaccharides or gangliosides. 
Furthermore evidence has been presented for the existence of 
different neurarninidases, with a different substrate specifi-
city and subcellular localization ( 1-4 ). 
Interest in human lysosomal neuraminidase has been sti-
mulated by the discovery that this enzyme is involved in 
different inherited lysosomal storage disorders (5-8). 
We have recently demonstrated that in various cell types 
lysosomal neuraminidase occurs in a complex with the lysosomal 
enzyme S-galactosidase (EC 3.2.1.23) and a 32000 molecular 
mass glycoprotein (9,10). This 32 kDa protein is known to be 
essential for the aggregation of 6-galactosidase monomers 
(11), and is required for the expression of neuraminidase 
activity (10). The molecular nature of neuraminidase, however, 
is still unknown. 
Since human placental neuraminidase can be activated, 
stabilized and subsequently copurified with B-galactosidase by 
6-galactosidase specific affinity chromatography, we have 
developed a purification procedure for neuraminidase subunits, 
which is based on the complex formation with a-galactosidase. 
This paper deals with this purification procedure, the prepa-
ration of specific antibodies and the characterization of the 
purified neuraminidase associated polypeptides. 
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EXPERIMENTAL PROCEDURES 
Dissociation of the 6-qalactosidase/ protective protein/neura-
minidase complex 
A by concanavalin A chromatography obtained glycoprotein 
fraction from human placenta, was excessively concentrated and 
subsequently incubated at 37°C for 90 min., to obtain active 
and stable neuraminidase activity (10). 
A 70 ul sample of this glycoprotein fraction was diluted 1 
to 1 with either water, or a 1.6 M or 3 M KSCN solution .to 
study the association and dissociation of the neuraminidase/6-
galactosidase complex. The analysis was performed by sucrose 
density gradient centrifugation as described ( 12 ) . Linear 
gradients of 20-40 % (w/v) sucrose in 20 mM sodium acetate · 
buffer containing 100 mM NaCl pH 5.2 were prepared in a total 
volume of 5 ml. After 15 h. centrifugation {40000 rpm, Beckman 
L5-65 centrifuge, SW-50 rotor} 200 ~1 fractions were collected 
and enzyme assays were performed. 
Purification of inactive neuraminidase polypeptides 
Neuraminidase was copurified with B-galactosidase by affi-
nity chromatography on p-aminophenylthiogalactoside-CH- Sepha-
rose (PAPS-Gal-Seph.) as described previously ( 9,10 ). The 
purified B-galactosidase/ protective protein/neuraminidase 
complex was then mixed with an ice-cold 3M KSCN solution to a 
final concentration of 0.8 M KSCN, which dissociates neurami-
nidase from the B-galactosidase I protective protein complex. 
Subsequently the KSCN concentration was lowered ten-fold 
by dilution with 20 mM sodium acetate buffer containing 100 mM 
NaCl pH 5.2 and the preparation was applied again on a PAPS-
Gal-Seph. column (3 ml bedvolume ) at a flowrate of 15 rnl/h. 
The unretained material of this column containing dissociated 
inactive neuraminidase was collected, dialysed and concen-
trated in an Amicon Ultrafiltration Cell, using a PM 10 fil-
ter. 
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The column was washed with 20 mM sodium acetate buffer 
containing 0.5 M NaCl, pH 5.2. and the 8-galactosidase/ pro-
tective protein complex was eluted with the same buffer con-
taining 100 mM y-galactonolactone. After concentration and 
dialysis this complex was dissociated by dropwise addition of 
a cold solution of 3M KSCN to a final concentration of 1.5 M. 
The KSCN concentration was lowered ten-fold by dilution with 
20 mM sodium acetate buffer containing 100 mM NaCl, pH 5.2 
before the preparation was chromatographed again on a PAPS-
Gal-Seph. column. The unretained material was checked for the 
presence of dissociated protective protein subunits and the 
eluate for 6-galactosidase polypeptides. All preparations were 
frozen and stored at -70°C. 
Polyacrylamide gel electrophoresis 
Electrophoresis in the presence of sodium dodecyl 
sulphate (SDS-PAGE) was performed on 10% slab gels according 
to Laemmli ( 13 ). 
Immunological methods 
The purified inactive dissociated neuraminidase prepara-
tion (20-50 ~g) was diluted to 1 ml with phosphate buffered 
saline pH 7.4 and mixed with 1 ml incomplete Freund's ad-
juvant. Rabbits were injected subcutaneously. After three 
weeks a first booster was given and ten days later a second 
one. Serum was collected eight days later. 
A glycoprotein fraction from human placenta containing 
about 4 mU S-galactosidase and about 0.1 mU activated and 
stabilized neuraminidase was imrnunotitrated with an IgG prepa-
ration, which was prepared from the antiserum raised against 
the purified inactive neuraminidase preparation, using- protein 
A-Sepharose. 
The experiment was performed as described earlier for 
antibodies against S-galactosidase (10 ); for the precipita-
tion of immunecomplexes 30 ~1 of a 1:1 suspension of protein 
A-Seph. in phosphate buffered saline was added. 
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The different aggregation forms of B-galactosidase/ pro-
tective protein/neuraminidase were imrnunotitrated as follows. 
After sucrose density gradient centrifugation of an activated 
and stabilized glycoprotein preparation the topfractions from 
peak I, II and III were diluted with 40 mM sodium phosphate 
buffer containing 200 mM NaCl and 1 mg/ml bovine serum al-
bumin, pH 6.0. 
Samples containing about 4 rnU 8-galactosidase and 0.1 mU 
neuraminidase (only in peak III) were used for each precipita-
tion. Immunotitration was performed as described (10). 
Immunoblotting was performed as follows. After SDS-PAGE 
the proteins (20-50 ~g) were transferred to a nitrocellulose 
filter by electroblotting as described by Towbin et al. 14 
). Strips of nitrocellulose containing the transferred pro-
teins were incubated 1 h at room temperature in phosphate 
buffered saline containing 100 mg/ml bovine serum albumin and 
subsequently overnight at 4°C in the appropriate antiserum 
dilution in phosphate buffered saline containing 0.5 % Tween 
20, pH 7.4. 
Bands were visualized by 2 h incubation at room tempera-
ture with an alkaline phosphatase goat-(anti-rabbit IgG) con-
jugate ( Tago ) (2 ).11 in 5ml PBS containing 0.5 % Tween 20 ) . 
Then strips were 
substrate solution 
incubated in an alkaline phosphatase 
( l mg Naphtol AS-MX phosphate disodium 
salt, Sigma, and 3 mg 4-aminodiphenylamine diazonium sulphate, 
Sigma, per m1 0.2 M Tris-HCl containing 10 mM MgCl2 , pH 9.1 ). 
After l to 5 min blue-coloured spots developed and the 
reaction was terminated by washing with water. 
Assays 
Protein was measured as described by Lowry et al ( 15 ). 
Neuraminidase and 8-galactosidase activities were measured 
with the appropriate 4-methylumbelliferyl substrates as repor-
ted earlier ( 16 ). One Unit of activity is defined as the 
amount of enzyme releasing 1 ~mol 4-methylumbelliferone/min at 
37oc. 
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RESULTS 
Dissociation of the 8-qalactosidase/protective 
protein/neuraminidase complex 
Lysosomal neuraminidase was activated and stabilized in a 
glycoprotein fraction from human placenta by excessive concen-
tration and subsequent incubation at 37°C. 
Sucrose density gradient centrifugation shows that the 
high density molecular mass complex between 6-galactosidase, 
the 32 kDa protective protein and neuraminidase can be disso-
ciated by treatment with 0.8 M KSCN (Fig.1A and B). This 
dissociation is accompanied by a total loss of neuraminidase 
activity. When the preparation is treated with KSCN, and not 
separated on sucrose density gradients, but dialysed rapidly 
to remove KSCN, the neuraminidase activity can be partially 
restored (data not shown). The middle peak, representing an 
aggregation form of B-galactosidase and protective protein, 
without neuraminidase, dissociates only after treatment with a 
higher concentration ( 1.5 M) of the chaotropic agent KSCN 
(Fig.1C). 
Purification of the different molecular components of the 
complex 
The observations described above have led to a purifica-
tion procedure for the different neuraminidase associated 
~olypeptides. A summary of the procedure is shown by the flow 
chart in Fig .2. 
Firstly, neuraminidase is activated and stabilized in a 
glycoprotein fraction from human placenta and copurified with 
B-galactosidase by PAPS-Gal-Seph.chrornatography. Neuraminidase 
activity can still be measured in the purified complex as is 
shown in Table 1. 
To separate the different components of this complex KSCN 
was first added to a concentration of 0~8 M, under which con-
ditions the very high density complex containing neuraminidase 
activity is lost, whereas the S-galactosidase-32 kDa protein 
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Fig.l Dissociation of the 6-galactosidase/ protective 
protein/neuraminidase complex by KSCN treatment. A glycopro-
tein fraction containing B-galactosidase and activated and 
stabilized neuraminidase activity was treated with different 
concentrations of KSCN and subsequently applied on sucrose 
density gradients to study the dissociation of the different 
aggregation forms. a) no treatment b) 0.8 M KSCN treatment 
c) 1.5 M KSCN treatment. 
Fig.2 
for the 
subunits 
123 
HUMAN PLACENTA 
25000 XG SUPERNATANT 
I CONCANAVAL!N A-SEPK. f CHROMATOGRAPHY 
GL YCOPROTE INS 
I CONCENTRATE AND 
ftNCUBATE 90 MIN, AT 3rc 
GLYCOPROTEIN PREPARATION 
W!TK ACTIVE AND STABLE 
NEURAMINIDASE 
I PAPS-GAL -SEPH. 
tAFF!NlTY CHROMATOGRAPHY 
ISOLATED 
,'1-GAL,/PROTECT, PROTEI N/NEURAM!NlDASE 
UNRETAINEO 
PURE 
INACTIVE NEURAMINIDASE 
SUBUNITS 
UNRETAINED 
PURE 
PROTECT, PROTEIN 
COMPLEX 
EATMENT WITH 0.8 M KSCN 
LLOWED BY PAPS-GAL-SEPH, 
F!NITY CHROMATOGRAPHY 
ELUTED 
(I-GAL, /PROTECT, PROTEIN 
COMPLEX 
TREATMENT WITH 1.5 M KSCN 
FOLLOWED BY PAPS-GAL -SEPH, 
AFFINITY CHROMATOGRAPKY 
ELUTED 
PURE 
~ 
Flow chart of the purification procedure developed 
purification of the two different neuraminidase 
(for details see text). 
complex remains intact. The proteins that are no longer asso-
ciated with the 6-galactosidase-32 kDa protein complex are 
recovered from the run through from a second PAPS-Gal-Seph. 
column, whereas the remainig 6-gal./32 kDa complex is specifi-
cally eluted with y-galactonolactone. This cOmplex is then 
dissociated with a higher concentration of KSCN (1.6 M), and 
its components are separated by affinity chromatography on 
PAPS-Gal-Seph. The neuraminidase activity, 6-galactosidase 
activity and protein concentrations of all fractions during 
purification are listed in Table 1. 
Table l 
Purification of 
human placenta. 
the different ~-galactosidase and neuraminidase subunits from 3 kg 
n,d, = not detectable, Neur. = neuraminidase, p-Gal. = ~-galactosidase 
purification step 
supernatant after 
homogenization 
and centrifugation 
(25000 x g. 30 min.) 
Con-A-Seph.chromatogr. 
followed by activation 
and stabilization 
treatment 
PAPS-gal.-Seph. 
chromatogr. 
0 • 81·1 KSCN treatment 
followed by 
PAPS-gal.-Seph. 
chromatogr. eluted 
unretained 
l.SN KSCN treatment 
follmved by 
PAPS-gal.-Seph. 
chromatogr. eluted 
unretained 
protein 
mg 
180000 
1968 
l. 41 
0,52 
0.22 
0.20 
0.10 
total activity 
Neur. ,ll-Gal. 
u 
n.d. 
1.6 
0.29 
n.d. 
n.d. 
n.d. 
n.d. 
94.0 
63. 0 
26.3 
9.5 
n.d. 
6.0 
n.d. 
specific activity 
Neur. ,ll-Gal. 
mU/mg protein 
0.5 
0.81 32.0 
206 18650 
18460 
30000 
recovery 
,ll-Gal. 
% 
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Fig.3 SDS-PAGE pattern of the different purified polypep-
tides. Lane A purified 6-gal./prot.protein/neur.complex. 
Lane B purified inactive neuraminidase preparation. 
Lane C purified protective protein. 
Numbers show molecular mass in kDal. 
The SDS-polyacrylarnide gel electrophoresis pattern of the 
preparations during the different stages of purification is 
shown in Fig.3. 
Lane A shows that the purified intact complex consists of 
two major protein bands. The band with a relative molecular 
mass of 64 kDa is known to be the mature form of 6-galactosi-
dase and the 32 kDa band represents the earlier described 
protective protein. Lane B shows that the 0.8 M KSCN run 
through of the second PAPS-Gal-Seph. column contains two major 
bands with molecular masses of 76 kDa and 66 kDa, which could 
thus represent dissociated subunits of neuraminidase. The 
purified 32 kDa protective protein after the third PAPS-Gal-
Seph. column is shown in lane C. 
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Immunotitration of B-galactosidase and neuraminidase 
with neuraminidase specific antibodies. 
A glycoprotein preparation containing B-galactosidase 
( C---D) and activated and stabilized neuraminidase ( ---• 
was titrated with an IgG preparation prepared from antiserum 
against the purified inactive neuraminidase preparation. 
Immunological studies of the neuraminidase associated poly 
peptides 
Antibodies were raised in rabbits against the puri-
fied inactive neuraminidase polypeptides illustrated in Fig.3 
lane B. The antibodies were tested ~ith a total glycoprotein 
preparation from human placenta containing both B-galactosi-
dase and neuraminidase (Fig.4). The antibodies precipitated 
20% of the a-galactosidase activity and all neuraminidase 
activity. 
The specificity of the antibodies was further investi-
gated by immunoprecipitation of the different aggregation 
forms of a-galactosidase as observed after sucrose density 
gradient centrifugation (Fig.S middle and bottom}. 
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Immunotitration and immunoblotting of the different 
molecular forms of S-galactosidase/ protective protein/neura-
minidase using sucrose density gradient centrifugation of a 
placental glycoprotein preparation. 
Fractions from peaks I, II, and III (middle ) were immunoti-
trated with an IgG preparation prepared from the neuraminidase 
specific antiserum (bottom). 
c--o ,S-galactosidase; o--e ,neuraminidase 
The same fractions were also subjected to SDS-PAGE 
followed by irnmunoblotting with the same IgG prepa-
ration (top, inserted photograph). Numbers are 
shown in kDal. 
The antibodies precipitated neuraminidase activity and 
a-galactosidase activity present in the high density multime-
ric complex of the two enzymes (peak III ). The other aggrega-
tion forms of B-galactosidase (peak I and II) could not be 
precipitated by this antiserum. 
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To further specify the nature of the immune recognition 
and to identify the 76 kDa and 66 kDa molecular components of 
the neuraminidase complex immunoblotting experiments were 
performed on a total glycoprotein preparation. The results for 
the different aggregation forms after activation and stabili-
zation of neuraminidase are shown in Fig~ 5 (top inserted 
photograph). In peak III, where all neuraminidase activity is 
present, only the 76 kDa polypeptide is reacting with the 
antibodies raised against inactive dissociated neuraminidase. 
This polypeptide is also present in peak II, probably 
representing inactive not fully associated neuraminidase. The 
66 kDa polypeptide could be visualized only in peak I, which 
is known to contain monomeric B-galactosidase. 
Similar results were obtained when a purified B-galacto-
sidase/protective protein/neuraminidase complex was subjected 
to SDS-PAGE followed by immunoblotting. 
Immunoblotting of the purified inactive neuraminidase 
preparation revealed that the antibodies were mainly directed 
against the 76 kDa component. 
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DISCUSSION 
Recently we have demonstrated that lysosomal neuramini-
dase from human placenta consists of at least two different 
polypeptides which upon aggregation yield active neuraminidase 
(10). 
One of these polypeptides was already known as the 32 kDa 
S-galactosidase protective protein, which 
aggregation of S-galactosidase molecules. 
is necessary for the 
This high molecular 
mass multirner protects 6-galactosidase against rapid intraly-
sosornal proteolytic degradation (11,17). 
This 32 kDa polypeptide is also essential for the cataly-
tic activity of lysosomal neuraminidase (10). Its genetic 
deficiency occuring in the human lysosomal storage disorder 
galactosialidosis consequently results in a combined deficien-
cy of B-galactosidase and neuraminidase (5,18). So far other 
neuraminidase specific polypeptides had not been identified. 
In the present paper we describe the purification and 
partial characterization of different neuraminidase polypep-
tides. 
The purified inactive neuraminidase preparation contains 
a 76 kDa and 66 kDa polypeptide. 
Irnmunoblotting studies showed that the 66 kDa component 
is not associated with neuraminidase activity. At sucrose 
density gradient centrifugation this polypeptide is found in 
the same position as monomeric S-galactosidase. The 66 kDa 
polypeptide could either be a breakdown product or a 
contaminant, which perhaps represents some 
which remained associated with neuraminidase. 
S-galactosidase 
The 76 kDa protein on the other hand is associated with 
neuraminidase activity and is present together with the high 
density multimeric form of S-galactosidase. These characteris-
tics suggest that the 76 kDa polypeptide is a subunit of 
neuraminidase essential for its catalytic activity. 
The 76 kDa subunit is also present in the low density 
molecular mass complex consisting of S-galactosidase and 
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protective protein without neuraminidase activity (Fig.S peak 
II) • Extensive concentration of dialysed fractions from this 
complex did however generate some higher molecular mass form 
with neuraminidase activity. 
In conclusion it appears that neuraminidase is composed 
of two different subunits with molecular masses of 32 kDa and 
76 kDa, which are both essential for the expression of the 
enzyme activity. In glycoprotein fractions of human 
bovine testis and some other tissues neuraminidase 
placenta, 
activity 
can be generated upon association of these two subunits with 
each other and with lysosomal a-galactosidase. It is still 
unclear how these observations relate to the in vivo situation 
and further studies on the stoichiometry of the complex are 
required. 
Several neuraminidases with different substrate specifi-
city and different subcellular localization have been des-
cribed (1), but only a few reports deal with purified prepara-
tions of lysosomal neuraminidase. Partial purification of a 
lysosomal neuraminidase from rat liver has been described 
( 19 ). This enzyme was reported to be a monomer of 60 kDa and 
aggregation with 8-galactosidase or any other polypeptide was 
not required for its catalytic activity. The enzyme presented 
cleavage specificity for oligosaccharides and glycopeptides. 
Also a neuraminidase from human leucocytes was partially puri-
fied. This enzyme has an average molecular mass of 48 kDa and 
specificity for oligosaccharides and glycoproteins ( 20 ). 
Since human leucocytes contain at least two different neurami-
nidases ( 4 ) , it is not clear which enzyme has been purified. 
In the studies mentioned above ( 19,20 } no relationship 
between neuraminidase, a 32 kDa polypeptide and 8-galactosi-
dase was demonstrated, which makes it unlikely that the en-
zymes concerned are the same as the one involved in the human 
genetic disorders sialidosis and galactosialidosis. 
One report deals 
homogenates from 
with neuraminidase 
human placenta and 
in rough 
the 
characteristics of this enzyme are similar to those 
tissue 
kinetic 
of our 
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activated and stabilized form (21). 
Our previous work (10) indicated the presence of two 
different subunits in human placental neuraminidase and in the 
present paper this work is extended by their purification. The 
antibodies raised against the inactive neuraminidase prepara-
tion will enable us to further study the stoichiometry of the 
S-galactosidase/neuraminidase complex and to elucidate the 
nature of the molecular defect in different variants of the 
autosomal recessive lysosomal disorder sialidosis. 
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Human leucocytes contain two different MU-NANA neuraminidases, which can be 
distinguished by Concanavalin A binding. The Con A binding form is predominant 
in lymphocytes (more than 80%) and the non-binding form predominates in granulo-
cytes. The pH optima of both these neuraminidases as well as their subcellular 
localization as determined by Percoll gradient centrifugation suggest that they 
are both lysosomal. Immunological studies indicate that the Con A binding form 
is present in a complex with B-galactosidase whereas the non-binding form is 
not. Leucocytes from patients with sial idosis or galactosial idosis are deficient 
in the Con A binding neuraminidase, whereas the non-binding form is normal. Jn 
sialolipidosis both forms are normal. These results demonstrate that leucocytes 
contain at least two genetically different MU-NANA neuraminidases. Thus, the use 
of leucocytes should be avoided for the diagnosis of sialidosis and galacto-
sial idosis, and isolated lymphocytes should be used to obtain reliable results. 
ln man several inherited disorders are known with a deficiency of neUra-
minidase activity (1). With the present biochemical knowledge these disorders 
can be separated in three distinct groups; within each group clinical hetero-
geneity is observed. Firstly, there is a group of patients, classified as sial i-
dosis, characterized by a deficiency of a lysosomal neuraminidase specific for 
glycoproteins and ol igosaccharides with terminal sialic acid (2). This group 
includes disorders previously described as mucolipidosis I and cherry-red spot 
myoclonus syndrome (1-7). The second group, galactosialidosis, is characterized 
by a combined deficiency of a-galactosidase and neuraminidase (8,9). The primary 
defect lies in a glycoprotein which normally prevents degradation of B-galacto-
sidase (9-12). Neuraminidase is deficient as well, which may find its origin in 
the fact that B-galactosidase and neuraminidase occur as enzyme complex (13). 
The third group has recently been classified as sialolipidosis (i.e. mucolipi-
~MU-NANA, 4-methy\umbelliferyi-~-D-N-acetylneuraminic acid 
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dosis IV), in which the enzyme deficiency is a ganglioside specific neuramini~ 
dase (14, 15). 
For the diagnosis of sialidosis and galactosialidosis hydrophilic substrates 
were employed: glycoproteins or oligosaccharides and 4-methylumbelliferyl ~-0-N­
acetylneuraminicacid (MU-NANA). Sialolipidosis has been diagnosed using labelled 
ganglioside substrates. Nearly complete enzyme deficiencies have been detected 
in cultured fibroblasts from patients with these different disorders (1-9, 15). 
However, using leucocytes as the source of neuraminidase, considerable residual 
activities (sometimes close to normal) were found in sialidosis and galactosia-
lidosis (16-20). 
Recently it was proposed that leucocytes contain two MU-NANA neuraminidases 
distinguished by slight physical differences (17,20,21). In contrast to these 
reports, we demonstrate the presence of two neuraminidases with qualitative 
biochemical differences and have extended the studies to all three_disorders. 
Our results indicate that both MU-NANA neuraminidases are of different genetic 
origin. The imp! ications for diagnosis of sial idosis and galactosial idosis are 
discussed. 
MATERIALS AND METHODS 
Blood cell isolation 
Isolation of leucocytes was performed by sedimentation of freshly collected 
heparinized blood samples in 3% Dextran (T-500, Pharmacia) in 0.9% NaCJ, where-
after lymphocytes and granulocytes were separated on Fico! I Paque (Pharmacia). 
Remaining erythrocytes in leucocytes and granulocytes were lysed during 
10 minutes in 50 mM NaCJ at 4°C, after which the cells were spun down at 300 x g 
for 10 min. 
Preparation of cell homosenates 
Cell homogenates for specific act1v1ty determination were made by homogen-
izing the eel Is in 60 f.!] 0.1% sodium taurocholate (Sigma, synthetic) using a 
glass-teflon Potter homogenizer. Leucocytes derived from 2-3 ml blood samples 
were used, and lymphocytes and granulocytes from 4-7 ml. 
Assay of protein and enzyme activity 
Protein was measured by the method of Lowry (22). Neuraminidase was measured 
with 4-methylumbelliferyl N-acetylneuraminic acid (MU-NANA) (a generous gift of 
Prof. R. Brossmer, Heidelberg). 20 f.!] Cell homogenate was added to 10 f.!] 2 mM 
substrate solution in 0.25 M sodium acetate buffer pH 4.3. Incubation was at 
37°C for one hour. The reaction was terminated by addition of 500 f.!], 0.5 M 
sodium carbonate buffer pH 10.7. S-Galactosidase was assayed in a thirtyfold 
diluted homogenate as described earlier (23). FluoreScence was measured with a 
Perkin Elmer fluorimeter. 
Solubilization of neuraminidase and S-galactosidase. 
Cells derived from 10-25 ml blood were homogenized in 50 f.!] 20 mM sodium 
phosphate buffer containing 100 mM NaCl and 1% Zwittergent 3.12 (Calbiochem.) 
pH 6.0 using a glass-teflon Potter homogenizer. The homogenates were centrifuged 
at 10000 x g for 15 minutes at 4°C. The supernatant containing solubilized 
neuraminidase and S-galactosidase was used in the precipitation experiments with 
Con A-Sepharose and anti placental S-galactosidase lgG. 
Con A-Sepharose precipitation 
5 f.!] Supernatant was addeid to 5 f.!] 20 mM sodium phosphate buffer pH 6.0 
containing 100 mM NaCl, 1% Zwittergent 3.12 and various amounts of Con A-
Sepharose-48 (Pharmacia). The tubes were gently rotated at 4°C. After one hour 
all tubes were centrifuged at 10000 x g for 20 seconds. Supernatants were assayed 
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for both neuraminidase and a-galactosidase. The incubation volume was reduced to 
3 ~~ and the reaction was terminated with only 200 ~1 sodium carbonate buffer 
pH 10.7. 
lmmunot i trat ion 
3 ~I Supernatant was added to 2 ~1 of a serial dilution of lgG (13) in 
20 mM sodium phosphate buffer containing 100 mM sodium chloride pH 6.0. After 
two hours incubation at 4°C, 5 ~1 of a 1:1 Protein A Sepharose-4B (Pharmacia6 
suspension in the same buffer was added. After one hour gently rotating at 4 C, 
all tubes were centrifuged at 10000 x g for 20 seconds. Supernatants were assayed 
for both neuraminidase and a-galactosidase activity as described under Con A-
SepharOse precipitation. 
Subcellular fractionation in Percell gradients 
Lymphocytes or granulocytes isolated from 200 ml respectively 100 ml 
freshly collected blood from healthy donors, were suspended in 0.5 ml 0.25 M 
sucrose. 10 mM sodium phosphate buffer pH 6.8 and disrupted by 25 strokes in a 
2 ml glass-teflon Potter homogenizer. Nuclei and intact cells were removed by 
centrifugation for 10 min. at 600 x g. About 90% of granulocyte 8-hexosaminidase 
(lysosomal latency :>80%) and about 80% of lymphocyte a-hexosaminidase (lyso-
somal latency :>60%) was recovered in the postnuclear supernatant. Percoll 
(Pharmacia) was made iso-osmotic with 0.25 M sucrose and this solution (100% 
Percoll) was diluted to a final Perco\1 concentration of 40% with 0.25 H sucrose, 
10 mH sodium phosphate buffer pH 6.8. 0.3 ml Postnuclear supernatant was applied 
on top of 8 ml of 40% Percell solution underlayed with 0.5 ml 2.5 H sucrose. The 
samples were centrifuged at 25000 rpm (~48000 x g) for 45 minutes at 4°C in a 
Beckman type 50 fixed angle rotor. Fractions of 300 ~1 were collected with a 
density-gradient removing apparatus {Auto densi-flow I I, Buchler instruments). 
For neuraminidase assay 15 ~1 gradient fraction was mixed with 15 ~1 H 0 and 
incubated with 10 ~1 substrate containing 0.4% taurocholate and 4% Zwi!tergent 
3.12. Recovery of neuraminidase activity after the Percoll centrifugation 
was :>70%. Alkaline phosphatase activity was measured with 1.5 mM methylumbelli-
feryl phosphate (Koch-light) in 1 mM MgC1 2 and 75 mM 2-amino-2 methyl-1-propanol/ HCJ pH 10.1 in the presence of 0.1% triton X-100 (24). 
Total leucocytes and isolated lymphocytes and granulocytes from patients 
with sial idosis (patient of Dr. H.O. Bakker, (9)), galactosial idosis (patient of 
Dr. M.C.B. loonen, (9,25)) and sialol ipidosis (15), were tested for neuramini-
dase and a-galactosidase activity (Table 1). leucocyte neuraminidase activities 
of sialidosis and galactosialidosis patients were found to be close to the 
lowest control value (up to 39% of the normal mean value). Leucocytes from a 
patient with sialol ipidosis had neuraminidase activities in the control range. 
However, isolated lymphocytes from sialidosis and galactosialidosis patients 
were clearly deficient in neuraminidase activity (<(15% of the mean control 
value). whereas lymphocytes from the patient with sialolipidosis had normal 
activity. In contrast granulocytes from all different types of patients showed 
normal neuraminidase activities. As expected, ~-galactosidase activities were 
normal in all cell types of the sialidosis and sialolipidosis patients and 
clearly deficient in all cell types of the galactosialidosis patient. The fact 
that neuraminidase activity in both sialidosis and galactosialidosis. which are 
two genetically distinct diseases, is deficient in lymphocytes, but normal in 
granulocytes. suggests that there are at least two genetically different neura-
minidases. 
138 
NORMAL 
''~-------------,.--------------r·,--------------; 
SlALIDOSlS G.>.l.ACTOSIAUOOSIS 
:·· ~------t.:h\\\, ~ 
~ \\0--·---o------- o •• ____ o.. _____ _ 
;; 
~~~,~~\-,' .. ------T,\c-\-------,r--------, 
~ \., \ 
'*,---c':~;=-=--=-~-o'-=;,;:.:=!:4,~--c:::'~c-=--"-"-"-=-o;;_.r.=o:J'4~l--------------=~;:;o--o-o-,-~,,:--+ 
CON A SEPHAROSE I jJL l 
~- Con A-sepharose precipitation of neuraminidase and S-galactosidase from 
normal, sial idosis and galactosial idosis cells. 
Upper graphs: lymphocytes 
Lower graphs: granulocytes 
e Neuraminidase 
()a-Galactosidase 
To pursue this hypothesis the neuraminidases were further characterized. 
Neuraminidase, which is insoluble under our standard assay conditions using 
sodium taurocholate, was solubilized with a zwitterionic detergent. In normal 
lymphocytes 40 to-70% of the total activity could be solubilized, whereas in 
granulocytes the solubilization was 85 to 100%. From the solubilized neuramini-
dase activity of normal human lymphocytes only 40 to 60% could be precipitated 
with Con A (Fig. 1). Granulocytes contain only minor amounts of Con A precipi-
table neuraminidase activity. a-Galactosidase activity was precipitated complete-
ly. In sial idosis and galactosial idosis the residual neuraminidase activity of 
lymphocytes and the normal activity of granulocytes could not be precipitated, 
whereas a-galactosidase activity could be precipitated normally. Apparently two 
different neuraminidases are present in leucocytes: a Con A binding form, defic-
ient in sialidosis and galactosialidosis, and a non-binding form, normal in 
sial idosis and galactosial idosis. 
It has been demonstrated that acid neuraminidase and a-galactosidase form 
an enzyme complex in bovine testis (13). To investigate whether the neuramini-
dases from human leucocytes are also complexed with S-galactosidase, immune-
titration using an antiserum raised against purified a-galactosidase was per-
formed (fig. 2). In normal lymphocytes 40 to 60% of the solubilized neuramini-
dase activity coprecipitated with a-galactosidase. ln granulocytes only minor 
amounts could be coprecipitated. The residual neuraminidase activity of neither 
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lymphocytes nor granulocytes from the patients coprecipitated with 13-galactosi-
dase. Apparently the Con A binding form of neuraminidase is complexed with a-
galactosidase while the non-binding form is not. 
We investigated whether both forms of neuraminidase are lysosomal or in 
contrast might be plasma membrane associated. Fig. 3 shows the results of Perco\1 
gradient centrifugation studies and it is evident that lysosomes and plasma 
membranes are clearly separated. In both lymphocytes and granulocytes neuramini-
dase sedimented in a single band, coinciding with the lysosomal marker. 
Finally a number of biochemical properties of neuraminidase from lympho-
cytes and granulocytes were analysed (Table 2). No differences were observed in 
pH optimum and Km for the MU-NANA substrate. In lymphocytes neuraminidase was 
somewhat more labile than in granulocytes during sonication, freeze-thawing and 
heat denaturation. Cu 2+, which is reported to be an inhibitor of gang I ioside 
neuraminidase (26), inhibited both lymphocyte and granulocyte neuraminidase to 
the same extent. Similar results were obtained with 2,3-dehydro-2-deoxyNANA, a 
possible inhibitor of the lysosomal glycoprotein and oligosaccharide specific 
neur.:~minidase (26). 
DISCUSSION 
Our results demonstrate the presence of two different neuraminidases in 
human leucocytes: a Con A binding form, complexed with a-galactosidase and a 
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non-binding form which is not complexed. Only the binding form is deficient in 
sialidosis and galactosialidosis. The residual activities of neuraminidase in 
cell homogenates of white blood cells from patients (Table 1) indicate that 
normal lymphocytes contain predominantly (:>80%) the binding form. whereas 
normal granulocytes contain mainly the non-binding form. It should be noted that 
studies with solubilized neuraminidase (Con A binding and immunotitration experi-
ments) are not informative for the relative amounts of the two neuraminidases 
present in leucocytes, since different degrees of polubilization were observed 
for both forms. 
Diagnoses of sial idosis and galactosi.:;~l idosi-s, using total leucocytes, have 
been reported and often very high residual neuraminidase activities were found 
(1,16-20) similar to the activities found in our cases (Table 1). This is caused 
by the normal activity of the non-binding neuraminidase in these patients. For 
this reason granulocytes and hence total leucocytes should not be used for 
diagnosis. On the other hand we show that lymphocytes can be used satisfactorily. 
Multiple forms of neuraminidase have been described previously. Nguyen Hong 
et al. (27) reported on two neuraminidases ir> human leucocytes, a heat stabile 
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TABLE I 
ENZYME ACTIVITIES IN VARIOUS WHITE BLOOD CELLS IN SIALIDOSIS, 
GALACTOSIALIDOSIS AND SIALOLIPIDOSIS 
NEURAMINIDASE~ ~-GALACTOSIDASE~ 
Normal(n=l9) Sial. Gal.sial. Sialolip. Normal(n=l9) Sial. Gal.sial. Sialolip. 
range mean range mean 
Leucocytes 
1.4-4.3 2.8 1.1 0.74 2.3 95-200 133 129 9.2 98 
Lymphocytes 
3. 9-11 7.4 1.1 0.84 4.3 135-280 203 132 13 191 
Granulocytes 
0.46-1.2 0.94 1.3 0.59 1.2 65-150 102 284 6.5 148 
2 enzyme activity in nmol/h/mg protein 
and labile form, both deficient in sial idosis patients. This indicates that both 
forms are re 1 a ted to our binding form. Tsuji et a 1. (20) and Suzuki et a l. ( 17) 
distinguished two neuraminidase activities in leucocytes with different sonica-
tion and freeze·thaw stability. Only the more labile form was deficient in their 
galactosialidosis patients. Our binding and non-binding neuraminidase exhibit 
comparable freeze-thaw and sonication stability and are probably the same 
enzymes as those described (17,20). 
TABLE 2 
PROPERTIES OF NEURAMINIDASE 
IN NORMAL LYMPHOCYTES AND GRANULOCYTES 
pH optimum 
KM for 4MU-NANA (mM) 
Inhibition by 5mM Cu 2+ 
Inhibition by 0.05 mM 
2,3 dehydro-2-deoxy-NANA 
Sonication stability (t!J 
Freeze/thaw stability~ 
Heat stability pH7/37°C (til 
LYMPHOCYTES 
4.1 
0.18 
46% 
69% 
15 sec 
32% 
13 min 
GRANULOCYTES 
4.0 
0.26 
51% 
76% 
58 sec 
55% 
50 min 
: residual enzyme activity after 10 freeze/thaw cycles. 
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Subcellular fractionation showed that both neuraminidase activity of lympho~ 
cytes ()>80% Con A binding form) and neuraminidase activity of granulocytes 
{mainly non~binding form) sedimented in a peak coinciding with the lysosomes 
clearly separate from the plasma membranes. Together with the acid pH optima, 
this suggests lysosomal localization of both forms. This deviates from the 
report by Yamada et al. (Z1) proposing a plasma membrane localization of their 
analogue of our non-binding neuraminidase. 
Since j,, sial idosis as well as galactosial idosis only the Con A binding 
neuraminidase is deficient we conclude that the binding and non-binding neura-
minidases are of different genetic origin. The physiological significance of the 
lysosomal Con A binding neuraminidase and the ganglioside neuraminidase is 
emphasized by the existence of lysosomal storage disorders caused by a defic-
iency of one of these neuraminidases. The function of the non-binding neuramini-
dase is still unknown and future studies on the substrate specificity should 
help to reveal its physiological importance. It is unlikely that this enzyme 
represents ganglioside neuraminidase since a patient with sialo\ ipidosis with a 
proven deficiency of ganglioside neuraminidase {15) had a normal non-binding 
neuraminidase activity. The present results may lead to the discovery of a 
lysosomal storage disorder which is associated with an abnormal non-binding 
neuraminidase. 
ACKNOWLEDGEMENTS 
We thank Dr. F.C.H.A. Kothe and the staff of the "Bloedbank, Rotterdam" for 
providing fresh blood samples. Drs. A.J.J. Reuser and H.J. Sips are kindly 
acknowledged for helpful discussions. We thank Mr. T. van Os and Ms. M.J.C.H. 
van Woensel for preparation of figures and manuscript .. 
REFERENCES 
1. Lowden, J.A. and O'Brien, J.S. (1979) Am. J. Hum. Gen. 31, 1-18. 
2. Cantz, M. and Messer, H. (1979) Eur. J. Biochem. 97, 113-118. 
3. Cantz, M., Gehler, J. and Spranger, J. (1977) Biochem. Biophys. Res. Comm. 
74, 732-738. 
4. 
5. 
6. 
7. 
8. 
9. 
1 0. 
11. 
12. 
Durand, P., Gatti, R., Cavalieri, S., Borrone, C., Tondeur, M., Michalski, 
J.-C. and Strecker, G. (1977) Helv. Paediat. Acta 32, 391-400. 
O'Brien, J.S. (1977) Biochem. Biophys. Res. Comm. 79, 1136-1141. 
Kelly, T.E. and Graetz, G. (1977) Am. J. Med. Genet. 1, 31-46. 
Thomas, G. H., Tipton, R.E., Ch' ien, L.T., Reynolds, L.W. and Miller, C. 
(1978) 13, 369-379. 
Wenger, D.A., Tarby, T.J. and Wharton, C. (1978) Biochem. Biophys. Res. 
Comm. 82, 589-595. 
Hoogeveen, A.T., Verheijen, F.W., d'Azzo, A. and Galjaard, H. (1980) Nature 
285, 500-502. 
van Diggelen, D.P., Hoogeveen, A.T., Smith. P.J., Reuser, A.J.J. and 
Galjaard, H. (1982) Biochim. Biophys. Acta 703, 69-76. 
d'Azzo, A., Hoogeveen, A., Reuser, A.J.J., Robinson, 0. and Galjaard, H. 
(1982) Proc. Nat!. Acad. Sci. USA 79, 4535-4539. 
Hoogeveen, A.T., Verheijen, F.W. and Galjaard, H. (1983) J. Bioi. Chern., in 
press. 
143 
13. Verheijen, F., Brossmer, R. and Galjaard, H. (1982) Biochem. Biophys. Res. 
Comm. 108, 868-875. 
14. Bach, G., Zeigler, M., Schaap, T. and Kahn, G. (1979) Biochem. Biophys. 
Res. Comm. 90, 1341-1347. 
15. Caimi, L., Tettamanti, G., Berra, B., Omodeo sale, F., Borrone, C., Gatti, 
R., Durand, P. and Martin, J.J. (1982) J. lnher. Metab. Dis. 5. 218-224. 
16. Mueller, O.T. and Wenger, D.A. {1981) Clin. Chim. Acta 109, 313-324. 
17. Suzuki, Y., Sakuraba, H., Potier, M., Akagi, M., Sakai, M. and Beppu, H. 
(1981) Hum. Genet. 58, 387-389. 
18. Kuriyama, M., Someya, F., Miyatake, T. and Koseki, M. (1981) Biochim. 
Biophys. Acta 662, 220-225. 
19. Matsuo, T., Egawa, J., Okada, $., Suetsugu, M., Yamamoto, K. and Watanabe, 
M. (1983) J. Neur. Scienc. 58, 4s~ss. 
20. Tsuji, S., Yamada, T., Tsutsumi, A. and Miyatake, T. (1982) Ann. Neural. 
11, 541~543. 
21. Yamada, T., Tsuji, S., Ariga, T. and Miyatake, T. (1983) Biochim. Biophys. 
Acta 755. 106-111. 
22. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) J. Biol. 
Chern. 193, 265~275. 
23. Galjaard, H. (1980) Genetic Metabolic Diseases, early diagnosis and pre-
natal analysis. Elsevier/North Holland, Amsterdam. 
24. Vanneuville, F.J. and Leroy, J.G. (1981) J. Jnher. Metab. Dis. 4, 129~130. 
25. Loonen, M.C.B., van der Lugt, L. and Francke, C.L. (1974) Lancet ii, 785. 
26. Veh, R.W. and Sander, M. (1981) in: Perspectives in Inherited Metabolic 
Diseases (Tettamanti, G., Durand, P., DiDonato, D., eds.) Vol. 4, pp. 71-
109. 
27. Nguyen Hong, V., Beauregard, G., Potier, M., Belisle, M., Mameli, L., 
Gatti, R. and Durand, P. (1980) Biochim. Biophys. Acta 616, 259-270. 

145 
Publication VII: 
Am. J. Hum. Genet. 
38' 137-148 

147 
Am 1 Hum Genet 38:137-148, 1986 
Galactosialidosis: Molecular Heterogeneity among 
Distinct Clinical Phenotypes 
SILVIA PALMERI.I.2 ANDRE T. HooGEVEEN. 1 FRANS W. VERHEIJEN. 1 
AND HANS GAUAAR0 1 
SUMMARY 
The lysosomal storage disorder galactosialidosis has been recognized 
as a distinct genetic and biochemical entity. associated with a com-
bined )3-galactosidase and neuraminidase deficiency that is due to the 
lack of a 32-kilodalton (kDa) glycoprotein. The molecular basis of 
different clinical variants of galactosialidosis has been investigated. 
In the early-infantile form. the synthesis of the 52-kDa precursor of 
the 32-kDa "'protective protein"" is markedly reduced and the absence 
of the latter protein explains the severe neuraminidase deficiency. In 
the juvenile-adult form. there is relatively more 52-kDa precursor but 
no 32-kDa protein can be detected. 
Cells from the late-infantile form have in comparison with controls. 
besides a small amount of the 32-kDa glycoprotein. an accumulation 
of the 52-kDa precursor. Apparently. this protein is genetically altered 
in such a way that its further processing is impaired. Furthermore, in 
this mutant. the residual neuraminidase activity is stimulated four- to 
sixfold upon leupeptin treatment together with an increase of the 32-
kDa glycoprotein. 
INTRODUCTION 
During the last few years. about 30 patients with galactosialidosis have been 
described (for reviews. see [1-3]). Somatic cell hybridization studies have 
shown that this autosomal recessive disease. associated with a combined defi-
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ciency of lysosomal !3-galactosidase and neuraminidase. is a genetic entity 
distinct from GM 1 -gangliosidosis and sialidosis [4]. 
D'Azzo et al. [5] elucidated the responsible molecular defect in galacto-
sialidosis that appears to be a lack of a 32-kDa glycoprotein. subsequently 
shown to be required for the aggregation of !>-galactosidase monomers [6]. This 
conformation was found to be essential to protect the 64-kDa !>-galactosidase 
monomers against intralysosomal proteolytic degradation. Also. the 32-kDa 
protective protein is essential for the activation of neuraminidase that forms a 
complex with !>-galactosidase [7. 8]. 
As in most other lysosomal storage diseases. different clinical phenotypes of 
galactosialidosis have been recognized. Patients with an early-infantile form. 
showing severe edema. ascites. skeletal dysplasia. and ocular abnormalities. 
die shortly after birth [9. 10]. In the late-infantile form. patients present symp-
toms after 6-12 months and the main features are dysmorphism. dysostosis. 
and skeletal dysplasia. visceromegaly, macular cherry-red spot. and mild men-
tal retardation [3. 11. 12]. The largest number of patients. mainly of Japanese 
origin. are those with the juvenile/adult form [2. 13. 14], where symptoms have 
appeared between infancy and adulthood. The major features are skeletal dys-
plasia. dysmorphism, corneal clouding. cherry-red spot, angiokeratoma. neu-
rological manifestations. and mental retardation. 
In our present studies on the molecular background of these different clinical 
phenotypes. we found marked differences in the biosynthesis of the 32-kDa 
"protective protein ... These findings also explain the discrepancy in earlier 
studies on the effect of leupeptin on the residual neuraminidase activity m 
galactosia1idosis [12, 14. 15]. 
MATERIALS AND METHODS 
Cell Culture 
Fibroblasts from normal individuals and patients with an early-infantile form [9] and a 
juvenile/adult form of galactosialidosis [16] were derived from the Rotterdam Cell Re-
pository (Prof. M. F. Niermeijer). Cells from patients with the late-infantile form were 
provided by Dr. G. Andria [3] and Dr. L. Pinsky [11]. Early passages from all cell strains 
were used and were maintained in Ham's F-10 medium (Flow Laboratories. McLean. 
Va.) supplemented with antibiotics and 10% fetal calf serum. 
Radioactive Labeling. Immunoprecipitation. and Electrophoresis 
One week prior to radioactive labeling. the medium was replaced by Dulbecco's 
modification of Eagle's medium (Flow Laboratories) supplemented with 10% fetal calf 
serum and antibiotics and cells were grown in 25-cm2 falcon flasks. One hour prior to 
labeling. this medium was ,replaced by Dulbecco's medium free of leucine. fetal calf 
serum. and antibiotics. 
Biosynthetic labeling was performed using the same medium plus 2% of dialyzed fetal 
calf serum and 0.15 ml of L [4-53H]Jeucine (0.15 mCi: 135 Ci mmol: Amersham 
Radiochemical Centre. England). After 48 hrs. cells were harvested and comparable 
amounts of cell material. based on the protein content. were immunoprecipitated. A 
polyclonal antiserum raised against 13-galactosidase purified from human placenta was 
used [5]. Since the enzyme exists in a complex with its 32-kDa ""protective protein."" the 
antiserum reacts with 13-galactosidase. its protective protein. and their precursor forms 
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[6]. Polyacrylamide gel electrophoresis. in the pfesencc of sodium dodecyl sulfate. was 
performed according to Laemmli [17] with minor modifications. The radioactive bands 
were visualized by ftuorography and exposure for I week at -70"C using X-Omat R film 
(Eastman Kodak. Rochester. N.Y.). The [14C]methyl-labeled protein molecular weight 
standards used were: phosphorylase B. 92,500: bovine serum albumine. 69.000; ovalbu-
min. 46.000: and carbonic anhydrase. 30.000 (Amersham Radiochemical). 
To study the effect of inhibition of lysosomal proteases. leupeptin. at a final concen-
tration of 0.02 mM. was added to the medium. In addition to immunoprccipitation 
studies. as described above. the activities of [3-galactosidase and neuraminidase were 
measured 4-5 days after leupeptin administration using 4-methylumbe\liferyl substrates 
according to Galjaard [18]. 
For the pulse-chase study. five 25-cm~ flasks were prepared for every strain. and after 
·labeling for 30 min. the cells were subjected to chase with fresh unlabeled Dulbecco's 
modification of Eagle's medium for 0. 15. 30. 60, and 120 min. respectively. 
Analysis in the Medium ofNH4 CI-induced Secretions 
The cells were prepared as described above. but at the moment of labeling. the 
medium was supplemented with 10 mM NH.1Cl for 48 hrs. Then. the medium was 
collected and prepared for immunoprecipitation as in previous studies [5. 19]. For the 
study of glycoprotein phosphorylation. 200 JJ.Ci 3~P 1 -carrier free was added to a 25-cm::: 
Falcon flask, in the presence ofNH-1Cl. and the medium was prepared as described [20]. 
Uprake studies. Confluent fibroblasts from the late-infantile galactosialidosis form 
were maintained in 75-cm~ Falcon flasks for 48 hrs in Dulbecco's modification of Eagle's 
medium containing eHJJeucine and NH.1Cl. The medium from two falcon flasks -was 
collected. and the (precursor) glycoproteins secreted by the cells were precipitated with 
(NH4): S0-1. The pellet was dissolved in 400 JJ.l water and desalted on a small column of 
Sephadex G:;0 that was equilibrated with phosphate-buffered saline [21]. Subsequently, 
the sample was added to 5 ml Ham's F-10 medium. which was then added to control 
fibroblasts in a 25-cm::: falcon flask and incubated for 48 hrs. After harvesting. immune-
precipitation studies were performed. Reversely. the same procedure was carried out 
with medium containing secretions from control cells. which was added to mutant cells. 
RESULTS 
Biosynthesis in Normal and Mutant Cells 
lmmunoprecipitation studies were performed with conventional antiserum 
reacting with 13-galactosidase. protective protein. and their precursor forms. 
The results for normal fibroblasts and cells derived from the three clinical 
phenotypes of galactosialidosis are shown in figure I. In all cell lines. the 85-
kDa precursor of 13-galactosidase is synthesized. but in the three mutant lines, 
the amount of mature 64-kDa 13-galactosidase is decreased compared with the 
control (fig. lA). In cells from both patients with the late-infantile form of 
galactosialidosis (fig. IB and£). there is a large amount of a 52-kDa protein and 
a band at the 32-kDa position. In the two other mutant cell types. no 32-kDa 
band is visible and the amount of 52-kDa protein is less than in the control or in 
the late-infantile form. The juvenile/adult form (fig. !D) shows more 52-kDa 
protein than the early-infantile form (fig. I C). 
The pulse-chase experiments. illustrated in figure 2. indicate that the 52-kDa 
protein is the precursor of the 32-kDa protective protein. In control fibroblasts. 
this precursor is visible after 30-min labeling and the 32-kDa band appears after 
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FIG. 1.-lmmunoprccipitation of ~-galactosidase and 32-kDa protective protein and their precur-
sors in normal and mutant fibroblasts. after eHJleucine labeling for 48 hrs followed by SDS-PAGE. 
Lane A: control; lane B: late-infantile galactosialidosis (Andria et al. [3]); fane C: early-infantile 
form: lane D: juvenile/adult form: fane£: late-infantile form (Pinsky et al. [11]): fane F: standards. 
15-min chase: after 60-min chase. the 52-kDa band has disappeared whereas the 
32-kDa protective protein remains visible. 
In cells from the late-infantile form of galactosialidosis. the 52-kDa precursor 
remains during the whole chase period and no 32-kDa band appears. These 
results suggest that the processing of 52-kDa precursor into 32-kDa protective 
protein is impaired. In the early-infantile form. hardly any 52-kDa precursor is 
detectable. and in the juvenile/adult form. the amount of precursor is somewhat 
higher. The 32-kDa protective protein is detectable in neither of these two 
mutants. 
Secretion and Uptake of Precursor 
Immunoprecipitation studies on medium above ['H]leucine-labeled cells af-
ter NH.CJ stimulation show equal amounts of the secreted 88-kDa precursor of 
13-galactosidase in normal and mutant cells (fig. 3A-D). Medium above control 
cells also contains the 54-kDa precursor of the protective protein (fig. 3A). This 
precursor can also be demonstrated in the medium above late-infantile galac-
tosialidosis cells (fig. 3B). although much Jess than in controls. No 54-kDa 
protein band is seen in the medium above the two other mutant cell types (fig. 
3C and D). Labeling w!th "P,-carrier free showed that the secreted precursors 
in the medium are all phosphorylated (results not shown). 
To investigate whether the 54-kDa precursor secreted by the late-infantile 
galactosialidosis cells can be processed into 32-kDa protective protein. the 
following experiment was carried out. Medium above [3H]leucine-labeled mu-
tant cells was collected after 48 hrs treatment with NH4CJ (see MATERIALS AND 
METHODS) and added to control fibroblasts. lmmunoprecipitation studies of 
these latter cells were performed after 48 hrs. and the results are shown in 
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FIG. 3.-lmmunoprecipitation of secreted precursor glycoproteins in the medium above normal 
and mutant fibroblasts after NH4 Cl treatment in the presence of [3H)leucine. Lane A: medium 
above control cells: lane B: medium above cells from late·infantile galactosialidosis: lane C: 
medium above cells from early·infantile form: lane D: medium above cells from juvenile/adult 
galactosialidosis. 
figure 4A. It is clear that the 54-kDa precursor secreted by the mutant cells has 
been taken up by the control fibroblasts but only a very faint 32-kDa band is 
visible. 
In the reverse experiment (fig. 4B). the 54-kDa precursor secreted by normal 
cells is taken up by the mutant cells and is rapidly processed into 32-kDa 
protective protein~ also. a clear 20-kDa band appears. which is derived either 
from the 54-kDa or the 32-kDa protein. These results indicate that the cells 
from late-infantile galactosialidosis are capable of processing normal 54-kDa 
precursor. The uptake experiments also show that the mutation in this clinical 
phenotype alters the 54-kDa precursor in such a way that its processing is 
impaired. 
Inhibition of lntralysosomal Proteolytic Degradation 
Since the [3-galactosidase deficiency in galactosialidosis is due to enhanced 
intralysosomal proteolytic degradation [5. 14. 15]. we investigated the effect of 
inhibition of lysosomal cathepsins by leupeptin in the different clinical pheno-
types of galactosialidosis. The results in table I show that the activity of ~­
galactosidase increases three- to sevenfold in the three mutant cell types after 4 
days treatment with leupeptin. The effect on neuraminidase activity. however. 
is different among the mutants. Leupeptin leads only to an increase of neura-
minidase activity in the late-infantile form. 
To study the molecular background of this effect. we performed immune-
precipitation studies after leupeptin treatment (fig. 5). In the late-infantile form 
of galactosialidosis. leupeptin treatment results in an increased amount of the 
85-kDa precursor of i)-galactosidase (as in controls) and to an increased amount 
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FIG. 4.-Uptake of radiolabeled glycoprotein precursors secreted into the medium. Lane A: 
uptake and processing of secreted precursors from late-infantile mutant fibroblasts by control cells; 
lane B: uptake from control fibroblasts by late-infantile galactosialidosis cells. 
of the 32-kDa protective protein. The latter effect was not seen in the two other 
mutant cell lines (results not shown). 
DISCUSSION 
The accumulation of knowledge about the biosynthesis of human 13-
galactosidase [5]. its different forms [6. 22. 23]. and its relationship with ly-
sosomal neuraminidase [7. 8. 24] made our present study on the molecular 
background of different clinical variants of galactosialidosis feasible. 
The results of immunoprecipitation studies with conventional antiserum 
reacting with ~-galactosidase and its 32-kDa protective protein show that in all 
three types of galactosialidoses there is little 64-kDa 13-galactosidase monomer. 
This is reflected in the 10% residual enzyme activity found in a variety of cells 
in these patients [1-3. 23. 25]. Previous studies [5] indicated that the reduced 
amount of 64-kDa 13-galactosidase is due to enhanced degradation of the mono-
meric form of the enzyme. In the lysosomes of normal cells. !?>-galactosidase 
exists for at least 80% as a high molecular weight aggregate [6. 22. 23]. and. 
more recently. it was demonstrated that the 32-kDa "protective protein'" is 
needed for this aggregation process [ 6]. 
The results of our oresent study show that the intracellular 52-kDa protein is 
the precursorform of this 32-kDa "protective protein" and a 20-kD protein that 
is present in minor amounts in the high molecular weight aggregate and that 
probably is a degradation product. The amount of the 52-kDa precursor varies 
markedly among the different clinical phenotypes (figs. I and 2). In the late-
infantile form of galactosialidosis [3. II]. the 52-kDa band is even stronger than 
in control cells but the amount of32-kDa "protective pro:-:in" is much smaller. 
ln the early-infantile form [9]. there is very little 52-kDa precursor. and in the 
TABLE I 
EFFECT OF LEUPEPTIN ON THE ACTIVITY OF ~-GALACTOSIDASE AND NEURAMINIDASE IN CONTROL CELLS AND IN DIFFERENT TYPES OF GALACTOSIAUDOSIS 
TYPE Of CELlS 
Early-infantile galactosialidosis [9] .......... . 
Late-infantile galactosialidosis [3] ........... . 
Late-infantile galactosialidosis [II] ....... , .. . 
Juvenile/adult galactosialidosis [16] ......... . 
Control .................................. . 
p-GAI.ACTOSIDASE ACTIVIT¥ 
-Lcupeptin 
33.3 
27.0 
73.0 
38.6 
706 
(Range 350-1 ,050) 
• Leupeptin 
207 
181 
357 
132 
675 
NEURAMINIDASE ACTIVITY 
-Leupeptin 
0.4 
2.6 
1.2 
0.5 
106 
(Range 40-lJO) 
+Leupeptin 
0.6 
9.0 
7.1 
0.8 
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Nou: Enzymatic activities are expressed in nmolfhr/mg protein. Each value is the mean of three or four separate experiments. 
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FrG. 5.-Immunoprecipitation of [3-galactosidase and 32-kDa protective protein in fibroblasts 
from controls and from a patient with the late-infantile form of galactosialidosis: eH]leucine 
labeled for 4 days with and without leupeptin. 
juvenile/adult form [13]. only some more is present. No 32-kDa protein can be 
detected in both forms. 
In the pulse-chase experiment. the labeling period is too short to demonstrate 
the 85-kDa precursor of !>-galactosidase and the 32-kDa protective protein in 
the late-infantile form of galactosialidosis. but these bands are visible after 48 
hrs labeling. Precursor forms secreted into the medium after NH4CI stimulation 
show a 2.000-3.000 higher molecular mass than the intracellular forms. an 
observation made earlier for other lysosomal proteins [19]. 
The immunoprecipitation studies of ·the medium after NH"CI stimulation 
indicate equal amounts of secreted 88-kDa precursor f3-galactosidase in normal 
and mutant cells. which points to a normal synthesis of this protein in all forms 
of galactosialidosis. The secreted 54-kDa precursor of the protective protein is 
seen only in medium above controls and above cells from the late-infantile 
form. The discrepancy between the large amount of 52-kDa precursor intracel-
lularly in this mutant and the smaller amount (compared with control) of the 
secreted 54-kDa precursor suggests that the mutation interferes with normal 
intracellular routing from the Golgi to the lysosome so that NH4CI does not 
effectively stimulate secretion. 
The uptake studies (fig. 4) prove that 54-kDa precursor secreted by normal 
cells can be processed into 32-kDa ··protective protein·· by cells from the late-
infantile form of galactosialidosis. Consequently. the mechanism needed for 
this processing is not affected in the mutant. On the other hand. the 54-kDa 
precursor secreted by the mutant cells is hardly processed after uptake by 
normal cells. This indicates that the gene mutation in this clinical phenotype 
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affects the 54-kDa precursor protein in s~ch a way that it cannot be effectively 
processed into functional 32-kDa protective protein. This might be related to 
aberrant intracellular routing. 
The residual amount of 32-kDa protective protein in the late-infantile form 
explains the discrepancy between previous studies on the effect of leupeptin. 
After addition of this inhibitor of proteolytic degradation by cathepsins. our 
group found in galactosialidosis cells a marked increase of the activities of both 
!3-galactosidase and neuraminidase [15]. Others [14]. however. did not find an 
effect of leupeptin on neuraminidase activity. The explanation is the use of 
different mutant cell types in these studies. In fibroblasts from the juvenile/ 
adult form. studied by Suzuki et al. [ 14]. or in cells of a similar patient reported 
earlier by Loonen et al. [16]. there is no effect of leupeptin on the neuramin-
idase activity (see also table 1). which seems to be related to the absence of 
32-kDa protective protein in these patients. A four- to sixfold increase of 
neuraminidase activity occurs. however. in the two patients with the late-
infantile form. both of which also have residual 32-kDa protective protein. 
Recent experiments [8} explain this relationship on a molecular basis. because 
the 32-kDa protective protein appears to be an essential subunit for lysosomal 
neuraminidase activity. 
Our present study provides a molecular basis for some differences among 
patients with galactosialidosis. The three main clinical forms have in common a 
I 0%-15% residual !3-galactosidase activity that is based on the monomeric 
form of the enzyme. The differences between the clinical phenotypes must be 
due to differences in lysosomal neuraminidase activity and in the 32-kDa pro-
tective protein and its precursor. In the late-infantile fOrm, there is a normal 
synthesis of 52-kDa precursor of the protective protein but its processing is 
impaired. The small amount of32-kDa protein is sufficient for some 2% residual 
neuraminidase activity. which might be sufficient to explain the relatively mild 
clinical course [3]. 
In the early-infantile form. the mutation results in a marked reduction of the 
amount of 52-kDa precursor and no 32-kDa protein. essential for neuramini-
dase activity, can be detected. The pulse-chase experiments suggest a reduced 
rate of synthesis rather than an enhanced degradation of the precursor. 
In the juvenile/adult form. there is relatively more 52-kDa precursor than in 
the early-infantile form. but the amount of 32-kDa protective protein is below 
detection level even after 48 hrs labeling. We do not yet know whether the 52-
kDa precursor may play any functional role. nor can we as yet relate the 
molecular observations and the clinical features in the juvenile/adult form. It 
should, however. be mentioned that these molecular studies are limited to 
fibroblasts and defective processing might have fewer consequences in other 
cells and organs. Also. the neuraminidase activities have been measured with 
artificial substrates under in vitro conditions. It may well be that the differences 
between the early-infantile form and the juvenile/adult forms are based on small 
differences in residual neuraminidase activity toward their natural substrates 
under in vivo conditions [26]. 
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